Identification of cancer genes using Sleeping Beauty mutagenesis of the Ptch1 murine tumour model by Al-Afghani, Hani Mohammad A
    
 
 
 
 
 
 
 
 
 
Identification of cancer genes using Sleeping 
Beauty mutagenesis of the Ptch1 murine 
tumour model 
 
 
 
Hani Mohammad Al-Afghani 
 
 
 
 
 
Thesis submitted in partial fulfilment of the requirements  
for the degree of Doctor of Philosophy 
 
Newcastle University 
 
Faculty of Medical Sciences 
 
Institute of Genetic Medicine 
 
November 2013 
 II 
Abstract 
 
Medulloblastoma (MB) is a paediatric tumour of the cerebellum which is 
responsible for 15-20% of all childhood brain tumours. Mortality due to this disease is 
high (~40%) and successful treatment is associated with significant neurological and 
cognitive consequences, making new therapies desirable. Disruption of the Sonic 
Hedgehog (SHH) signaling pathway, including mutations in PTCH1, define a major 
subset of human MB. Mice heterozygous for loss of function mutations in the Ptch1 
ortholog develop MBs at low frequency. 
To identity genes that co-operate with Ptch1 in MB development, a Sleeping 
Beauty insertional mutagenesis screen in this murine model was performed. 
Mutagenesis significantly increased the frequency of MB formation in Ptch 
heterozygote mice from ~3% to ~25% after 8 months (p<0.0001). To identify the genes 
responsible for this enhanced tumour formation, Splinkerette-PCR and 454-FLX 
sequencing were applied to define SB insertion sites within 40 tumours. Statistical 
analysis of these data using Monte Carlo and Kernel Convolution methods identified 18 
candidate medulloblastoma genes defined by common insertion sites (CISs), including 
11 identified by both methods used. Many of these are genes known to be involved in 
neuronal development and cell fate determination. Subsequent ARACNe network 
analysis of the candidate genes in human gene expression datasets has established that 
seven (Nfia, Nfib, Tead1, Tgif2, Myt1l, Fgf13 and Crebbp) lie within a single network 
which is enriched for both neuronal genes and transcription factors, and includes genes 
known to interact with the SHH pathway. Bioinformatic analysis confirmed that the 
tumours generated from SB mutagenised mice were similar in their gene expression 
pattern to human SHH subgroup tumours, while microarray expression analysis of SB 
induced tumours identified Igf2, a gene previously implicated in MB development, as a 
key output of network activity.  
Finally, analysis of gene expression within granule neuron precursor cells 
(GNPCs), the cell of origin of SHH subgroup MB, identified Tgif2 and Myt1l as prime 
candidate genes for downstream functional analysis. Lentiviral based modulation of 
their gene expression was therefore attempted in primary GNPCs. shRNA based knock-
down of Myt1l was achieved, and shown to be associated with significantly increased 
expression of both Gli1 (the downstream effector of the Shh pathway) and Math1 (a 
marker of undifferentiated neuronal cells), consistent with a reduction in MYT1L 
expression playing a role in human MB development. Further analysis of this gene, and 
others defined here, should both improve our understanding of MB and define potential 
targets for therapeutic intervention. 
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Chapter 1 
 
INTRODUCTION 
 
1.1. Cancer 
 Cancer, which can be defined as uncontrolled cell proliferation which exceeds 
the body’s normal restrictions, is one of the leading causes of death worldwide.  It was 
responsible for approximately 7.9 million deaths in 2008, and if current trends continue 
this figure is expected to dramatically increase by 2030, reaching a maximal level of 
about 13.2 Million (World Health Organisation, 2013a). However, in 2008 the 
estimated cancer incidence (as opposed to mortality) was 12.7 million new cases per 
annum, and this is likely to rise to approximately 22 million by 2030 worldwide if the 
present trends in cancer are continued (World Health Organisation, 2013a). In the 
United Kingdom (UK), it is estimateded that 1 out of every 3 persons will be affected 
by one or more forms of cancer during their lifetime (Cancer Research UK, 2013a). 
Almost all body organs can be affected by cancer.  The incidence of the most common 
cancers in the UK, and the numbers of deaths they caused are shown in Figures 1.1. and 
1.2 for the year 2008.  The 4 most common cancers (breast, lung, colorectal and prostate 
cancer) are responsible for approximately 47% of cancer deaths (Figure 1.2, Cancer 
Research UK, 2013b).  
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Figure 1.1: New cases of the most common cancers in the UK in 
2008, split by gender. N-H-L = Non Hodgkin Lymphoma (adapted 
from www.cancerresearchuk.org). 
Figure 1.2: Deaths due to the most common cancers in the UK in 2008, 
split by gender (Adapted from www.info.cancerresearchuk.org). 
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 Carcinogenesis arises as a consequence of mutations affecting single cells. 
These mutations usually are due to either external (environmental) or internal 
(inherited) factors, or a combination of both. Major environmental agents include 
radiation and carcinogens integrated within chemicals, food additives and tobacco 
smoke. Multiple mutagenic insults are generally required for normal cells to be 
transformed into malignant invasive cells. This could happen via two main mechanisms. 
Firstly, stimulation of cellular proliferation, which may be caused by specific mutations 
that in turn may stimulate target cell expansion favouring further mutations. The 
second, through a mechanism known as chromosomal instability, that leads to increase 
further mutation rates (Hanahan and Weinberg, 2011). 
 A recent review has highlighted six important functional changes as the essential 
transformative features of all immortalised cancerous cells: 1 - self-sufficiency from 
growth signals, 2 - insensitivity to anti-growth signals, 3 - Avoidance of apoptosis, 4 - 
unlimited replication, 5 - continued angiogenesis, and 6 - tissue invasion and metastasis 
(Hanahan and Weinberg, 2011). Although functional changes involved in cancer can be 
defined into these six categories, individual genes which are mutated in cancer are often 
classified as either genes which have the ability to inhibit tumourgenesis (tumour 
supressors) or genes which promote tumourgenesis (oncogenes). Mutations affecting 
these two classes of gene are loss of function and gain of function respectively, and can 
drive healthy cells toward malignancy (Osborne et al., 2004;Zhang et al., 2007).  
Oncogenes are the transformed stages of proto-oncogenes (normal genes with 
oncogenic potential) after a gain of function mutation, and have the capability to 
promote the cancer phenotype. Individuals may be highly tumour prone when a proto-
oncogene within their somatic cells becomes oncogenic as a result of chromosomal 
instability, gene amplification, or mutation. A large number of proto-oncogenes have 
been identified and many of them, such as RAS (rat sarcoma), MYC (myelocytomatosis 
oncogene cellular homolog), ERK (extracellular signal-regulated kinase), and EGFR 
(epidermal growth factor receptor), encode proteins that are responsible for managing 
cell regulation and differentiation (Todd and Wong, 1999);(Vogelstein and Kinzler, 
2004) . Oncogenes can be further subdivided into five main subtypes. These subtypes 
are intracellular transduction system (cell surface receptors), growth factors, DNA 
binding nuclear proteins (e.g. c-Myc), cyclin-dependent kinases (e.g. CDK4) and cyclin-
dependent kinase inhibitors (e.g. CDKN2D) (Osborne et al., 2004).  
Tumour suppressor genes are those genes where loss of function mutations 
increase the risk of tumourgenesis (Haber and Harlow, 1997)). In the context of cancer, 
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the normal function of these genes can be considered as being protective against 
uncontrolled cellular overgrowth. Alterations that lead to down-regulation or ablation of 
the function of such genes will compromise their protective function as overgrowth 
inhibitors, leading to conversion of normal cells into malignant invasive cells (Knudson, 
1993).  
Tumour suppressor genes can be further classified into three broad groups 
according to their function: 1. Caretakers: These encode proteins that protect the 
genome from mutation accumulation (i.e. indirect protection) such that their mutation 
creates genomic instability.  Examples would be genes involved in DNA-repair, such as 
MLH1 and MSH2 which are frequently mutated in some forms of colorectal cancer. 2. 
Gatekeepers: These encode proteins that limit cellular overgrowth by encouraging 
affected cells to commit to the apoptotic cell death mechanism. The classic example is 
p53 which is mutated in a wide variety of cancers (Macleod, 2000). Both of these kinds 
of genes required two hits in order to affect both alleles and promote malignancy, and it 
is noteworthy that individuals carrying inherited mutations of such genes are at a greatly 
increased risk of developing tumours relative to the population as a whole. For example, 
Lynch syndrome is an inherited predisposition to colorectal cancer defined by 
inheritance of mutant forms of MLH1 or MSH2, while LiFraumeni syndrome is a 
familial cancer predisposition caused by inheritance of p53 loss of function mutations 
(Macleod, 2000).  3. Landscapers:  These encode proteins that are involved in the 
tumourigenesis process after mutation, for example by modifying the microenvironment 
of the tumour cells, such as genes which control the extra cellular matrix (ECM) 
proteins (Macleod, 2000; Kinzler and Vogelstein, 1997; Kinzler and Vogelstein, 1998). 
 
1.2. Childhood cancers 
 The overall incidence of cancer within the population is highly age dependent, 
consistent with an increased mutagenic burden associated with increasing age.  As an 
individual’s age increases, the opportunities for their cells to be exposed to carcinogens 
and gain mutations will also increase. Despite this, children have a high risk of 
developing specific forms of cancer, mainly leukaemias, lymphomas, central nervous 
system (CNS) tumours, and bone tumours. Yearly, about 1500 new cancer cases are 
reported in children in the UK. The mortality rates in children affected by the most 
common cancers (Haematological and CNS malignancy) under the age of 15 years in 
the UK between 1996-2005 are shown in Figure 1.3. Leukaemia (blood cancer) 
accounts for approximately 30% of childhood cancers. Improvement in diagnostic and 
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therapeutic procedures over the last few decades have led to gradual improvement in 
survival rates within effected children, although this varies between different tumours. 
For instance, survival rates have improved to about 80% in children with acute 
lymphoplastic leukaemia (ALL) – the most common blood malignancy effecting 
childhood (Tubergen et al., 1993), whereas the brain tumours survival rate has 
remainded relatively unaltered at approximately 65% (Cancer Research UK, 2013c). 
 
 
1.2.1 Brain tumours 
Central nervous system (CNS) tumours are the second most common group of 
tumours affecting children after blood malignancies, and the incidence of major 
subgroups in relation to age is shown in Figure 1.4. They account for approximately 
27% of all tumours affecting children up to the age of 14 years in the UK over the 
period from 2008 – 2010 (Cancer Research UK, 2013).  Histologically, brain tumours 
can be subdivided into glial tumours and nonglial (neuronal) tumours. Gliomas, which 
account for a majority of brain tumours in childhood, are generally classified on the 
basis of shared similarities with specific lineages of glial cells. In line with this scheme, 
tumour cells resembling astrocytes are classified as astrocytomas, while those similar to 
oligodendrocytes are classified as oligodendrogliomas (Rich and Eyler, 2008). During 
 
 
Figure 1.3 The most common cancer causing death in children between 1996-2005 
in the UK (Adabted from Cancer research UK, 2013). 
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the period 1996–2005, astrocytomas accounted for about 43% of all childhood brain 
tumours, with low grade tumours constituting approximately 76% of these. The second 
most common subgroups of the CNS tumours are the intracranial and intraspinal 
embryonal tumours and these account for about 19% of all childhood brain tumours. 
Among these, 73% are medulloblastomas. Medulloblastomas (MBs), are found in the 
posterior fossa. The least frequent subgroup of CNS tumours is ependymomas, which 
account for only 10% (Cancer research UK, 2013).  
 
 
 
 
In general, neurologic tumours present challenges to clinicians as the biology of 
most of these tumours is poorly defined. Indeed, the fact that the pathogenesis of these 
tumours is poorly understood has impacted negatively on the nature of treatment 
options available. While recent advances have considerably improved the treatment 
options for other forms of cancer such as leukaemias, the median survival for primary 
brain tumours has remained low (15 months for glioblastoma), although, slight 
improvement in overall survival for primary brain tumours has been observed over the 
last 30 years (Rich and Eyler, 2008). However, a recent comparison of survival rates for 
brain tumours in the UK and US revealed that children and young adults diagnosed with 
CNS tumours in general in the UK have relativelypoor survival rates (children with MB 
in particular, suffer from relatively high recurrence rates within 2 years of diagnosis 
(Mathew et al., 2014).  
  
FIGURE 1.4 Frequency of Brain and CNC cancers in children, 
according to age (Adapted from cancerresearchuk.org). 
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1.3. Medulloblastoma 
 
1.3.1. Overview of disease 
 Medulloblastoma (MB) is responsible for between 20 and30% of all childhood 
brain tumours (Li et al., 2013). In 2007, the World Health Organisation (WHO) 
classified medulloblastoma as a highly severe (grade IV) form of CNS tumour. This 
new classification was based on the consensus reached by an international working 
group consisting of pathologists, geneticists and other international experts. The 
international classification of disease for oncology (ICD-O) was founded more than 30 
years ago and in the fourth edition of this system, publically available in 2007, 
medulloblastoma was risk stratified into two groups (high risk and average risk), 
depending on characterised macroscopical morphology, location, age, and biological 
behaviour (Louis et al.,2007). However, with the inclusion of immunohistochemical 
and recently analysed molecular genetic markers, MB tumour stratification has been 
revised into three risk groups with highly significantly different outcomes (P<0.0001); 
low-risk, standard-risk and High-risk,  (Ellison et al., 2011). Low-risk MBs (13% of 
total) are β-catenin nucleopositive, with no metastasis, large-cell/anaplasia (LC/A) or 
MYC expression. High-risk MBs (28%) are tumours with metastasis, LC/A appearance 
and MYC expression. Finally, those tumours lacking the above parameters (59%)  are 
defined as standard-risk (Ellison et al., 2011). 
Macroscopically, medulloblastoma is defined as a tumour of the midline that 
arises in the cerebellar vermis or/and hemispheres. Moreover, the classification states 
that medulloblastoma is a poorly outlined pinkish or greyish soft tissue growth, possibly 
with foci of haemorrhages, necrosis or calcification (Batra et al., 1995;Ellison et al., 
2011). Approximately 7-10% of all cases are associated with the spreading of the 
disease outside the CNS; termed extraneural metastasis or ENM, (Mazloom et al., 
2010). In children, the various morphological phenotypes of medulloblastoma account 
for 40% of tumours of the cerebellum, and 33% of posterior cerebral fossa tumours. The 
annual incidence of medulloblastoma is 6.0 per million populations per year, with a 
significantly higher incidence in boys than girls. In children, the incidence peaks 
between 5 and 7 years of age. Overall, 10% of cases are diagnosed within the first year 
of life, while approximately 30% of all cases occur in children above 10 years of age. 
However, less than 1% of MBs occur in adulthood. Furthermore, research indicates that 
medulloblastoma is more common in Caucasians than in other races. (Dhall, 2009).  
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With the recent use of multimodal treatment of MB, the overall five year 
survival rates for patients with high-risk and average-risk MB are about 70% and 90% 
respectively (Gajjar et al., 2006). However, the survival rates for disseminated disease, 
associated with poorer prognostic outcomes and recurrent MB, is still low at 
approximately 36% (Packer et al., 2006). In addition, patients who undergo treatment 
and survive the disease often have long term side effects, such as bone marrow 
suppression, growth and hormonal disruption, impaired fertility, and learning, 
behavioural, and coordination problems (Massimino et al., 2011).  
 
1.3.2. Histopathological and Molecular Classification of Medulloblastoma 
Historically, medulloblastomas and other neuro-embryonal tumours have been 
classified according to their histological appearance and location within the central 
nervous system (Rossi et al., 2008). In the first classification schema for neurological 
tumours, Bailey and Cushing grouped medulloblastoma with other embryonal tumours 
characterised by rapid proliferation and minimal differentiation (Ellison et al., 2003). 
To classify embryonal tumours that could not be neatly categorised, Hart and Earle in 
1973 introduced the term primitive neuroectodermal tumours (PNET). While the term 
PNET was originally used to classify cerebral high-grade undifferentiated 
neuroepithelial tumours of childhood such as medulloblastoma, the term has been 
extended to include all tumours of a similar nature (Gilbertson and Ellison, 2008). More 
recently, to take account of new molecular genetic findings, WHO recently developed a 
new classification scheme for neurologic tumours. Within this scheme the WHO define 
five histopathologic variants of medulloblastoma. These are: classic medulloblastoma 
6470/3, desmoplastic/nodular medulloblastoma 9471/3, medulloblastoma with 
extensive nodularity (MBEN) 9471/3, anaplastic medulloblastoma, 9474/3, and large-
cell medulloblastoma 9474/3 (Navajas and Giralt, 2010).  
Molecular profiling techniques have been extensively applied to MBs and 
genetic mutation and gene expression profiles have proved useful for sub-classification 
of the disease. Indeed, the observation that the different MB subtypes have distinct 
cytogenetic profiles provided the first clues that different subtypes may develop via 
distinct molecular processes. However, the first comprehensive scheme for molecular 
sub-typing of MBs was proposed by (Kool et al., 2008). These researchers combined 
the mRNA expression profiles of a series of 62 medulloblastomas (using Affymetrix 
HG-U133 Plus 2.2 Gene Chips) with comparative genomic Hybridization (CGH) 
analysis. Unsupervised two-way, hierarchical cluster analysis identified 5 molecular 
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subtypes of medulloblastomas (subgroups A—E), each with distinct clinicopathological 
features, characteristic gene expression signatures, and distinct mutations. Cluster A 
exhibited alterations in WNT and TGF-beta signalling – this cluster corresponds to MBs 
with alterations in the WNT pathway (including β-catenin, APC, AXIN); cluster B was 
characterised by alterations in sonic hedgehog (SHH) signalling (including PTCH1 and 
SUFU mutations) and low levels of OTX2 expression; and the closely-related clusters 
C, D and E were sub-typed on the basis of the expression of genes involved in neuronal 
differentiation, biogenesis and cytoskeleton organisation (Kool et al., 2008).  
A subsequent study carried out on a larger series (103) of primary human MBs 
using gene expression profiles, DNA copy number aberrations, and the application of 
unsupervised hierarchical cluster analysis (Northcott et al., 2011), concluded that there 
was clear evidence for only 4 clinicogenetic subgroups of MB [defined as WNT, SHH, 
Group C and Group D (Northcott et al., 2011)]. The SHH subgroup showed a 
preponderance of desmoplastic MBs, with the exclusive and statistically significant 
expression of known SHH target genes HHIP, SFRP1 and MYCN. The WNT group 
showed an exclusive statistically significant expression of WIF1, DKK1, and DKK2. 
According to age prevalence, the authors identified the SHH subgroup as being 
prominent within either infants <3years, or adults >16 years old. They also noticed that 
the known MB oncogenes OTX2 and FOXG1B are highly expressed within group C and 
D. MYC, however, was highly expressed within both WNT and C groups. Regarding 
gender, the SHH subgroup was more common within males more than females; 1.55:1, 
respectively. Another important outcome established in this study was a new diagnostic 
classifier based on immunohistochemistry, with exclusive expression of DKK1 in WNT 
subgroup, SFRP1 in SHH, NPR3 in C subgroup, and KCNA1 in D subgroup (Northcott 
et al., 2011). 
In 2012, a further metagene analysis advanced the consensus view that MB can 
be subdivided into four subgroups, and put forward a revised group nomenclature - with 
Group C and Group D of Northcott et al., (2011) becoming Group 3 and Group 4 
respectively (Taylor et al., 2012). Despite these advances in molecular classification, 
there is no clear correspondence between the new molecular subgroups and established 
histopathological subtypes. For instance, half of SHH subtypes present with 
desmoplastic histology and the remaining half of SHH MBs with anaplastic 
histopathological features (Hatten and Roussel, 2011). This overlap suggests that further 
genetic characterisation and identification of further genes involved in MB development 
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will be required to resolve phenotype/genotype relationships. The following sections 
will discuss the different MB subgroups in more detail. 
 
1.3.2.1 SHH subgroup tumours 
 Approximately 25-30% of MB samples are defined by disruption of the SHH 
signalling pathway (Jones et al., 2012;Kool et al., 2012;Robinson et al., 2012).  The 
most frequent histological feature within the SHH subgroup is desmoplastic histology 
which is observed in ~89% of tumours from infants (0 < 4 years), and in 25% of 
tumours from older children (4 – 16 year) (Kool et al., 2012). The age distribution of 
this subgroup is characterised by a bimodal distribution shape as patients are either 
infants or adults (>16 years) (Kool et al., 2012). In adults, SHH subgroup tumours 
account for almost half of all tumours (Remke et al., 2011). In terms of prognosis, 
patients with SHH supgroup tumours have a better prognosis if they are infants (77% 
survival) rather than older children (51%) or adults (34%) (Kool et al., 2012).  
In regard to the gene expression that characterises this subgroups, several genes 
known to have roles in both SHH signalling pathway regulation and MB generation are 
exclusively expressed at a high level in this subgroup, such as PTCH1, SUFU, ATOH1, 
PTCH2, SERP1, SMO and GLI1 (Thompson et al., 2006;Kool et al., 2008;Jones et al., 
2012). The most frequent chromosomal aberration in SHH tumours is Chr9q deletion, 
observed in anything from 21–47% of tumours analysed (Kool et al., 2008;Northcott et 
al., 2011;Kool et al., 2012;Pugh et al., 2012;Li et al., 2013). Genes involved in other 
pathways, such as P53 and PI3K, have been recently shown to be disrupted in SHH 
subgroup MBs (MDM4 and PPM1D mutations and focal deletions of TP53, and 
PIK3C2G and PIK3C2B mutations). This suggests that these pathways could contribute 
to MB generation beside the SHH pathway (Northcott et al., 2012). Interestingly, 
(Northcott et al., 2011) established that 55/151 SHH MBs were from infants and were 
mainly localised in the vermis zone and were commonly metastatic. In contrast, 96/151 
SHH subgroup MBs were from adults, arose in hemispheres of the cerebella, and no 
metastases were observed. This suggests that further clinical and/or genetic subdivisions 
within the SHH subgroup remain to be defined. In regards to the medulloblastoma 
created from the Ptch1 model in this project, there was considerable variation in the size 
and position of tumours observed. Some were clearly confined to a single hemisphere of 
the cerebellum, while others affected both hemispheres equally. However, the precise 
position was not routinely recorded as material was collected on the basis of genotype 
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and/or the existence of neurological symptoms only. No confirmation of tumour 
presence was attempted at post-mortem. 
 
1.3.2.2 WNT subgroup tumours 
The WNT MB subgroup comprises about 10–15% of all MB samples (Li et al., 
2013). The study conducted by (Kool et al., 2012) reported that almost all (97%) of 
WNT subgroup tumours analysed by immunohistochemistry showed classic histology. 
WNT supgroup tumours were found to affect children and adults, but seem to be rarely 
observed in infants (1%). As mentioned above, (Kool et al., 2008) showed that mutation 
of CTNNB1 are common in WNT subgroup tumours, and 88.7% of all WNT subgroups 
tumours analysed by (Northcott et al., 2012) also had mutations of CTNNB1. In 
addition, at the chromosomal level, the complete or partial deletion of chromosome 6 
was recorded in 76.3 – 85% of WNT subgroup tumours, making it a hallmark of this 
group of MBs (Kool et al., 2012;Northcott et al., 2012). In children, this subtype of MB 
is usually associated with a good prognosis (Northcott et al., 2011). Analysis of the 
mouse model (Blbp-Cre, Ctnnb1lox
(ex3)/lox(ex3)
, Atoh1-Cre and Tp53
flx/flx
), where the 
WNT pathway is activated, suggests that the WNT MB subgroup may arise from the 
lower rhombic lip of the cerebellum (Gibson et al., 2010). 
 
1.3.2.3 Subgroup 3 and 4 tumours 
 These subgroups of MB have been collectively termed the non-WNT and 
non-SHH subgroups as they do not map to mutation/activation of known signalling 
pathways. Both subgroups do have some identifying clinical and molecular features. 
Most of the tumours in these subgroups are characterised by classical histology. 
However, at low frequency, subgroups 3 and 4 present with a desmoplastic appearance 
(Kool et al., 2012). These subgroups rarely present among infants and adults and both 
subgroups show a 2:1 excess of males to females within all ages analysed (Kool et al., 
2012). Furthermore, both subgroups display metastatic features at high frequency at all 
age groups; 30% for group 3 and 31% for Group 4, rising to 47% for Group 3 and 36% 
for group 4 tumours when infants only are analysed. Because of the high frequency of 
metastatic disease in these subgroups, it is not surprising that prognosis for both groups 
is poor relative to WNT and SHH subgroups. 
In terms of cytogenetic alterations, Group 3 is associated with gain of 
chromosome 1q, loss of 5q 10q, and MYC amplification. Both Group 3 and 4 tumours 
have a high incidence of isochromosome 17q, although this is higher in group 4 (66%) 
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than Group 3 (26%) (Jones et al., 2012), while Group 4 shows frequent loss of the X 
chromosome in affected females (Taylor et al., 2012). Although these subgroups show 
similar expression patterns to each other for most genes, which makes them difficult to 
distinguish, they both have some distinctive genetic expression patterns. Specifically, 
high expression of genes involved in the cell cycle and the p38 mitogen-activated 
protein kinase (MMAPK) pathway in Group 3, and high expression of genes involved in 
neuronal differentiation/development and cytoskeleton organisation in Group 4 (Kool et 
al., 2008;Northcott et al., 2011).  
 
1.4 Signalling pathways involved in MB 
  Through molecular analyses, including those outlined above, several known 
signalling pathways have been implicated in the development of MB, with the pathways 
known to have the most critical role being the Shh and Wnt pathways which define two 
of the MB subgroups (Northcott et al., 2011). 
 
1.4.1 The SHH/PTCH signalling pathway 
Signalling by the hedgehog (Hh) family of secreted glycoproteins is implicated 
in the determination of embryonic cell proliferation and migration, specification of 
organ size, and patterning of several tissues including skin, lung, brain, bone, and blood. 
The Hedgehog family of proteins includes Sonic Hedgehog (SHH) {7q36}, Desert 
Hedgehog (DHH) {12q13.1}, and Indian Hedgehog (IHH) {2q33–q35} (Pola et al., 
2003). The SHH pathway plays a critical role in histogenesis, and dysfunctions in the 
pathway have been associated with several human syndromes and neoplasms. Indeed, 
the elucidation of the molecular pathways involved in medulloblastoma initiation and 
promotion came from the association between SHH with Gorlin syndrome (Dhall, 
2009). SHH is known to stimulate the proliferation of cerebellar granule neuron 
prescursor cells (GNPCs) by activating the Gli transcription factors (GLI1, GLI2), and 
inhibition of SHH signalling in vivo leads to a reduced number of granule neurons (Hui 
et al., 1994). Mutations (resulting in pathological activation) in a subset of SHH-
responsive cells result in unrestrained cell division and, eventually, medulloblastoma. 
Initial mutations were identified in the PTCH1 gene (Pazzaglia, 2006). PTCH1 is a 
trans-membrane protein that acts as a receptor for SHH. In the absence of a signal from 
SHH, PTCH1 switches off the pathway by binding to Smoothened (SMO). Upon SHH 
binding to PTCH1, the pathway is switched on and the signal is transduced to SMO, 
then into the nucleus where it activates Gli transcription factors (Rossi et al., 2008). 
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Loss-of-function mutations in PTCH1 and Suppressor-of-Fused (SUFU) (a downstream 
molecule in SHH signalling cascade) occur in medulloblastomas (Zurawel et al., 2000), 
and according to (Pazzaglia, 2006) 25% of sporadic human medulloblastomas have 
PTCH1, SMO or SUFU mutation. 
Based on the above findings, researchers have argued that tumours associated 
with excessive hedgehog signalling might result from dysregulated self-renewal 
properties of cancer stem cells (CSC) (Sutter et al., 2010); however, many questions 
remain regarding the repertoire of genes activated by the SHH pathway and the extent 
of their overlap in different subtypes of MB. 
 
1.4.2 Wnt/Wingless (WNT) signalling pathways in Medulloblastoma  
The association between medulloblastoma and the WNT pathway was initially 
suggested by patients with Turcot syndrome. These patients have germline mutations in 
the adenomatous polyposis coli (APC) gene and have a 92-fold higher risk of 
developing medulloblastomas and other neuroepithelial tumours relative to the general 
population (Hamilton et al., 1995). Like SHH, the WNT pathway also plays a key role 
in embryogenesis. In this pathway, Wnt ligand associates with its receptor Frizzled 
(FZD), which in turn phosphorylates Dishevelled. Dishevelled then triggers the release 
of β-catenin from an inhibitory complex comprising (APC) and the Axin proteins 
(AXIN1, AXIN2). Subsequent translocation of β-catenin into the cell nucleus is 
presumed to mediate tumourigenesis via the aberrant activation of oncogenes such as 
cyclin D1 (CCND1), MYC, AXIN2 and RE1-silencing transcription factor (REST) (Huse 
and Holland, 2010). The association between Wnt pathway mutations and 
medulloblastoma tumourigenesis has been confirmed by a study which found that 
approximately 20% of patients with medulloblastomas have mutations in APC, AXIN1, 
AXIN2 or CTNNB1 (which encodes β-catenin) (Huse and Holland, 2010). 
 
1.4.3 Other signalling pathways involved in MB 
In addition to the pathways which define specific subgroups, alterations in a 
number of other known signalling pathways have been implicated in MB. For instance, 
Fan et al., (2006), has suggested that NOTCH signalling is involved. The Notch 
signaling pathway is initiated by ligand binding to transmembranous receptors (Notch 1 
– 4) followed by an intracellular signal transduction cascade initiated by the g-secretase 
complex at the intracellular portion of Notch. Cleavage of Notch results in the release of 
the intracellular domain of Notch (ICN) into the cytoplasm and its subsequent 
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translocation into the nucleus where it promotes the transcription of several target genes 
(Hairy/Enhancer of split (Hes 1-7); cyclin D1 and apoptosis related genes, among 
others). Overexpression of Notch2 and Hes1 has been shown to promote 
medulloblastoma tumorigenesis in mice, while Notch1 inhibits the process. 
Furthermore, NOTCH2 over-expression has been demonstrated in human MB (Fan et 
al., 2004;Xu et al., 2009). However, precisely how NOTCH signaling affects 
tumorigenesis has yet to be elucidated (Hatton et al., 2010). 
  The epidermal growth factor receptor (EGFR) family of receptor tyrosine 
kinases (including ERBB1- ERBB4) have also been implicated in MB. Approximately 
80% of all medulloblastomas have been shown to overexpress ERBB2, while 
overexpression of ERBB4 is observed in tumours showing GLI1 repression (de Bont et 
al., 2008). The over expression of ERBB2 and ERBB4 has also been linked to poor 
prognosis (Kim et al., 2010). EGFR signalling can lead to sequential phosphorylation of 
several proteins downstream, including proteins within the Ras/Raf pathway, signal 
transducers and activators of transcription (STAT) pathway, the Akt pathway and 
mitogen-activated protein kinase (MAPK) pathway, which collectively affect cellular 
functions such as differentiation, proliferation, apoptosis, and survival (Huse and 
Holland, 2010).  
Finally, Bone morphogenetic proteins (BMPs), soluble effectors of 
differentiation belonging to the Transforming growth factor (TGF-b) family of 
cytokines (Fogarty et al., 2007), have been implicated in MB development by (Rios et 
al., 2004). They demonstrated that BMP2 antagonizes SHH dependent proliferation by 
expressing TIEG1 which downregulates MYCN transcription. Subsequent gene profiling 
by (Zhao et al., 2008), reported that several genes within the BMP signaling pathway 
are repressed in medulloblastomas with constitutive SHH pathway activation.  The 
BMP signaling pathway has been implicated in cell cycle exit, migration and 
differentiation of GNPCs during embryogenesis (Roussel and Hatten, 2011).  
 
1.4.4 Epigenetic and MicroRNA silencing in medulloblastoma  
While the role of loss of function mutations in the tumorigenesis of 
medulloblastoma is well defined, recent evidence indicates that both epigenetic and 
microRNA silencing also play significant roles in tumorigenesis (Shahi et al., 2011), 
and in some instances may affect genes involved in the pathways outlined above.  
Epigenetic changes linked to cancer include histone modification via 
acetylation, methylation and phosphorylation, and hypermethylation of CpG motifs in 
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DNA promoter regions (Vibhakar et al., 2007). Several oncogenes have been shown to 
be epigenetically silenced in medulloblastomas. These include: SFRPs genes, the S100 
gene family, Kruppel-like factor 4 (KLF4), HIC1 and RB1 (de Bont et al., 2008;Roussel 
and Hatten, 2011). Furthermore, a recent study by Nakahara et al., (2010), concluded 
that KLF4 is repressed either by a genetic or epigenetic mechanisms in 
medulloblastomas and that it may function as a tumor suppressor. Using whole-genome 
microarray analysis in combination with trichostatin A (TSA), a histone deacetylase 
inhibitor (HDAC), Vibhakar et al., 2007, demonstrated that several genes including 
Dickkopf -1 (DKK1), a Wnt antagonists, are upregulated on HDAC inhibition. 
MicroRNAs are 18-22 nucleotide long RNA sequences which are transcribed 
from noncoding parts of the genome and have post transcriptional gene silencing 
activity (Venkataraman et al., 2010b). Generally, miRNAs repress translation of mRNA 
by base pairing with the 3’-untranslated region (3’ UTR). In some instances, they can 
mediate mRNA degradation. While the exact role of miRNA is only beginning to 
emerge, some reports have implicated them in tumor formation and inhibition (Kefas et 
al., 2009).  Overexpression of miRNA 21 is associated with glioblastoma while miRNA 
128a is strongly down regulated in medulloblastoma (Venkataraman et al., 2010a). 
Consistent with these findings, Northcott et al., (2009), demonstrated that miRNAs in 
the 17/92 cluster function as oncogenes in MBs with an SHH signature. In another 
study, it has been demonstrated that neuronal miRNA-326 acts in a feedback loop with 
NOTCH1 and has prospects as a therapy against neurologic tumors (Kefas et al., 2009). 
 
1.5 High throughput MB cancer gene discovery.  
Microarray analyses, and particularly their integration with clinical information, 
cytogenetics, and details of tumour pathology, have provided insight into MB subgroup 
structure and their potential importance in prognosis and treatment. However, they have 
also highlighted the need to dissect tumorigenesis further, to identify additional genes 
involved in the disease progression in different subgroups, and identify new 
therapeutics tagets. Critically, while microarray analyses have identified hundreds or 
thousands of genes which show subgroup specific expression patterns, establishing 
which are critical to the disease process, as opposed to incidental or downstream 
correlates, is not straightforward. The development of next generation sequencing 
technologies has recently enabled an additional layer of information to be cross 
referenced to such analyses.  
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The first large scale MB sequence analysis used high-density microarray 
analyses and sequencing of almost all coding exons of known genes and miRNAs to 
analyse a cohort of 22 human MB (Parsons et al., 2011). In total, 96% of target 
amplicons and 95% of target bases were successfully amplified and sequenced. 225 
somatic mutations were identified, 199 of them point mutations, with 183 being non-
silent mutation (Parsons et al., 2011). Importantly, in addition to the detection of 
alterations in the SHH and WNT pathways, inactivating mutations of the histone lysine 
N-methytransferase genes (MLL2 or MLL3) were identified in approximately 16% of 
analysed MB (Parsons et al., 2011).  
Although comprehensive, studies such are this are not capable of identifying all 
mutagenic events. For instance, noncoding mutations, copy number changes, and 
epigenetic alterations will not be identified. It is noteworthy that the authors of this 
exome sequence analysis pointed out that the initiating events in over 50% of MBs 
remained to be identified (Parsons et al., 2011).  
 
1.6. Transposons and their application to cancer gene discovery 
There is clearly a need for complementary, experimental, cancer gene 
identification methods (Parsons et al., 2011), both to identify cancer genes not 
qualitatively altered during cancer development, and to provide confirmatory evidence 
of the relevance of genes already implicated in disease by high throughput quantitative 
analyses such as those described above. The primary aim of the work described in this 
thesis is to use one such technique, transposon mutagenesis screening, to identify genes 
involved in medulloblastoma. Such screens are performed in murine models of disease, 
and comparative analyses of human and mouse datasets can then be employed to 
identify key genes involved in disease in both species for further investigation, and to 
shed light on the underlying biology of tumour development. 
 
1.6.1 Transposons 
Transposons are mobile segments of DNA which are present in virtually all 
genomes. In man, they constitute close to 45% of the entire human genome (Feschotte 
et al., 2002). These mobile segments of DNA use mechanisms that are distinct from 
recombination to insert themselves at different locations within the host DNA. These 
segments of DNA can travel not just within a particular genome but also between 
species. Interspecies transfer of transposons is referred to as horizontal gene transfer (de 
la Cruz and Davies, 2000). 
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Structurally, transposons exhibit great variability, with some containing only 
those sequences which are essential to their own transposition. Other transposons have, 
in addition, genes which code for many other functions that have no bearing whatsoever 
on their movement. However, they all have certain features that are common (Grabher 
and Wittbrodt, 2007): First, most transposable elements are flanked by direct repeats. 
These repeats are usually 3 to 12 bp long and do not move with the elements as they are 
not part of the transposon. These repeats are generated during transposition as a result of 
DNA repair at the insertion points, and the repeat sequences differ depending upon the 
insertion site. However, each type of transposable element has an unchanging flanking 
repeat length. These flanking direct repeats are indicative of staggered cuts which are 
made when insertion takes place. This process is depicted in Figure 1.5. Once the 
staggered cuts are made, short single stranded DNA sequences are generated on either 
side of the transposon, and flanking direct repeats created once replication of these 
sequences takes place ((Zayed et al., 2004). 
 
 
Figure 1.5. Generation of flanking direct repeats during the insertion of a transposable 
element into DNA. Firstly the DNA will be open via a struggered cut. Then the insertion of the 
transposable element will take place. This will leave a small footprint sequences in the DNA. 
The last step is the replication of flanking direct repeats. (Adapted from Pierce 2008). 
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Second, most transposons have terminal inverted repeats. These are sequences 
which are seen at the ends of the transposons and which range in size from 9 to 40bp. 
The terminal inverted repeats are important in the movement of the transposons. Figure 
1.6 depicts the features that are commonly found in different transposable elements 
(Grabher and Wittbrodt, 2007). 
 
Figure 1.6. Features common to most transposable elements. Many transposable elements 
create flanking direct repeats upon insertion, and many contain terminal inverted repeats 
(Adapted from (Pierce, 2008). 
 
Eukaryotic transposons can be split into two subdivisions: The first group 
replicates using DNA intermediates; the second group consists of retrotransposons 
which replicate via an RNA intermediate. They do not code for a transposase enzyme 
and typically replicate like retroviruses (Kalendar et al., 1999).  
 
1.6.2. Transposition 
Transposition is the transfer of a short segment of DNA to another position on 
the DNA strand. The steps involved in transposition are common to eukaryotic and 
prokaryotic elements. First, staggered cuts are created in the DNA where the 
transposable element will be inserted. Next, the transposon attaches to the single-
stranded ends of the target DNA. Finally, replication of the DNA at the single stranded 
openings occurs. Transposition may be carried out via DNA or RNA intermediates; 
when DNA intermediates are used, either replicative or non-replicative transposition 
can occur (Izsvak et al., 2009).  
 Replicative transposition involves an increase in the number of transposons. A 
new copy of the transposon is inserted at a new location even as the old one is left at the 
original location. This method is also called copy and paste transposition (Kazazian, 
2004). This mode of replication can take place between 2 distinct DNA molecules or 
between 2 segments within the same DNA molecule. Unlike replicative transposition, 
non-replicative transposition does not involve the replication of the complete 
transposable element. Rather, the element moves from one location to another location. 
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This involves only the cleavage of the target DNA and the insertion and joining of the 
transposon in the opening that has been created by the cleavage. The cleavage is carried 
out by a transposase which is encoded by the transposon (Tavakoli and Derbyshire, 
2001) . 
Retrotransposons are transposons which use RNA intermediates. The use of 
RNA intermediates requires an additional step of conversion to double-stranded DNA 
with the use of the enzyme reverse transcriptase (Kalendar et al., 1999). 
 
1.6.3 Transposition and Cancer 
There is a strong association between transposition and mutagenesis. This is 
because transposons can interrupt genetic function when inserted into genes. Studies 
shown that more than 50% of all mutations in the fruit fly Drosophila melanogaster that 
are caused by spontaneous mechanisms are a direct consequence of transposition of 
elements into, or adjacent to, a functional gene (Chung et al., 2008b). The mutations 
induced by transposition are usually harmful but some have also been noted to be of 
considerable benefit to the affected organism. For instance, some transposons carry 
genes that code for antibiotic resistance in some bacteria (de la Cruz and Davies, 2000). 
Neurofibromatosis is an example of a human cancer which can occasionally result from 
knockout of one copy of the NF1 gene as a result of transposition. This has been 
observed to be caused by an Alu sequence inserting into an intron of the NF1 gene 
(Wallace et al., 1991). Insertion of the Alu sequence into this gene induces an error in 
RNA splicing and the net result is that one of the exons of the gene is omitted in the 
resultant mature mRNA. The omission of this exon causes the reading frame to shift. As 
a result, translation of the mRNA yields abnormal proteins that precipitate the disease.  
Rearrangements can also occur due to the transfer of genetic material and 
recombination during transposition, and these can induce mutations that are 
carcinogenic. Inversions, deletions, and duplications can result due to homologous 
recombination (Ivics et al., 1997;Izsvak et al., 1997;Izsvak et al., 2009). Non-
replicative transposition can also lead to rearrangements which can then cause cancers. 
This can happen if repair of the broken DNA is not carried out effectively. If the repair 
fails to take place, a deletion will occur since the acentric fragment will get lost. Other 
diseases which have been linked to transposition events include muscular dystrophy and 
haemophilia (Li et al., 2001;Ostertag et al., 2007).  
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1.7 Transposons as a cancer gene discovery tool 
A wide variety of techniques and strategies have been developed to identify 
genes responsible for the promotion of cancerous cells. In addition to genetic mapping 
and mutation detection techniques that can identify germline and somatic mutational 
events within human tumours (Mattison et al., 2009), a variety of mutagens have been 
used in forward genetic screening to induce mutations within model organisms (Starr 
and Largaespada, 2005). Until relatively recently, matagenesis screens were usually 
performed using radiation or chemicals, and have been associated with a high mutation 
frequency (Starr and Largaespada, 2005). However, the task of identifying the genes 
responsible for any resultant phenotype was usually time consuming and challenging, 
due to the fact that large-scale mutations affecting multiple genes can be induced, and 
because mutations induced by these methods need to be mapped genetically (Collier 
and Largaespada, 2007b;Grabher and Wittbrodt, 2007). 
Retroviruses and transposon mutagenesis have become popular alternatives to 
the above techniques to identify the genes that predispose an organism to cancer, and 
make identification of the mutagenic events more straightforward as the mutations have 
the molecular tag of insertion. However, retroviruses are active in a limited number of 
cell types, and these are invariably actively dividing cells (Pajer et al., 2006). Recently, 
several transposon systems have been developed which circumvent this limitation. One 
system, known as Sleeping Beauty (SB), has the ability to perform in a wide variety of 
somatic cells of the target organism, thereby allowing for a wide range of cancer types 
to be analysed (Collier et al., 2005).  SB is a deployed system, consisting of a defective 
transposon (T2/Onc) or its derivatives (T2/Onc2 and T2/Onc3), and the active enzyme, 
the transposase (SB10 or SB11) (Collier et al., 2005;Dupuy et al., 2009). This system is 
based on a “cut-and-paste” mechanism, in which the transposase excises T2/Onc from 
donor DNA and inserts it into the target DNA (Ivics et al., 1997). The inserted 
transposons can cause pseudo-random insertional mutations. Because the T2/Onc 
transposon has been engineered to contain splice acceptor (SA) and splice donor (SD) 
signlas, poly-adenylation (PA) signals, and an enhancer (from the murine stem cell 
virus, MSCV), it can induce both loss and gain of function mutations (Collier et al., 
2005). 
The SB system of murine cancer mutagenesis has become a useful tool for 
identification of cancer genes since the proof of principle was published in 2005. This 
landmark work (Collier et al., 2005), used SB to increase the frequency of sarcomas 
generated in Arf-deficient mice. A series of 45 common insertion sites were identified 
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and mutations in Braf were detected in 22 tumours. SB mutagenesis has since been used 
successfully as a tool to identify candidate cancer genes in adult tumours, such as Zmiz1 
in squamous-cell carcinoma and Rian in hepatocellular carcinoma, Smad4, Pten and 
ApcI in colorectal cancer, Pde4d in prostate cancer, and Csf1 in high-grade astrocytoma 
(Dupuy et al., 2009;Rahrmann et al., 2009;Starr et al., 2009;Bender et al., 2010).  In 
addition, several SB studies have generated MBs at low frequency in both tumour 
models and wild-type mice (Dupuy et al., 2005;Su et al., 2008;Collier et al., 2009). 
This suggests that this system is capable of causing mutations within one or more MB 
cell of origin, and suggests that it might prove effective if applied to a MB specific 
cancer model. 
 
1.8 MB murine models available for transposon screens. 
The aim of the work described here is to identify cancer genes relevant to MB. 
Screens which analyse a specific cancer type have mutagenised existing cancer models, 
aiming to identify genes which interact with the cancer predisposition (when mutated by 
the SB transposon) by altering tumour penetrance or latency. The choice of cancer 
model used in the mutation screen is therefore likely to have a major impact upon the 
spectrum and relevance of the genes identified. A model which clearly recapitulates the 
human disease, and where the predisposition is understood, would be preferred to a non-
specific model.  
At the outset of this work there were several MB mouse models which could be 
used for mutagenesis studies, all modelling the SHH subgroup of tumours and each 
created by targeting components of the Shh pathway. One is a Sufu+/-/Tp53-/- model 
(Lee et al., 2007) where a gene trap approach was applied to obtain the Sufu mutation. 
The Sufu null mice are embryonic lethal, with arrest at embryonic day 10 (E10). The 
median survival of Sufu+/-;p53-/- mice is 4 months with a tumour penetrance of 58%. 
The Sufu+/-;p53-/- tumours express genes which are hallmarks of Shh signalling 
pathway activation such as N-myc, Sfrp1, Ptch2, and cyclinD1. These results indicate 
that this model could be used for mutagenesis, although Tp53 mutations are not a 
hallmark of this tumour type. 
 Another model was created by expressing a constitutively active form of 
Smoothened (SmoA1 and SmoA2) – a down stream target gene of Shh signalling – under 
the control of NeuroD2 (ND2) (Hallahan et al., 2004). This ND2;SmoA1 line 
developed MB in about 48% of animals with a median age of 25.7 weeks. The tumours 
showed significant proliferation of GNPCs and the expression of Gli1 and N-myc were 
 22 
also observed at high levels, indicating the stimulation of the Shh pathway. Notch 
signalling was also investigated in these tumours via down stream targets (Notch2 and 
Hes5) and their expression was enhanced, confirming the efficient induction of the 
Notch pathway by Shh pathway activity (Hallahan et al., 2004). The authors concluded 
that both the Shh and Notch pathways contribute to the development of MB tumours in 
this mouse model and in humans as well. The same group of researchers have more 
recently generated a further model with homozygous knock out of Smoothened 
(Smo/Smo), (Hatton et al., 2008). With this double mutation, MB incidence was 
significantly elevated up to 94% within 4-8 weeks. It is noteworthy that tumours in this 
model present with leptomeningial metastases.  The elevated tumour incidence, early 
mode of onset, and metastases make it useful for analysis of the SHH subgroup of MB. 
However, by far the most extensively studied model is the Ptch1+/- mouse 
model (Goodrich et al., 1997), and this will be described in the following section.  
 
1.8.1 Ptch1 Murine Model of Medulloblastoma  
The PTCH1 gene is the human homolog of the Drosophila patched gene and is 
localized on chromosome 9q22.3 (Gailani et al., 1992;Johnson et al., 1996). This gene 
codes for the Patched 1 (PTCH1) receptor which plays an important role in 
embryogenesis. This receptor is an attachment site for the Sonic hedgehog-signalling 
molecule (Shh) that is vital for the development of several tissues and organs. The 
activation of the signalling pathway occurs when Shh binds to the Ptch1 receptor 
(Figure 1.7). In the absence of Shh, another protein called Smoothened or Smo is 
inhibited. This inhibition is removed when Shh attaches to Ptch1, causing the Gli 
transcription factors to stimulate the expression of downstream target genes which 
regulate the differentiation and proliferation of cells (Pazzaglia, 2006). However, 
artificial mutations of Ptch1, SMO, and SuFu have been shown to stimulate the Shh 
pathway continuously, leading to major disruption in cellular microenvironmental 
conditions within the affected organs, and this may leads to tumourigenesis (Goodrich 
et al., 1997; Hallahan et al., 2004; Lee et al., 2007) 
Mutations of the PTCH1 gene have been associated with the basal cell nevus 
(BCN) syndrome. Studies also show that neoplasias such as MB and the basal cell 
carcinomas (BCC) can harbour mutations on this gene. These are autosomal dominant 
conditions (Dhall, 2009). Several other studies have linked prostate cancer, breast 
cancer, human small-cell lung cancers, human pancreatic carcinomas and digestive tract 
tumors to dysregulation of the Shh pathway and consequently to mutation of the 
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PTCH1 gene (Lewis et al., 2001;Berman et al., 2003;Thayer et al., 2003;Karhadkar et 
al., 2004;Kubo et al., 2004;Sanchez et al., 2004;Sheng et al., 2004). 
  
 
 
In the Ptch1 +/- model developed by Goodrich et al., 1997, part of exon 1 and 
all of exon 2 of Ptch1, the murine ortholog of the human PTCH1 gene, were replaced 
with LacZ. Homozygous Ptch1-/- mice died during embryogenesis, and this was 
concluded to be due to heart malformation. Medulloblastoma frequency in heterozygous 
mice was originally recorded as 14%, with MB development reaching the peak between 
12 – 25 weeks, although the genetic background does affect this (Wu et al., 2012). 
Histologically, the tumours generated by this model have similar features to those from 
human medulloblastomas, being characterised by small undifferentiated tumour cells 
consisting of dark carrot-like nuclei and small cytoplasmic volume.  
The Pcth
+/-
 model has since been crossed to Tp53
+/-
 mice to investigate the 
incidence of MB formation (Wetmore et al., 2001). This increased the incidence of MB 
Figure1.7: Summary of the sonic Hedgehog (Shh) pathway: When Shh ligand is 
absent the pathway is inactivated via the inhibition of Smoothen (Smo) by Ptch1, 
where both are located on the cell wall. Activation of the signalling pathway occurs 
when Shh binds to the Ptch1 receptor, causing a protein called suppressor of Fused 
(Sufu) to release the Gli transcription factors into the nucleus. Consequently, Gli 
factors stimulate the expression of downstream target genes which regulate the 
differentiation and proliferation of cells. Mutations in Ptch1, Smo or Sufu, can make 
Shh pathway continuously active, which may leads to tumourgenesis. 
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to more that 95% and reduced the latency to 10-12 weeks postnatally. On the other 
hand, Tp53-/- mice develop MB like tumours in ~5% of experimental animals. To 
investigate the role of the retinoblastoma  (Rb) pathway in MB incidence, the model 
was also placed in an Ink4c-/- background (Ink4c is a downstream target of Rb). The 
incidence of MB was appreciably increased in Ptch+/-;Ink4c+/- or Ink4c-/- mice from 
7%-30% with a very short latency. However, the Ink4c-/- mice did not show tumours 
production (Uziel et al., 2005). 
Because of the extensive characterisation of this model to date, the strong 
similarities between the tumours it generates and human tumours, and the relatively low 
penetrance of the original model (potentially allowing any interaction with a mutagen to 
be easily observed), it was chosen for the mutagenesis study reported here.
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1.9 Cerebellar structure and development 
Medulloblastoma, like many childhood tumours, is considered a disease of 
development. As a result, the impact of aberrant SHH signalling upon tumour 
development can only be fully understood within the context of its role in normal 
cerebellar structure.  The word cerebellum was originally coined from latin, and means 
small brain. The cerebellum is located at the base of the skull, above the pons and brain 
stem, and below the cerebral cortex. It consists of a massive number of neurons, 
principally granule cells. The cerebellum has several functions, the most important and 
well characterised relating to fine motor control (processing neuronal outputs of activity 
to coordinate muscular movement), cognitive functions (including learning), balance, 
and muscle tone (Martin, 2003). 
The adult cerebellum is composed of two structures; the cortex (outer layer) and 
the medulla. The cerebellar cortex itself consists of 3 layers. The first is the outer 
molecular layer, which contains 2 types of neurons, known as the stellate and basket 
cells, in addition to specialised structures called parallel fibres. These fibres are present 
in large numbers and are the extended axons of granule cells, the most abundant neuron 
type in the cerebellum. The next layer, the intermediate/ganglionic or Purkinje layer, is 
composed of purkinje cells, neurons which can be stimulated by the parallel fibres 
present in the molecular layer. Their axons have the ability to stimulate the deep 
cerebellar nuclei. The last layer, the cortex or inner granular layer, consists primarily of 
the cell bodies of granule cells and Golgi cells. Five types of neurons are, however, 
found in this layer and most are considered inhibitory, as they secrete the inhibitory 
neurotransmitter GABA. In addition to these structures, 2 types of sensory fibers are 
found in the cerebellum; climbing fibers (derived from the inferior olivary nucleus) 
which synapse with purkinje cells, and mossy fibers. The basic structure of all 3 layers 
is shown in Figure 1.7 (Voogd and Glickstein, 1998). In humans, granule neuron 
precursor cells (GNPCs) account for ~40% of all neurons, and approximately 45 billion 
out 110 billion neurons in the brain are GNPCs. 
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At early stages of embryonic development (~E10.5 in mouse) brain tissue is 
organised into three different segments known as the prosencephalon (forebrain), 
mesencephalon (midbrain) and rhombencephalon (hindbrain) (Figure 1.8A). The 
cerebellum arises from the most caudal of these, the rhombencephalon. The 
rhombencephalon is composed of 8 loops, known as rhombomeres, and the cerebellum 
develops from rhombomere 1, the most proximal of these. The neurons of the 
cerebellum develop from two main germinal zones - the ventricular zone and the 
rhombic lip, a structure which skirts the roofplate of the 4
th
 ventricle of the brain (Figure 
1.8B). The cerebellar cortex and cerebellar nuclei are generated by a complex pattern of 
cell movement and signalling (Fink et al., 2006). In this process, GABAergic neurons 
of the cerebellar cortex (the Purkinje cells and neurons of the cerebellar nuclei, among 
others) arise in the ventricular zone (VZ) and migrate to the core of the developing 
cerebellum (Lin and Cepko, 1999;Morales and Hatten, 2006). After this, at 
Figure 1.8: Cerebellar anatomic structure: The two main cerebellar layers, the 
cerebellar cortex and the white matter are shown. The cerebellar cortex consists of 
molecular, ganglionic (Purkinje) and granular layers.  Stellate and basket cell are 
within the molecular layer. Purkinje cells are within the Purkinje layer. Granule 
and Golgi cells are within the granule layer. Climbing fibers and mossy fibers are 
shown. Purkinje cells axon projected towards cerebellar nuclei are shown. 
niversity of Tartu, http://sisu.ut.ee/histology/cerebellum)(Adapted from U 
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approximately E12, the granule neuron precursor cells (GNPCs) start to proliferate and 
migrate from the secondary germinal zone, the rhombic lip, forming the external 
granular layer (EGL). These then exit the cell cycle, begin to differentiate and migrate 
internally to form the internal granular layer below the Purkinje cells with which they 
have synapsed. Loss of the EGL is complete after approximately 2 weeks of postnatal 
development in the mouse to leave the three layers of the adult cerebellar cortex. 
 
 
 
 
  
 
Figure 1.9: Schematic showing different parts of the embryonic developing brain, 
and position of the rhombic Lip relative to hindbrain. (A) The three different segments 
of the developing brain. (B) Dorsal appearance of the neural tube and the neuroepithelium 
of the rhombic lip (dark gray) and the roof plate (light grey). The empty grey arrows show 
the divergent movement behavior of the LRL. Figures adapted from (Landsberg et al., 
2005) and Early brain development (http://mdc06kb.webnode.com). 
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1.10 Medulloblastoma cells of origin  
Although the precise origins of the various subtypes of medulloblastoma remain 
to be elucidated, recent evidence point to the existence of cancer stem cells (CSC) or 
cancer propagating cells (CPCs) which maintain the neoplastic cells (Uchida et al., 
2000;Reya et al., 2001). These cells are thought to be similar to normal stem cells 
which are involved in the development of cerebellar tissue; however it is presumed that 
their replication and differentiation pattern is aberrant (Gilbertson and Ellison, 2008). 
Currently, different models, including the stochastic model, queen model, hierarchical 
model and plasticity model, have been proposed to account for the clonal evolution of 
brain cancer propagating cells (BCPCs) from CSC (Hadjipanayis and Van Meir, 2009). 
In medulloblastoma, the first BCPC candidate was isolated by (Singh et al., 2004). The 
cells were identified by virtue of expressing prominin 1 (CD 133) – a marker of normal 
neural stem cells. Subsequent studies demonstrated that between 1-21% of freshly 
isolated medulloblastoma cells express CD 133 (Singh et al., 2004;Calabrese et al., 
2007). Other markers which have been linked to BCPCs include Musashi1, an RNA-
binding proteins (Kaneko et al., 2000); the oncogene Bmi1 (Leung et al., 2004;Bao et 
al., 2006); the transcription factor Sox2 (Bao et al., 2006) identified in Glioma stem 
cells; the cell cycle regulator MELK (Nakano et al., 2008); the signaling pathway 
protein NOTCH (Fan et al., 2006) and A2B5, a ganglioside antigen (Read et al., 2009). 
However, the existence of BCPCs is still controversial (Rich and Eyler, 2008).    
Related to the controversial notion of the existence of CPCs, is the suggestion 
that the large population of proliferating GNPCs includes subpopulations of pre-cursors 
with distinct genetic profiles which may give rise to one or more of the different 
subtypes of medulloblastoma (Gong et al., 2003;Hatten and Roussel, 2011). Support for 
this hypothesis has come from a large-scale CNS gene expression atlas (GENSAT 
Project), which established that some genes implicated in MB are differentially 
expressed in particular subsets of GNPCs at various developmental stages (Gong et al., 
2003). Indeed, research has shown that cells isolated from MB samples express GNPCs 
markers such as p75NTR, TrkC, Zic1 and Math1 (Pomeroy et al., 1997;Salsano et al., 
2004).  
Recently, (Yang et al., 2008) has provided evidence that medulloblastomas 
originate from GNPCs. Furthermore, they also implicate stem cells in medulloblastoma 
generation. They conditionally knocked out Ptch1 through Math1-Cre to create a 
Math1-Cre/Ptch1
C/C
 mouse. These mice should generate Ptch1 knockout in GNPCs 
only. This was confirmed by the expression of a GFP reporter in the cerebellum only of 
 29 
P8 neonatal mice. The deletion of Ptch1 was confirmed by detection of Shh signalling 
activation and by increased expression of Gli1, Cyclin D1 and N-Myc as assayed by 
qPCR, and increased proliferative activity compare to wild-type cells. The authors also 
showed that the E.14.5 Math1-CreER/Ptch1
C/C
 mice (a stage when Math1 is only 
expressed in GNPCs) when treated with tamoxifen - a substance that activates estrogen 
receptor (ER) - developed tumours at a frequency of 100%. Furthermore, postnatal 
examination of tamoxifen treated mice showed the development of cerebellar tumours 
by the age of 19 weeks giving further evidence that GNPCs are the cells of origin of 
MB. The effect of Ptch1 deletion upon neuronal stem cells (NSCs) was investigated in 
terms of tumours formation. The authors used Cre controlled by human glial fibrillary 
acidic protein (hGFAP-cre) mice to delete Ptch1 in NSCs. Tumours formation was 
observed in the hGFAP-cre/Ptch1
C/C
 mice during development and by 4 weeks of age 
these mice showed symptoms of neurological disease and tumour formation in their 
cerebella. Thus, while the precise cellular origin of MB subgroups remains to be 
established, in terms of whether these are true cancer stem cells or a pluripotent 
progenitor cell (Sutter et al., 2010), current evidence suggests that lineage commitment 
is required for MB development, and that the cells of origin of the SHH MB subgroup 
are GNPCs.  
 
1.11 The role of SHH in Cerebellar Development 
The role of the Shh signalling pathway as a mitogenic factor upon normal 
cerebellar GNPCs isolated from P4-7 mice has been examined. The proliferation rate 
was significantly higher within Shh+/+ GNPCs compared to Shh-/- GNPCs. This is 
consistent with the known proliferative role of Shh pathway upon GNPCs. Culturing 
purified GNPCs without recombinant Shh protein showed modest cellular 
proliferation. However, upon the addition of recombinant Shh protein t the 
proliferation rate increased to ~2.5X on average (Dahmane and Ruiz i Altaba, 1999).  
These results are supported by an independent study where GNPCs treated with 
recombinant Shh protein were analysed by flowcytometric analysis. The Shh GNPCs 
were abundantly distributed in G0/G1 phase, and ~16% were in S phase, compared to 
2.5% cells without Shh, being in S phase (after 36 hours experimental life). 
Interestingly, about 11.5% of all tested GNPCs were in S phase at 0 time (Kenney and 
Rowitch, 2000). The ectopic induction of the Shh signalling pathway was assessed by 
analysis of Gli1 expression. Gli1 is an Shh downstream target gene, the primary effector 
of the signalling pathway, and was utilised to give a direct sign of Shh pathway 
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induction. The Gli1 expression was higher in Shh+/+ GNPCs compared to Shh-/- 
GNPCs. This confirms that Shh pathway induction was obtained and that it has a 
functional effect on GNPCs in culture.  
These analyses are also in agreement with a previous study where GNPCs were 
treated with recombinant Shh protein and showed higher expression of Gli1 
(Wechsler-Reya and Scott, 1999). Importantly, the Shh pathway is known to maintain 
the treated cells in an undifferentiated state. Math1 expression was used as an indicator 
for undifferentiated neuronal cells (Wechsler-Reya and Scott, 1999). Math1 is a TF that 
is primarily expressed in the developing mammalian centeral nervous system (Helms 
and Johnson, 1998). The expression of this gene was found predominantly in the dorsal 
region of the neural tube near to the roof plate (Alder et al., 1996;Zhang and Goldman, 
1996). Helms and Johnson, (1998), found that Math1 was exclusively expressed within 
proliferating GNPCs, as Math1
+
 cells were localised only withing the proliferating zone 
of the external germinal layer (EGL).  The observation that Math1 expression was 
higher in Shh+/+GNPCs, relative to untreated, is indicative of maintenance of an 
undifferentiated state. 
Because of the early link between SHH signalling and Gorlin Syndrome, the 
impact of Shh signalling upon cerebellar development has been extensively analysed. 
Wallace, 1999, established in mice that Purkinje cells have the ability to control the 
proliferation processes of GNPCs by releasing Shh postnatally, creating a morphogenic 
gradient within the developing cerebellum. Furthermore, the authors demonstrated that 
key proteins mediating Shh signalling, such as, Ptch1, Gli1 and Gli2, are primarily 
expressed within the EGL during the postnatal period (Figure 1.9). The hypothesis of a 
morphogenic gradient was supported by the application of Shh proteins in vitro to 
sections of murine postnatal EGL which resulted in increased expression of Gli1, 
reduced differentiation, and a 20X increase in mitotic activity compared to other known 
mitogens (IGF1, EGF and bFGF) as assayed by the presence of bromodeoxyuridine 
(BrDu) (Wechsler-Reya and Scott, 1999). Conversely, in vivo experiments using Shh 
blocking antibodies by hybridoma cell implantation directly influenced the size and 
foliation of the developing cerebellum, indicating that Shh supports the definition of 
cerebellar size and foliation (Wallace, 1999).  
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1.12 Project Aim and outline of results chapters 
The analyses outlined above indicate that the primary defects of many MBs 
remain to be elucidated despite recent genome wide mutation analyses, that the 
Ptch1+/- murine model of MB produces tumours with a similar gross morphology to 
human tumours, and that the basic role of SHH signalling in cerebellar formation is 
understood. The primary aim of this project was to identify novel genes involved in 
SHH subtype MB using murine mutagenesis. As there is some evidence that the SB 
mutagenesis system is capable of generating MBs, this system was chosen as the 
mutagen and applied to the Ptch+/- murine model.  
In the first results chapter (Chapter 3), I will outline the screen and the initial 
results, which establish that SB mutagenesis impacts significantly upon MB frequency 
in the Ptch+/- model, and also generates additional tumour types including liver 
adenomas. I will also describe the subsequent mapping and identification of candidate 
cancer genes.  
Figure 1.10: The expression of downstream target genes for Shh signalling 
and its impact in/on the developing cerebellum. (A and B) Show expression 
of Gli1 in the cortex of the cerebellum; C and D, show expression of Ptch in the 
cerebellar cortex; E and F show that expression of Shh is confined to the 
Purkinje cells. cerebellar cortex. Expression appears as blue staining in both 
low and high magnification images. (Adopted from Wallace 1999) 
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In the second chapter (Chapter 4), I outline the results of gene specific PCR 
analyses which I applied to three genes; Tgif2, Nfia and EGFR, to confirm the validity 
of the insertion site data, together with gene ontology analyses which identified a 
significant excess of transcription factors and neuronal genes among the candidate 
genes identified. 
In the third results chapter (Chapter 5), bioinformatic analyses are presented 
which establish that the candidate genes not only share common ontologies, but are 
linked within a single gene expression network, the activity of which differs 
significantly among tumour subgroups and is associated with survival in human 
tumours. Additional evidence for the role of this network in tumour formation is also 
presented in the form of a comparative analysis with mouse gene expression I have 
generated from SB induced tumours.  
Finally, in Chapter 6, I prioritise genes for downstream analysis using existing 
gene expression data from murine GNPC cells, and identify the genes Myt1L and Tgif2 
as prime candidate for experimental validation. I also successfully knock down Myt1L 
expression in GNPC cells and show that the expression of genes involved in both SHH 
signalling and neuronal differentiation are significantly altered, further validating the 
importance of the network in SHH subgroup tumour development and neuronal 
development.
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Chapter 2  
 
Materials and Methods 
 
2.1 Mouse Husbandry 
 Mouse strains used in this project are as follows: B6 Ptchtm1mps/J mice 
(developed by targeted mutation of exons 1-2 of the Ptch1 gene, (Goodrich et al., 
1997); CBA wild type (Charles River Laboratories, Margate, UK); T2/Onc Line 76 
(Collier et al., 2005); and SB11 Rosa26 (Dupuy et al., 2005). All mouse work was 
conducted under, and in accordance with, UK Home Office standards and was 
completed under Project licence PLL/60/3621. All transgenic strains were first back 
crossed for a minimum of 3 generations to wild type CBA mice to reduce any influence 
of genetic background. Then, double transgenic Ptch1+/-;T2/Onc+/- mice were mated 
to heterozygous SB11+/- mice to produce triple transgenic experimental mice, and 
double transgenic control genotypes (see Figure 3.2). All animals were checked 
minimally 3 times a week, and those with symptoms of illness were humanely culled. 
Due to the different tumours arising within the cohort, symptoms of illness were varied. 
These included weight loss, disinterest in environment, abdominal distention, and 
behaviour changes indicative of balance problems such as leaning to one side, and head 
shaking or spinning. 
 
2.2 PCR genotyping 
Identification of the various genotypes from young transgenic animals was 
performed as follows: 
 DNA templates were prepared by heating ear punch material in 100μl of 25mM 
NaOH/0.2 mM EDTA at 95°C for 30 minutes. Then, 100 μl of 40 mM TrisHCl was 
added. Genotyping was carried out in a total volume of 20μl, containing 2μl of genomic 
DNA (~200ng), 18μl master mix containing 2μl of 6μM forward primer (SB11 5' – 
ATGGGAAAATCAAAAGAAATCAGCCAAG–3', or Ptch1 5' -
GTTGCAGTGCACGGCAGATACACTTGCTGA-3'), 2μl of 6μM reverse primer 
(SB11 5' –GCCAAACAGTTCTATTTTTGTTTCATCAGACCA–3', or Ptch1 5' -
GCCACTGGTGTGGGCCATAATTCAATTCGC-3'), 2μl dNTPs mix, 4μl 5X buffer 
and 7.7μl distiled water. The amplicon size for SB11 is 483bp and Ptch is 482bp. Cycle 
conditions were as follows: Initial denaturation at 94°C for 5 minutes, followed by 34 
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cycles of 1 minute at 94°C (denaturation), 1 minutes at 55°C or 60°C for SB11 or Ptch 
respectively (primer annealing), and 1 minute at 72°C (for extension), followed by a 
final extension at 72°C for 5 minutes. Then 5μl of PCR products were electrophoresed 
on 1.5% agarose gel at 90V for 40 minutes, with 5μl of a 100pb ladder as size standard. 
 
2.3 Insertion Site Amplification using Linker-mediated PCR 
 
2.3.1 DNA template preparation for insertion site amplification 
The samples from both control and tumour were treated as follows: 
Approximately 3mm cubed sample was transferred to an eppendorf tube. 500μl of lyses 
buffer and 50μl (10mg/ml) of proteinase-K (Bioline Reagents Limited, London, UK) 
were added, and incubated at 50°C overnight. The mixture was centrifuged at 
10,000rpm for 5 minutes. DNA was then extracted using the Qiagen Bio Robot EZ1 
machine (Qiagen, Hilden, Germany) according to the manufacturer recommendations 
and resuspended in 200ul of water. The final concentration of the DNA was measured 
using a NanoDrop ND-1000 spectrophotometer (Thermo, Wilmington, Delaware, 
USA), and each sample was adjusted to a final concentration of ~100ng/μl. 
 
2.3.2 First Digestion 
For each LM-PCR reaction (Figure 2.1), 2g of genomic DNA was digested 
with BfaI (left hand side of the transposon) or NlaIII (right hand side of the transposon) 
in a total volume of 50μl containing 20U of enzyme and 5μl of 10X reaction buffer. 
Reactions were incubated at 37°C overnight, deactivated by heating at 80°C (BfaI) or 
65°C (NlaIII) for 20 minutes, and then purified using a QIA quick PCR purification 
column (Qiagen, Hiden, Germany). All digestions were resuspended in 35μl distilled 
H2O, with 15μl of the resuspension being used for quality control on a 1.5% agarose gel 
as required. 
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Figure2.1: LM-PCR protocol. (A1 and A2) digestion of sample 
DNA with Bfa1 (Left hand side of the T2/Onc “Green”), or NlaIII 
(right hand side of the T2/Onc “Green”) enymes. (B1 and B2) 
Ligation with linkers (pink indicates unique single stranded sequence, 
black indicates phosphatase splink with hairpin complementarity). 
(C1 and C2) Further digestion with BamH1 (Lift handside of T2/Onc) 
or Xhol (Right handside of T2/Onc) restriction enzyms to eliminate 
the amplification of T2/Onc elementswhich remain in the transgenic 
array.(D1 and D2) Primary PCR with a common forward primer “5” 
and a primer complementary to the unique single stranded sequence 
in the lift had side of T2/Onc “6” and the right “7” linkers. (E1 and 
E2) Secondary PCR using a common nested primer”8” with end 
specific nested primers “9” for the Lift hand side of T2/Onc or “10” 
for the lift, which contain barcoded FLX sequencing primers (see 
methods). Figure 1.8: Cerebellar anatomic structure: The two main 
cerebellar layers, the cerebellar cortex and the white matter are 
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2.3.3 Splinkerette linker Ligation 
 For proper splinkerette linker attachment, two BfaI and NlaII linkers were used:  
 Top BfaI oligonucleotide sequence: 
 5' – GTAATACGACTCACTATAGGGCTCCGCTTAAGGGAC –3'  
Bottom BfaI oligonucleotide sequence:  
 3' –AAAAAAACTTTTTTTTTTAATCCGAGGCGAATTCCCTGAT-Phos 5'  
 
Top NlaIII oligonucleotide sequence:  
 5' -GTAATACGACTCACTATAGGGCTCCGCTTAAGGGACCATG-3'   
 Bottom NlaIII oligonucleotide sequence: 
3' -AAAAAAACTTTTTTTTTTAATCCGAGGCGAATTCCCTG-Phos 5'  
 
 In both cases, the top and bottom primers were annealed (final concentration 
100mM in 200mM NaCl) to generate single stranded overhangs complementary to the 
endonuclease sites (shown in italics). Primers complementary to each linker primer are 
subsequently used in the primary PCR reaction (sequence underlined). The ligation 
reaction conditions were as follows: 95°C for 5 minutes as first denaturation, followed 
by 95°C for 2 minutes, then primer annealing at 52°C for 10 minutes. Linker ligations 
were performed in a total volume of 20μl per reaction containing 10μl of either BfaI or 
NlaIII digested DNA, 2μl of 10X buffer, 6μl of annealed BfaI or NlaIII linkers, and 2μl 
of 800U T4 DNA ligase, and were incubated at room temperature overnight. The 
ligation reactions were then purified using a QIAquick PCR purification column 
(Quiagen, Hiden, Germany), and resuspended in 30μl H2O. Where necessary, ligation 
efficiency was checked using a digest only sample to enable visualisation of ligation 
products. 
 
2.3.4 Second digestion 
 Ligated DNA from 2.2.4 was digested with either BamHl or Xhol, for the left 
and right reactions, respectively. The total volume in both cases was 50μl, containing 
28μl DNA, 1μl one of the appropriate enzyme (20U), 5μl buffer, 0.5μl of BSA and 
15.5μl of H2O. Both reactions were incubated at 37°C overnight. Xhol digests were 
deactivated by heating at 65°C for 20 minutes, and digested DNA was then purified 
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using a QIAquick PCR purification column (Quiagen, Hiden, Germany), and 
resuspended in 30μl H2O. 
 
2.3.5 Primary PCR 
 Primary PCR was carried out using a splinkerette primer '5' (5' -
GTAATACGACTCACTATAGGGC-3' ), and either a left IR/DR primer (BfaI) ' 6' , (5' 
-CTGGAATTTTCCAAGCTGTTTAAAGGCACAGTCAAC-3'), or right IR/DR 
primer (NlaIII) '7'  (5' -GCTTGTGGAAGGCTACTCGAAATGTTTGACCC-3' ) in a 
total volume of 50μl, containing 3μl of BamHl or XhoI digested DNA, and 47μl of a 
master mix containing: 0.5μl of 2.5mM '5'  as a common primer, 0.5μl of either 2.5mM 
'6'  primer for BfaI or 2.5nM '7'  primer for NlaIII, 5μl 10X buffer, 2μl of 50mM MgCl2, 
1μl of 10mM dNTPs (2.5mM each) and 0.25μl high fidelity Platinum Taq (Invitrogen, 
Madison, WI, USA). PCR was performed with an initial denaturation step of 94°C for 2 
minutes, followed by 25 cycles of 15 seconds at 94°C (denaturation), 30 seconds at 
60°C (primer annealing), and 90 second at 72°C (for extension), followed by a final 
extension of 72°C for 5 minutes. The PCR products were subsequently diluted 1:75 in 
H2O to be used in the secondary PCR. 
 
2.3.6 Secondary PCR 
 Secondary PCR was carried out using diluted primary PCR product as a 
template, and used nested versions of the primary PCR primers carrying both the 
required fusion sequences for GS20 FLX Pyrosequencing (Fusion L left and right and 
Fusion B) and a unique 10bp barcode recognition sequence for each sample. Primers 
were designed such that the nested transposon primer had the Fusion A and barcode 
attached (Fusion A (Italic) – barcode (bold) – nested SB primer (underlined) in the 
sequences that follow): 
Primer  ' 9' ; 5'  CGTATCGCCTCCCTCGCGCCATCAGTCGGAGTCAAGACTTG 
TGTCATGCACAAAGTAGATGTCC3'  and  
Primer ' 10'  5' CGTATCGCCTCCCTCGCGCCATCAGTCGGAGTCAATAAGGT 
GTATGTAAACTTC3'  for left and right, respectively.   
The nested linker primer has the Fusion B sequence attached (linker nested (Italic) – 
Fusion B (underline)):Primer ' 8' ;  
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5' -CTATGCGCCTTGCCAGCCCGCTCAGAGGGCTCCGCTTAAGGGAC-3' .  
The reactions were performed in a final volume of 50μl containing 3μl of diluted 
primary PCR product (1:75) and 47μl of a master mix containing: 0.5μl of 2.5mM 
primer '8' as a common primer, 0.5μl of either 2.5mM primer '9' for BfaI or 2.5nM 
primer '10' for NlaIII, 5μl 10X buffer, 2μl of 50mM MgCl2, 1μl of 10mM dNTPs 
(2.5mM each) and 0.25μl high fidelity Platinum Taq (Invitrogen, Madison, WI, USA). 
PCR was performed with an initial denaturation step at 94°C for 2 minutes, followed by 
25 cycles of 15 second at 94°C (denaturation), 30 seconds at 60°C (primer annealing), 
and 90 second at 72°C (for extension), followed by a final extension at 72°C for 5 
minutes. 20μl of Secondary PCR products were checked on a 1.5% agarose gel 
electrophoresed at 90 Volts for 40 min. 
2.3.7 Sample preparation for FLX sequencing 
 Each secondary PCR sample was purified using a QIAquick PCR purification 
column (Qiagen, Hilden, Germany), and eluted in a final volume of 30μl H2O. DNA 
quality and quantity was checked using the Nanodrop ND-1000 spectrophotometer 
(Thermo Scientific, Wilmington, Delware, USA). Approximately, 100ng/μl DNA of 
each sample was pooled for FLX sequencing as appropriate, with adjustment to take 
account of average product size. Pooling was performed to generate on average 500 
reads per sample. Samples with less than 100 reads were re-sequenced prior to data 
analysis. After pooling, a final purification step using a Qiaquick PCR purification 
column (Quiagen, Hiden, UK) was performed. The samples were diluted to a final 
concentration of 2 Â 10s molecules/ml for pyrosequencing using the FLX LS20 or 
Titanium protocols (Roche, Penzberg, Germany). This final dilution, and all FLX 
sequencing, was performed by Dr Jonathan Coxhead (NewGene Ltd, Newcastle 
University), according to manufacturer’s recommended protocols. 
2.4 Sequence analysis 
 To generate sequence files specific for each PCR reaction, GSMapper software 
(Roche 454 Life Science, Branford, CT, USA) was used to map all sequence reads to a 
virtual genome consisting of all barcoded FLX sequencing primers. As a preliminary 
check of data quality, the left and right sequence data from one spleen tumour 
sequenced in the first FLX run (PTS11-21) were manually mapped to the mouse 
genome (build July 2007 [NCBI37/mm9]) using the BLAT algorithm (Kent 2002). In 
regards to the entire FLX sequencing data set, After trimming off all reads from the 
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linker fragments and FLX barcodes, all sequencing reads were mapped to the mouse 
genome using the methods described in March et al., (2011). These genomic sequences 
were then aligned to the mouse genome reference assembly (build July 2007 
[NCBI37/mm9]). The output was then further filtered utilising the following criteria: 
the best match cut off has to be at least 90% identical, including a perfect match to the 
“TA” at the bigininng of the alignment. 
2.5 Gel preparation and electrophoresis 
 1.5gm of Saekem Agarose gel (Lonza, Rockland, USA) was dissolved in 100ml 
of 1% tris-acetate-EDTA (TBE) Buffer. 100μl of (1:5) Gel red (Biotium Inc., Hayward, 
CA, USA) was added to the gel for visualization purposes. Electrophoresis was 
performed as 90 volts for 40 minutes. 
2.6 RNA Preparation 
 All reagents utilized in RNA preparations were prepared using Diethylene 
Pyrocarbonate (DEPC) treated water. All surfaces and required materials for RNA 
isolation and preparation were cleaned with RNAseZap (Ambion Inc., Austin, Texas, 
USA). 
 
2.6.1 RNA prepared from mouse brain tissue 
 Total RNA was isolated from ~10mg normal cerebellar tissue or MB tumours 
obtained by Dr Maria Lastowska or Dr. Mike Jackson (Institute of Genetic Medicine, 
Newcastle University) which were stored at -80°C. RNA was isolated using the RNeasy 
Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) in accordance with the 
manufacturer’s recommended protocol. The Isolated RNA was eluted with 50μl RNAse 
free water. 
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2.6.2 RNA prepared from primary and established cell lines 
 Total RNA was isolated from granule neuron precursor cells (GNPCs) or 3T3 
cell line pellets using the RNeasy Mini Kit (Qiagen, Hilden, Germany) in accordance 
with the manufacturer’s protocol. The Isolated RNA was eluted with 50μl RNAse free 
water. 
 
2.6.3 DNase treatment of isolated RNA samples 
 All isolated RNA samples were treated with RNase-Free DNase according to the 
manufacturer’s recommended protocol (Qiagen, Hilden, German) to remove remaining 
plasmid or genomic DNA. 
 
2.6.4 RNA quantitation and integrity ratio determination 
 Following elution, RNA concentration was determined using a Nanodrop 
(Labtech International, Uckfield, East Sussex, UK). All samples with an A260/A280 
ratio of less that 1.7 or greater that 2.2 were disposed of. The RNA integrity number 
(RIN) (8/10) and RNA quality were determined by using an Agilent 2100 Bioanalyser 
(Agilent Technology, Waldbronn, Germany).  
2.6.5 cDNA synthesis 
 cDNAs were synthesised using a High Capacity cDNA Reverse Transcriptase 
kit (Applied Biosystem, Warrington, UK).  A total of 50-100ng of RNA was used as 
template, with 2μl of 10X RT Buffer, a final concentration of 80mMdNTP mix, 20U of 
RNase inhibitor, 2μl of 10X RT random primers, and 50U reverse transcriptase, the 
volume being made up to a total volume of 20ul with distilled water. cDNA quantity 
and quality were determined by a using NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific, Wilmington, Delaware, USA). 
 
2.7 Quantitative real time PCR (qPCR) 
 All PCR products were designed to be in the size range of 90 – 150bp in length. 
qPCR was performed using the ABI 7900 HT Fast real-time PCR system (Applied 
Biosystems, Warrington, UK) in accordance with the manufacturer’s protocols. All 
qPCR probes were designed to be annealed at ~70°C; and included a FAM 
fluorochrome at the 5’ end of the probe, while the 3’ end was conjugated to the 
quencher TAMRA (Metabion, Martinsried, Germany). The primer concentration was 
optimized by assessing reaction efficiency at 3 different concentrations (100, 200 and 
300pM) with 3 different cDNA concentrations (1, 10 and 100ng). In a 15μl rection, 
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100pM TaqMan probe was used, with 10ng cDNA, and 7.5μl of TaqMan Universal 
PCR Master Mix (Applied Biosystem, Warrington, UK). All PCR reactions were 
carried out in triplicate using the following amplification conditions:  50°C for 2min to 
activate the polymerase, an initial denaturing step of 95°C for 10min, followed by 45 
cycles of 95°C for 15sec for denaturing, and 60°C for 1 min for the annealing and 
elongation steps. Noteworthy, all primer were designed by Primer3 software 
(http://flypush.imgen.bcm.tmc.edu/primer/primer3_www.cgi) with accemption of Gli1 
and Math1 being adabted from (Romer et al., 2004)  
Gene expression was normalised using a ubiquitously expressed gene as a 
calibrator (β-Actin). ΔCt was then determined as the difference between the average Ct 
values of the target gene and the average Ct values of the calibrator gene (ΔCT = CT 
(target) - CT (calibrator)). Relative expression was then calculated using the ΔΔCt 
method, as the difference between experimental samples and the calibration reference 
control sampls (either 0-time or normal cerebella cDNA, where applicable) 
(Comparative expression level = ΔCt target – ΔCt reference). The absolute comparative 
gene expression was calculated as 2
-ΔΔCt
 (Livak and Schmittgen 2001).  
Table 2.1: List of primers used in qPCR 
 
Primer Sequence 
Tead1_real_T_F CATCCACAAGCTCAAACACC 
Tead1_real_T_R CAAATACACAGGCCATGCAG 
Tead1_Probe TGGTGGTAACAAACAGGGATACACAAGAAA 
  
Myt1l_real_T_F AACCTGAGCCAGTCCCTGAT 
Myt1l_real_T_R CATTTCCGTCAAAGTAGTCACG 
Tead1_Probe CGCCAACATCCAGCTGCCTC 
  
Tgif2_real_T_F GGCTCTATCTGCACCGCTAC 
Tgif2_real_T_R GAAGCATGTCAGGGAGAAGG 
Tgif2 _Probe CCAACCTCTCGGTGCTGCAGA 
  
Igf2_real_T_F CGGACTGTCTCCAGGTGTC 
Igf2_real_T_R GTCCGAGAGGGACGTGTCTA 
Igf2_Probe GGAAGAACTTGCCCACGGGG 
  
Gli1_Real_T_F GCTTGGATGAAGGACCTTGTG 
Gli1_Real_T_R GCTGATCCAGCCTAAGGTTCTC 
Gli1_Probe CCGGACTCTCCACGCTTCGCC 
  
Math1_Real_T_F ATGCACGGGCTGAACCA 
Math1_Real_T_R TCGTTGTTGAAGGACGGGATA 
Math1_Probe CCTTCGACCAGCTGCGCA ACG 
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2.8 Granule Neuron Precusor cells (GNPCs) isolation 
GNPCs isolation was performed according to a protocol provided by Dr Beth 
Hatten (St Jude’s Hospital, USA). All chemicals were obtained from Sigma, Aldrich, 
Missouri, USA, unless otherwise stated. Cerebella were dissected from Post natal day 4-
6 (P4–6) mice, when most proliferation is occurring in the EGL. All animals were killed 
according to a schedule 1 method (dislocation). The head was cut off and skin was 
peeled off. The skull was then cut from the spine on each side of the head toward the 
eyes. The brain was removed from the skull in one piece and transferred into a petri dish 
containing ice cold CMF-PBS [consisting of NaCl 8g, KCl 1.2g , glucose 8g, 
NaH2PO4.H2O 2g, KH2PO4 1g, NaHCO3 8ml of 2% stock , EDTA 10ml of 1M EDTA, 
to a final volume of 1 litter H2O, PH 7.4). Pia and meninges were carefully teased off 
completely from the cerebellum, and the cerebellum was transferred into a 15ml falcon 
tube containing fresh ice cooled CMF-PBS to await GNPC isolation.  
Once all dissections were completed, the CMF-PBS was removed,  and 1ml 
Trypsin-DNAse [CMF-PBS 14.91ml, Trypsin 150mg (Worthington Biochem. Corp., 
NJ, USA), DNAse 15mg (Worthington Biochem. Corp., NJ, USA), 1N NaOH 0.09ml 
and MgSO4.7H2O 22.5mg to final volume 15ml) was added to a maximum of 6 
cerebella, and incubated for 5-15 min at 37°C. 
The trypsin-DNAse solution was then removed by pipetting, 1ml of DNAse 
solution was added [DNAse 7.5mg (Worthington Biochem. Corp., NJ, USA) dissolved 
in 14.83ml BME media (Gibco, Paisley, UK) and 0.113ml of Glucose] and the cells 
were dissociated by regular pressure using decreasing gauge needles (19 and 21 gauge). 
The cells were centrifuged for 5 min at 800g and 4°C (with break ON). After removal 
of the supernatant, the cell pellet was resuspended in 2ml fresh DNAse solution and 4ml 
CMF-PBS solution. The cells solution was then split into two 3ml aliquots and in 15ml 
falcon tube layered on to a Percoll gradient consisting of 5ml of 35% percoll solution 
[100 ml prepared by adding 25ml CMF-PBS-EDTA to 35ml Percoll and 40mldH2O), 
and 5ml of 60% percoll [100 ml prepared bt adding 25ml CMF-PBS-EDTA to 60ml 
Percoll 60ml, 15ml dH2O, and 0.3ml 0.4% trypan blue). The tubes were then 
centrifuged at 2000g for 10 min at 4 °C (Break ON). 
After centrifugation, the cell were gently and carefully harvested from the 
intermediate layer situated on top of the 60% percoll solution and transferred into new 
15ml falcon tube filled with ice cooled CMF-PBS solution to dilute the percoll. Cells 
were then centrifuged at 700g for 5 min at 4°C. The CMF-PBS was then removed and 
the cell pellets were resuspended in 50l of DNAse and 2ml GNPCs media [in 50ml 
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Neuro basal media (Gibco, Paisley, UK) add 0.5ml 100X Pen/Strep, 0.5ml 100X l-
Glutamin, 0.5ml of D-Glocose 45%, 1ml SITE and 1ml of 50X B27 (Gibco, Paisley, 
UK), 50μl of 1000X N-Acetyl Cystein] and centrifuged at 700g for a further 5 min at 
4°C. The next step was to remove the supernatant and resuspend the cell pellet in 50μl 
DNAse and 2ml GNPCs media. The cells were plated in a 35 mm cell culture plate, and 
incubated at 35°C with 5% CO2. After 1 hour of incubation the cells were transferred to 
a new 35mm culture plate and reincubated for 1 hour. The cells were plated at the 
desired density, ranging from 1–5X105/cm2, on a precoated culture plated with 
100μg/ml of poly-D-lycin (Millipore; Billerica, MA, USA) and matrigel (200μl in 
15mlCMF-PBS). Recombinant Shh protein at a concentration of 3μg/ml was added on 
the day of culturing where applicable. The media was changed every 3 days, and 
Accutase solution (Innovative Cell Technologies Inc., San Diego, CA, USA) was used 
for cells detachment purposes.  
 
2.9 Bacterial transformation and constructs 
 
2.9.1 Lentiviral constructs 
Five pLKO.1-puro based lentiviral plasmids (Mission-RNAi, Sigma-Aldrich, USA) 
containing shRNA-Myt1l were used for the Myt1L knockdown analysis: shRNA-Myt1l-
8 (TRCN0000012108), shRNA-Myt1l-9 (TRCN0000012109), shRNA-Myt1l-10 
(TRCN0000012110), shRNA-Myt1l-11 (TRCN0000012111), shRNa-Myt1l-12 
(TRCN0000012112), together with one pLKO.1-puro empty vector (Mission-RNAi, 
Sigma-Aldrich, USA). A pReceiver-Lv102-FLAG-epitope Tag plasmid, together with a 
puromycin based lentiviral vector containing the full length cDNA for Tgif2 (ORF-
Tgif2) with an N-terminal FLAG-epitope Tag driven by the CMV promoter (Ex-
Mm15242-Lv102, Genecopoeia, USA, http://www.genecopoeia.com), were used for the 
Tgif2 over-expression. Of these, only shRNA-Myt1l-8, shRNA-Myt1l-9, and ORF-
Tgif2 were used in transduction analyses. 
 
2.9.2 Transformation 
For each transformation, 50μl of competent E.Coli cells (DH5α, Gibco-BRL, 
Life Technologies, Rockville, MD) were thawed on ice, then 1μl (~50ng) of the 
appropriate Lentiviral vector was added and incubated for 20 minutes on ice. The cells 
were then heat-shocked at 42°C for 45 seconds, followed by a further incubation on ice 
for 5 minutes. Following this, 950μl of LB broth (with no antibiotic) was added to each 
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transformation, which were then incubated at 37°C for 1 hour. Each transformation mix 
was then spread out in different quantities onto agar plates containing ampicillin and the 
plates were incubated overnight at 37ºC. Individual white colonies were resuspended in 
5ml of media with 5μl of ampicillin (50μg/ml), to harvest the plasmids and 100μl of the 
above mixture was added to sterile water for colony PCR to check if the colony 
contained the vector. The DNA plasmids were then purified using mini prep columns 
(Qiagen, Hilden, Germany). 
 
2.9.3 Virus Production and titration 
The virus production was performed utilising Calcium phosphate transfection 
technology as previously described with lentiviral packaging vectors (Tarkkonen et al., 
2012), with slightly modification. The procedure was performed using a CalPhos 
Transfection Kit, according to the manufacturer’s protocol (cat. 631312, Caltech, 
Pasadena, CA, USA), by co-transforming 10μg of the appropriate lentiviral vector with 
5μg of pMD2.G and 10μg of psPAX2 into ~80% confluent of Human embryonic 
Kidney (HEK293T) cells (provided by Dr Dan Williamson, Newcastle University) 
cultured in DMEM complete media per 10-cm plate. After 48hrs the virus containing 
media was collected and filtered (0.45μm filter) and the lentiviral titer was established 
using 293T cells (Tarkkonen et al., 2012) using a 6-well plate format: 2μl of the viral 
supernatant was added to the second well, and a serial dilution was performed by 
transferring 200μl of viral containing media into the third well and repeating the 
dilution for wells 4-6. This resulted in viral concentrations of 1X10
3 
(well 2), 1X10
4 
, 
1X10
5
, 1X10
6
 and 1X10
7
 (well 6) cfu/ml (colony forming unit). Puromycin (1μg/ml) 
was added 24hr post infection. After 8 days, the cells were fixed and stained with 
crystal violet and the colonies were counted. 
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2.10 Generation of stable Myt1l Knockdown GNPCs 
The 2 shRNA-Myt1ls with the highest titration were used in the transduction 
procedure with GNPCs. shRNA-Myt1l-8 (4X10
6
), shRNA-Myt1l-9 (1.5X10
6
), PLKO.1 
empty vector (2.5X10
6
) were each used to infect 1.5X10
5
 GNPCs, seeded post isolation 
in 96-well plates with the presence of 3μg/ml recombinant Shh protein (Cell Guidance 
Systems, Cambridge, UK) where applicable. After 24hr of GNPC culture, 3 
multiplicities of infection (MOI) of the viral supernatants were added. Puromycin 
(1μg/ml) was added 24hr post transduction, then cells were harvested after 3 days for 
gene expression analysis. 
 
2.11 Generation of stable Tgif2 expressing cells 
Mouse 3T3 cells were obtained from Prof. Linda Lako (Institute of Genetic 
Medicine, Newcastle, UK). Around 187,500 cell/T25 flask were seeded in complete 
DMEM media. Twenty four hours post culturing, the lentivirus carrying ORF-Tgif2 
(2X10
6
 /ml titration) was added for transduction at 3 different MOIs (1MOI, 5MOI and 
10MOI; 93.75μl, 468.75μl and 937.5μl, respectively). After 24hr of transduction 2μg/ml 
of puromycin was added to select the vector containing cells. The cells were maintained 
according to standard cell culture protocols and harvested 3 days post transduction. 
Control cells were established in parallel to these experiments. 
 
 
2.12 Protein isolation from whole cell lysates 
 Protein was extracted from whole cell lysates using urea buffer. Briefly, 50μl of 
urea buffer, consisting of 90% urea (8.8M), 8% 1ml Tris and 2% sodium phosphate 
(5M), was added to cell pellets and vortexed for 30 sec. Protease inhibitor (1μl) was 
then added and the lysates were incubated for 30 min on ice. The lysates were then 
centrifuged at 4°C for 30 min, and the supernatant was collected and stored at -80°C for 
future use. 
 
2.13 Protein quantification 
  The proteins extracted from GNPCs, 3T3 cells, and whole brain were quantified 
using Micro BCA Protein Assay Kit (Pierce, Rockford IL, USA). All protocols and 
steps were conducted and completed in accordance with manufacturer’s recommended 
protocols. A standard curve was constructed using bovine serum albumin (provided 
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with the above kit between the concentration 0 - 200μg/ml). Absorption was measured 
at 562nm and all samples were quantified in duplicate. 
 
2.14 Wester Blot assay 
   
Protein extracted from cells or tissues was mixed with 2X SDS sample buffer 
(1.52g Tris base, 20ml glycerol, 2.0g SDS 2.0ml β-mercaptoethanol, 1mg Bromophenol 
blue, pH 6.8 to a volume of 100ml with H2O) and incubated at 95°C for 5 min. For each 
sample, 30-50μg of whole cell lysate was loaded on 4–20% Amersham ECL Gel 
(Amersham International, Amersham, UK). Samples were run on the gel with 1X 
running buffer  [consists of 100ml of 10X running buffer (10X buffer consists of 30.3g 
Tris base, 144g Glycine and 10g SDS and 1L of H2O) and 900ml H2O] for 45min to 1 
hour depending on protein size. The samples were then blotted using 1X blotting buffer 
[consists of 100ml of 10X blotting buffer (10X blotting buffer consists of 30.3g Tris 
base, 144g Glycin and 1L of H2O) diluted with 200ml absolute Ethanol and 700ml 
H2O] for 1–2 hours depending on protein size. Protein transfer was checked by staining 
the gel with Ponceau Red for 5 min. Non-specific binding was blocked by incubating 
the filter in a 10% milk solution [5g milk in 50ml 1X TBST (10X 24.23g Trizma HCl, 
80.06g NaCl) at 4°C overnight. After washing the membrane, primary antibody (Anti-
Myt1l Ab (Millipore, Germany) or AntiD Ab for ORF-Tgif2 protein (CGAB-DDK-
0050, Genecopoeia, USA) was diluted in 1% milk (0.5g milk in 50ml TBST) and 
applied for 1 hour with continuous agitation. The membrane was then washed and 
secondary Ab (BD-Pharmagene, Sandiago, CA) diluted in 1% milk, was applied for 1 
hour. Pictures of protein bands were developed by Syngene BOX-Gel Documentation 
and Analysis System (Syngene, Cambridge, UK). 
 
2.15 Illumina expression analysis 
 Approximately 200ng of total RNA was amplified and biotin labeled from each 
of 30 triple transgenic experimental mice tumours (Ptch1+/-;T2/Onc+/-;SB11+/-), 6 
tumours from Ptch1+/- predisposition only mice, and 6 normal cerebella, utilizing the 
Illumina TotalPrep RNA amplification Kit (Applied Biosystem, Foster City, USA) in 
accordence wth the manufacturer’s recommendations. The RNA Integrity number 
(RIN) was higher than 8.0 for all samples, with the exception of 2 samples where the 
RINs were 7.7 and 6.7. The size distribution of generated cRNA was checked using an 
Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA, USA. Around 750ng 
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of each cRNA  was then hybridised to Illumina Mouse8 reference Arrays (Illumina, 
Essex, UK) in accordance with the manufacturer’s protocols by the Wellcome Trust 
Clinical Research Services (Edinburgh, UK).  Microarray gene expression data 
generated was deposited in the Gene Expression Omnibus as submission GSE43994. 
 
2.16 Identification of common insertion sites within tumours and controls 
 In all, 41 MBs from the experimental genotype, and 30 cerebellum controls from 
the transposition-only genotype, were analysed by linker-mediated PCR designed to 
amplify across insert/genomic DNA junctions. In addition, 19 hepatocellular neoplasias 
were also analysed. The products were then bar-coded by nested PCR and sequenced 
using FLX pyrosequencing (Dupuy et al., 2009) that was aimed to a target depth of 
~500 reads/tumour. This resulted in a final total of 8,360 inserts with an average of 
~204 inserts/tumour. These inserts were further analysed with two statistical methods to 
identify statistically significant common insertion sites; Monte Carlo simulation (MC) 
and Gaussian Kernel Convolution (GKC) (Collier et al., 2005;de Ridder et al., 2006) by 
Dr Alastair Rust and David Adams at the Wellcome Trust Sanger Institute (Hinxton, 
Cambs, UK). 
 
2.17 Gene Expression Microarray and network analysis 
Human expression data were taken from publicly available data comprising 119 
Affymetrix HGU133p2 arrays (Kool et al., 2008;Fattet et al., 2009). Mouse expression 
data were taken from (Gibson et al., 2010;Subkhankulova et al., 2010). All analyses 
were performed on per chip and per gene normalised log2 transformed data using 
Genespring GX7.2 (Agilent Technologies, Wokingham, Berkshire, UK). Where 
multiple Affymetrix probes were present for a single gene, the probe with the highest 
mean expression value across all samples was analysed. Murine orthologs of human 
Affymetrix probes were specified using UCSC (http://genome.ucsc.edu). All t-test p-
values were adjusted using a Benjamini-Hochberg False Discovery Rate of 0.05. 
 ARACNe network generation and Metagene analyses were performed by Dr. 
Dan Williamson (Northern Institute of Cancer Research, Newcastle upon Tyne UK).  
Briefly, publicly available Affymetrix HGU133.2 expression data generated from 119 
human MB samples generated by Kool et al. (2008) and Fattet et al. (2009) were used 
to establish the ARACNE network. Management of CEL files was performed using the 
Bioconductor RMA package (Irizarry et al., 2003). The Affymetrix probes were filtered 
down from the original ~500,000 by retaining only  probes that were expressed in at 
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least 10% of samples with a range of expression greater than 500 and an overall fold 
change of 3 or more. Only probes with a significant Mutual Information (MI) 
association with at least one other node were retained. For retention in the full network, 
the genes had to be connected to each other by at least one neighbour node with a 
bootstrapped P-value of <10E-8. This left 8,749 probes in the network. 
For Non negative Matrix Factorization (Tamayo et al., 2007), metagenes 
defining the 4 MB subgroups generated from human tumours data were superimposed 
onto mouse arrays using orthologs and used as the basis of support vector machine 
(SVM) classification, where the classification training was performed using human MB 
data, and the classification was then tested on mouse primary tumours data. 
Two soft wares were used to create the Ontology results one is the Bingo 2.44 
Cytoscape plug (Maere et al., 2005), and the other is the Generic Gene Ontology Term 
Finder (http://go.princeton.edu/cgi-bin/GOTermFinder). 
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Chapter 3. (Results 1) 
 
Sleeping Beauty mutagenesis identifies candidate genes 
for involvement in Medulloblastoma. 
 
3.1 Introduction 
3.1.1 The SB transposon  
The Sleeping Beauty (SB) transposon belongs to the Tcl/mariner superfamily of 
transposons (Largaespada, 2009) which includes a large quantity of transposons in 
organisms such as fish and insects. The superfamily is defined by conserved amino 
acids responsible for equivalent processes in both families (Ivics et al., 1997). The SB 
transposon was first identified as a Tc1-like fossil in Salmonid species and the function 
element, which uses replicative transposition to insert into the target DNA, was 
reconstructed using phylogenetic inference (Ivics et al., 1997). Structurally, it is made 
up of a transposase which is delimited on both sides by terminal inverted repeats.  Like 
other transposons which insert using non-replicative transposition, SB transposes using 
a cut and paste mechanism. Briefly, the transposase identifies the inverted repeat ends 
and cleaves the transposon from surrounding DNA. The cleaved transposon is then 
inserted into the target DNA and the transposon and DNA are joined together (Essner et 
al., 2005). This is depicted diagrammatically in Figure 3.1  
 
 
 
Figure 3.1. The Sleeping Beauty transposon system. This is composed of two 
functional parts, the transposase and transposon vector. When both are present in 
the cell nucleus cut and paste transposition can take place. 
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A major advantage of the SB system for discovery of cancer genes compared to 
candidate gene approaches is that it allows the investigator to perform whole genome 
scans that are devoid of subjectivity (Collier and Largaespada, 2007a). Whereas the use 
of chemicals and radiation to induce mutagenesis is effective in causing mutations, 
identification of the candidate genes is often wrought with many difficulties. 
Identification using the SB system is much easier since the mutagen acts like a 
molecular tag allowing the easy detection of cancer genes through subsequent molecular 
analyses (Collier and Largaespada, 2007b). 
The ease of mutation detection is borne out by the results of landmark studies 
carried out by Dupuy et al., (2005) and Collier et al., (2005). Briefly, Collier et al., 
(2005) introduced T2/Onc transposons with a CAGGS-SB10 transposase in a 
background already predisposed to cancer (p19Arf+/-). In total, 28 sarcomas were 
generated, and PCR amplification of insertion sites followed by sequence analysis 
identified mutations within the Braf gene in 22 of these tumours. Missense mutations in 
Braf have previously been reported in several human primary sarcomas and a sarcoma 
cell line. In contrast, Dupuy et al, (2005) examined the impact of a modified transposon 
(T2/Onc2) with a more active transposase (Rosa26-SB11) in a wild type background. 
Hematological malignancies, such as T-cell leukemia and lymphoma were generated at 
high frequency. Notch1 was identified as an important candidate gene from this 
analysis. An important conclusion from these and other insertional mutagenesis studies 
was that the malignancies are primarily occasioned by the delivery of powerful 
promoters and enhancers quantitatively altering transcription, and do not occur solely as 
a result of  insertional gene disruption. 
Another factor which has a significant effect on the ability of the SB transposons 
to cause mutagenesis is their insertion site preference. Unlike retroviruses, lentiviruses 
and adenoviruses, which have a bias for promoter and transcriptional sites, SB 
transposons have been observed to integrate in a relatively indiscriminate manner when 
delivered by plasmid DNA. Other studies suggest that SB transposons do have some 
insertion site bias, with a tendency to integrate in regions that are rich in thymine and 
adenine (TA) sequences, and in places where the DNA is twisted or warped (Clark et 
al., 2004;Liu et al., 2004;Dupuy et al., 2005). However, when transgenic transposon 
arrays are used for mutagenesis, high levels of local hopping events are observed, with 
20%-50% of insertions mapping to within 40Mb of the array (Collier et al., 
2005;Dupuy et al., 2005). Despite this well documented non-random insertion of a large 
subset of inserts, SB has been successfully applied to a wide variety of solid tumours.  
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 3.1.2 The Sleeping Beauty Mutagenesis System 
 The SB mutagenesis system comprises two elements: The mutagen in the form 
of a tranpositionally competent but non coding transposon, and the transposase source 
which is encoded within a transpositionally incompetent  element. 
 
3.1.2.1 SB Transposons: T2Onc and its derivatives 
Different types of SB transposons have been engineered for cancer gene 
discovery. Collier et al., (2005) used the T2/Onc element to study transposon-mediated 
mutagenesis. The T2/Onc SB transposon contains a long terminal repeat of the murine 
stem cell virus (MSCV). The MCSV has powerful promoters and enhancers which play 
a dominant role in activities of stem cells. The MCSV is surrounded on the downstream 
site by a poly-A tail and this tail is delimited by a splice acceptor. Upstream of the 
MCSV long terminal repeat is a splice donor that causes over expression if it is located 
adjacent to or within a gene. Next to this splice donor site is a poly-A tail which is then 
flanked by a splice acceptor (Figure 3.2; Collier et al., 2005;Largaespada, 2009). The 
function of the poly-A tail is to precipitate premature transcript termination when it is 
inserted into a gene. This happens regardless of the orientation in which the transposon 
is placed since the poly-A tails at either ends are inverted. The splice acceptor-poly-A 
tails are used to interrupt the function of tumor suppressor genes (Collier and 
Largaespada, 2005). Several transgenic lines containing arrays of the T2/Onc element 
have been generated to act as transposon sources, including a 25 concatemer line (76) 
where the transgenic array maps to mouse chromosome 1, and line 68 that has the same 
concatemer number mapped to chromosome 15 (Collier et al., 2005). 
 
 
 
 
 
Figure 1.4: Diagrammatic illustration of the T2/Onc transposon. The transposon
consists of the MSCV 5’ LTR that can enhance transcription and the splice donor (SD). It 
also contains sequences that can inhibit transcription. (Largaespada, 2009)
Figure 3.2 The T2/Onc transposon. The MSCV 5’ LTR can enhance 
transcription of downstream exons picked up by the splice donor (SD). 
Transcript disruption can be caused by insertion in either orientation due to 
the presence of two splice acceptors (SA) (Largaespada, 2009). 
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Another type of SB transposon which has been used in mutagenesis studies is 
the T2/Onc2 element developed by Dupuy et al., (2005). The T2/Onc2 system 
resembles the T2/Onc in many respects. The only differences between the 2 are that one 
of the splice acceptors in the T2/Onc2 system is much longer, and the element is 
slightly shorter which may enhance transposition efficiency. Perhaps more importantly, 
the number of transposon copies found in the chromosome concatemer of the T2/Onc2 
transgenic line used in these analyses has approximately 6-14 times more copies than 
the T2/Onc lines used by Collier et al., (2005). It is thus referred to as a high copy line 
while the T2/Onc lines are termed as a low copy line. However, an increase in 
embryonic lethality rate has been recorded when the high copy number line is used 
(Dupuy et al., 2005;Collier and Largaespada, 2007b). 
More recently, a third Sleeping Beauty transposon concatemer has been derived; 
T2/Onc3. In this advanced version, the murine stem cell virus (MSCV) promoter has 
been replaced with chicken β-actin (CAG) promoter.  This harbours a hybrid 
cytomegalovirus enhancer / beta-actin promoter that is active in a wider range of tissues 
than the MSCV promoter (Dupuy et al., 2009). As a result, this transposon has been 
able to generate more than 20 different tumor types in mice, suggesting that it can be 
widely applied to understand the underlying molecular basis of a wide variety of 
cancers. 
 
3.1.2.2 SB Transposases: the CAGGS-SB10 and Rosa26SB-11 Transgenic Lines 
To date, two transgenic lines that can be used as sources of transposase have 
been developed. These are CAGG-SB10 and Rosa26-SB11 (Collier and Largaespada, 
2007). CAGGS-SB10 mice were developed using the conventional method of 
pronuclear injection (Okabe, 1997) and were conceived to produce the transposase in all 
tissues. However, it has been observed that high levels of this enzyme are expressed 
only in a limited number of tissues including connective tissue cells (CT), mesenchymal 
and male germ line tissues. Studies also show that it exhibits mosaicism in many tissues 
(Dupuy et al., 2001;Largaespada, 2009). 
The Rosa26-SB11 transgenic line was created by knocking in the SB 
transposase into the Rosa 26 loci of ES cells by use of homologous recombination 
(Colllier and Largaespada, 2005). Unlike the CAGGS-SB10 system, the Rosa26-SB11 
line produces transposase in all tissues, but when used with the T2/Onc2 system it 
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causes both a high degree of embryonic lehality, as well as a variety of tumours 
including leukaemias, sarcomas, Gastrointestinal Tract (GIT) tumours, and 
Hepatocellular carcinoma in almost all animals which survive to term (Collier et al., 
2005; Dupuy et al., 2005; Keng, et al., 2009; Largaespada, 2009; Starr et al., 2009). To 
overcome this drawback, some studies have utilised tissue specific promoters to 
regulate the transposase (Largaespada, 2009). Collier and Largaespada (2007) have 
found lower transposition rates when the Rosa-SB11 lines are used compared to the 
CAGGS-SB10 lines. This was attributed to the high level of expression of the 
transposase enzyme in the former, a factor that has previously been associated with a 
reduction in the efficiency of transposition (Geurts et al., 2003). 
 
3.3 SB mutagenesis of Ptch1+/- mice. 
To identify genes which interact with the predisposition to MB in the Ptch1+/- 
transgenic mouse model, an SB mutagenesis breeding program was initiated in the 
Institute of Genetic Medicine, Newcastle University, in 2007 utilising both the SB10 
and SB11 transposases in combination with T2/Onc to mutagenise mice heterozygous 
for the ortholog of the PTCH1 gene (Ptch1+/-). Initial experiments using SB10 failed to 
generate tumours in either a Ptch1+/- or wild type background, despite the fact that tests 
indicated that transposition was occurring in cerebellar tissue (M. Lastowska, personal 
communication). Previous studies showed that the combination of T2/Onc with SB10 
resulted in tumour production, predominantly sarcoma (Collier et al., 2005), suggesting 
that this system has tissue specificity. Subsequent experiments in Newcastle, utilising 
SB11 Rosa26 transposases in combination with T2/Onc line 76 to mutagenise mice 
heterozygous for the ortholog of the gene (Ptch1+/), did appear to impact upon the 
frequency of medulloblastomas in Ptch1+/- animals and generated haematological 
tumours such as lymphoma and leukaemia in both Ptch1+/- and wild type backgrounds. 
In addition, rhabdomyosarcomas and liver adenomas were also observed.  This 
combination of transposase and transposon was therefore chosen to perform a full 
mutagenesis screen of the Ptch1+/- model, as outlined below.  
 
3.1.3 SB11 mutagenesis breeding scheme 
All mice strains were initially backcrossed to the CBA wild type strain for a 
minimum of 3 generations to minimise background affects known to influence tumour 
pentrance in the Ptch1+/- model (Goodrich et al., 1997). Mice homozygous for T2/Onc 
and heterozygous for the Ptch1 null allele were then mated to mice heterozygous for the 
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SB11 transposase (Figure 3.3). This cross generated 4 genotypes, 3 of which were used 
for subsequent analysis: One genotype is both predisposed to cancer and subject to 
experimental mutagenesis (Ptch1+/-;T2/Onc+/-;SB11+/-), the second is a  
predisposition only control genotype (Ptch1+/-;T2/Onc+/-), and the third is a 
transposition only control genotype (T2/Onc+/-;SB11+/-).  
 
 
 
 In total, 243 experimental and 195 controls mice were aged for approximately 
15 months, with tumours arising in mice of all 3 genotypes being retained for 
pathological and immunohistochemical analysis. In addition, tumours arising in the two 
genotypes where transposition has occurred, together with normal tissues from 
transposition only controls, were also retained for insertion site analysis.  
 
  
Figure 3.3: Animal breeding, genotyping and sample analysis. The 
experimental animals (T2/Onc+/-;SB11+/-;Ptch1+/-), transposition 
controls (T2/Onc+/-;SB11+/-;Ptch1-/-) and predisposition controls 
(T2/Onc+/-;SB11-/-;Ptch1+/-) are analysed. 
 55 
3.1.4 Initial aims of the project 
 When I became involved in this project, the SB11 breeding scheme had already 
been underway for over 18 months, and the phenotypic analysis of tumours was being 
performed. The initial aims were therefore to complete the mutagenesis scheme in 
collaboration with those already involved in the project, and perform the intial analysis 
to identify lists of potential candidate genes. Specifically, the initial aims were to: 
 
 1. Complete the genotyping of all remaining mice within the cohort.  
2. Use genotype and tumour incidence data collected to establish the impact  
     of SB mutagenesis upon survival and frequency of tumour formation. 
3. Use linker mediated-PCR to amplify across the T2/Onc insertion  
     sites in all tumours and control tissues. 
4. Sequence at high depth all insertion sites amplified. 
5. Apply statistical analysis to the sequence data to identify common 
     insertion sites (CISs) within the tumours generated. 
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3.2 Results 
  
 
3.2.1 Genotyping of Ptch1, SB11 and T2/Onc in experimental mice 
The majority of the breeding programme had been completed at the outset of 
this project by Dr Michael Jackson and Dr Maria Lastowska. However, a small cohort 
of approximately 200 animals remained to be analysed. To establish the genotype of 
these mice, Ptch1 and SB11 status was established using ear punch DNA as template 
for established Polymerase Chain Reaction assays (see Methods). As the design of the 
breeding scheme generated animals heterozygous for T2/Onc+/-, this transgene was 
only assayed to confirm the genotype of breeding pairs.  Examples of results obtained 
for SB11 and Ptch1 are shown in Figure 3.4. Animals 407-1 and 407-2 are positive for 
Ptch1+/- (~460bp amplicon, Figure 3.4A), while animals 407-2 and 411-1 are positive 
for SB11 (~370bp amplicon, Figure 3.4B). From these results, animals which carry the 
T2/Onc transgene array are easily categorised. For instance, animal 407-1 can be 
categorised as predisposition only control (Ptch1+/- only). However, animal 407-2 can 
be categorized as the experimental genotype (Ptch1+/-;SB11+/-). Moreover, animal 
411-1 can be identified as a transposition only control (SB11+/-). Finally, animal 411-2 
can be categorised as wild type and omitted from future analyses.  
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In addition to genotyping the individual genes which are segregating, an 
additional check for transposition was also performed in a subset of animal to confirm 
transposition, and to rule out genotyping errors in tumours arising in predisposition only 
control animals. The excision assay (Collier et al., 2005) is able to identify complete, 
partial or even no excision. Figure 3.5 exemplifies the excision essay within 
rhabdomyosarcoma samples. This figure shows short (~210bp) amplicons generated 
from samples PM29, PM96, and PTS11-481, which indicates total excision of the 
transposons within the array. The larger amplicon observed in samples PM25, PTS11-
165, PTS11-215 and PTS11-432 (>600bp) indicates that no transposon excision events 
have occurred. However, sample PTS11-324 shows both small and large bands 
suggesting that some but not all of the transposons have excised from the array. 
Figure 3.4: Ptch1 and SB11 PCR genotyping assay.  Ear punch DNA was used for 
genotyping (A) Ptch1; expected amplicon ~460bp, arrowed. (B) SB11; expected 
amplicons ~370bp, arrowed. Positive controls are samples known to carry each 
transgene. Negative controls are wild type. H2O = no template. 
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In total, ~200 animals were genotyped and/or checked for transposition to finalise the 
tumour dataset for subsequent analysis. 
 
3.2.2 Tumour types observed in the mutagenized Ptch1+/-;T2/Onc;SB11 mice 
 A total of 243 mutagenised experimental mice and 195 transposition and 
predisposition control mice were aged for up to 15 months and were monitored for 
tumour formation. The total number of tumours generated in animals of each genotype 
are summarised in Table 3.1. Examples of the most frequent tumour types observed in 
the mutagenised Ptch mice are also shown in Figure 3.6. The pathology analyses were 
performed by Dr Chris Bacon and Professor Alastair Burt (Faculty of Medical Sciences, 
Newcastle University). Medulloblastoma lesions developed exophytically in 
approximately 23% of animals aged for >6 months (Figure 3.6 panels A, B). 
Macroscopically, an absence of meningeal masses has been reported in these affected 
animals. However, microscopically, these tumours were classified as desmoplastic 
forms, a typical form of human SHH-subgroup of Medulloblastoma. Collectively, these 
features presented them as a typical of Ptch1+/- model. Furthermore, MB like lesions 
were also observed within predisposition only controls (Ptch1+/-;T2/Onc+/-) but at a 
low frequency (6%). 
Slow growing rhabdomyosarcoma (RMS), the other form of tumour that is 
usually generated as a result of Ptch1+/- heterozygosity, arose in approximately 22% of 
mutagenized animals (Figure 3.6 panels C, D). Immunohistochemical staining analysis 
showed small round mitotical active cells and rhabdomyoblasts and large eosinophilic 
differentiated cells. Both the MBs and RMSs were morphologically similar to those 
Figure 3.5: Example of Excision essay in rhabdomyosarchoma samples. (A) PCR results 
showing the products size and different levels of excision. The arrow represents the 
expected size ~210bp of the excised transposon. Positive control shows complete excision. 
H2O = no template. 100bp ladder is on the extreme right of the gel. (B) Schematic diagram 
showing transposons and the relative amplicon structures/sizes before and after excision. 
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obtained from non-mutagenised Ptch1+/- mice and other murine MB models (Johnson 
et al., 1996;Marino et al., 2000;Fults, 2005;Hatton et al., 2008;Mancuso et al., 2008).  
In addition, multiple liver adenomas were generated in 19 mutagenised Ptch1+/- 
mice compared to none within predisposition controls. Immunohistochemically, these 
lesions were usually characterised by leukaemic infiltration and usually arose in animals 
who also had haematological tumours or rhabdomyosarcomas (Figure 3.3 E-G). It is 
noteworthy that the morphological features of these adenomas are similar to those 
observed and analysed in a previous SB screening study within mutagenized mice with 
a conditional SB11 for hepatocellular carcinoma (Keng et al., 2009).  
Finally, approximately 28% of mice succumbed to haematological malignancies 
that presented either as lymphoblastic leukaemia (presenting as hepatosplenomegaly) or 
large thoracic (probably thymic) lymphomas (data not shown). These haematological 
phenotypes were also observed in transposition only control mice at similar frequency, 
indicating that they can be induced by SB mutagenesis only. This is consistent with data 
from Collier et al., (2009) who first used the SB11 transposase in combination with 
T2/Onc.  
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Figure 3.6: Main tumour types obtained from the mutagenised Ptch+/- mice: A. 
a large prominent MB originating from the cerebellum; B and C. 
immunohistochemical staining showing a large exophytic MB which grew from the 
cerebellum. D. a large rhabdomyossarcoma on the right extremity. E and F. 
immunohistochemical appearance showing small round cells mitotical active and 
rhabdomyoblast and large eosinophilic differentiation. G and H. a typical 
haematological malignancies that appears in form of hepatosplenomegaly and large 
thoracic lymphoma lesion, respectively. I. microscopic feature representing 
hepatocellular carcinoma with leukaemic infelteration. J and K. microscopic 
appearance of immunohistchemical staining from adenomatous lesion with 
hepatocelular carcinoma, micro and macrovacular steatosis that often associated with 
leukaemic infiltration (Lastowska et al., 2013). 
  
 61 
 
Table 3.1: Primary tumours obtained by genotype 
 
 Genotype 
 Experimental Predisposition Transposition 
 No. Median 
(range) 
No
. 
Median 
(range) 
No. Median 
(range) 
 
Cohort Number 
 
 
243 
 
- 
 
95 
 
- 
 
120 
 
- 
Medulloblastoma 42 17.3 
(7 - 27) 
4 19 
(15 - 28) 
0 - 
Other Brain lesions 5 29.2 
(23 - 38) 
0 - 4 19.5 
(12 - 25) 
Haematological 51 27.9 
(8 - 52) 
0 - 25 34 
(13 - 54) 
Rhabdomyosarcom
a 
33 21.3 
(14 - 36) 
29 25.5 
(8 - 49) 
0 - 
Liver Adenomas 19 29 
(20 - 45) 
0 - 2 - 
Other Tumours 2 - 1 - 5 - 
 
All Tumours 
 
152 
 
- 
 
34 
 
- 
 
36 
- 
 
Hydrocephalus 
 
9 
 
- 
 
0 
 
- 
 
1 
 
- 
Median age of onset and range of onset is given for common tumour types. 
Genotypes: Experimental – Ptch+/-;SB11+/-;T2Onc+/-. Predisposition - 
Ptch+/-;T2Onc+/-. Transposition - SB11+/-;T2Onc+/-. 1Parenchymal brain 
lesions included one with pseudopalisading necrosis consistent with 
glioblastoma multiforme. 2Morphological and immunohistochemical analysis 
established that ~50% of haematological malignancies were precursor T-cell 
lymphoblastic lymphomas/leukaemias, ~5% were confirmed myeloid 
neoplasms, and the remainder were poorly differentiated haematological 
neoplasms, mostly of probable myeloid lineage. 3RMSs developed most 
frequently on the hindquarters and lower limbs. 4Adenomas were mildly 
dysplastic with frequent intralesional steatosis, although sufficient atypia and 
eosinophilic cytoplasmic inclusions were observed in 2 nodules to warrant 
classification as hepatocellular carcinoma. All but 2 were identified in animals 
where other malignancies were also present (4 RMS, 10 Haematological, 1 
with RMS+Haematological, and 2 unclassified). All animals with liver 
adenomas were male, a highly significant bias (p<0.0001). 5Hydrocephalus has 
previously been reported in this model (Goodrich et al., 1997) 
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3.2.3 Impact of predisposition and mutagenesis upon survival 
 
 After genotyping was completed, the data was integrated with survival 
information to establish if mutagenesis alone is capable of inducing tumours, and if 
mutagenesis interacts with the tumour predispositions of the Ptch1 allele. Kaplan Maier 
survival curve comparing experimental and control genotypes were analysed using the 
Log rank test; these analysis were performed by Dr Mauro Santibanez-Koref and Dr 
Maria Lastowska (Institute of Genetic Medicine, Newcastle University). These are 
shown in figure 3.7. The results indicate that the mortality rate in experimental animals 
was significantly higher (90%) than the predisposition or transposition only control 
groups (Figure 3.7A). Clearly, SB11 induced mutagenesis may interact with Ptch1 in all 
tumour types, although the impact is most clearly seen for medulloblastoma where 
approximately 23% of Ptch1+/-;T2/Onc;SB11 animals developed MB compared to less 
than 6% of predisposition controls  (p<0.0001 log rank test), with no tumours in the 
transposition only control (Figure 3.7B).  This confirms that the transposition enhanced 
the tumour predisposition and that further analysis of the insertional mutation should be 
informative. The frequency of rhabdomyosarcomas in the experimental and 
predisposition controls was similar, and the Kaplan Meier curve suggests no impact of 
transposition upon the frequency of these malignancies (p=0.31 log rank test, Figure 
3.7C). Finally, the impact of haematological malignancies upon survival was not 
significantly different between experimental or transposition controls (data not shown) 
and suggests that transposition alone induced these malignancies. 
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3.2.4 LM-PCR amplifications of T2/Onc insertion sites 
A total of 219 tumours from animals subjected to SB11 mutagenesis were 
harvested for linker mediated-PCR (LM-PCR) amplification (see Table 3.2). These 
consisted of 41 medulloblastomas (MB), 34 Rhabdomyosarcomas (RMS), and 123 
haematological malignancies manifesting as either leukaemic spleens with enlarged 
liver (LS) or thoracic Lymphoma (Lym) plus some other tumours generated by this 
mouse model (see Table 3.1). The haematological malignancies included 32 generated 
Figure 3.7: Kaplan Mier survival curve of SB mutagenised mice and controls. A. 
Mortality is significantly higher within transposition only than predisposion only 
controls (p<0.002), and was significantly higher in experimental than both controls 
groups (p<0.0001). B. Mortality due to MB alone is significantly higher in the 
experimental cohort compared to both control groups (p<0.0001), however, mortality 
between both controls was not significant (p=0.118). C. Mortality due to 
rhabdomyosarcoma malignancies was not significantly different between experimental 
and predisposition cohorts (p=0.31). The log rank test was used in all analysis. 
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during an independent analysis of mice positive for the human MYCN oncogene (M. 
Jackson and M. Lastowska unpublished, (Schwab et al., 1983). This was looking for 
interaction between SB11 and the predisposition of mice with the MYCN transgene to 
develop neuroblastoma; none was observed (M. Jackson unpublished). In addition, 
approximately 30-35 thymus, spleen, cerebellum and muscle samples from SB11+/-; 
T2Onc+/- transposition only mice were harvested at 6-7 weeks as to enable the 
distribution of insertion sites to be analysed in tissues relevant to the tumours under 
study. In total, therefore, the dataset for LM-PCR and insertion site sequencing 
comprised 230 tumours and >120 controls. 
Table 3.2: Number of samples processed and sequenced; tumours and controls. 
Samples Total Extracted and 
analysed by myself 
LM-PCR 
– Left 
LM-PCR - 
Right 
Spleen control 35 35 35 35 
Thymus control 35 10 10 10 
Muscle control 35 35 35 35 
Cerebellum control 35 10 10 10 
Haematological 
tumour 
123 84 84 84 
Rhabdomyosarcoma 34 34 34 34 
Medulloblastoma 41 20 20 20 
 
The full LM-PCR and sequencing pipeline is described in the Methodology 
section. DNA from all samples underwent automated extraction following overnight 
digestion with Proteinase K, and an example of the DNA produced is shown in Figure 
3.8. All DNAs from leukemic samples (PTS11-348, PTS11-263 and PTS11-70a) are of 
relatively high molecular weight, migrating at a size of between 2 and 23kb. Lambda-
HindIII and a 100bp ladder (Fermentas) were used as molecular weight markers.  
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To define the insertion sites of T2/Onc elements, splinkerette PCR (Collier et 
al., 2005) was used to amplify both the left and right end of T2/Onc elements in all 
tumours and controls. This involved DNA extraction of 359 samples (including both 
tumours and controls) followed by digestion with Bfa1 (left) or NlaIII (right). Typical 
products of Bfa1 and NlaIII digestion are shown in Figure 3.9. All samples gave a 
smear of digestion products. The BfaI digests produce a larger average size than NlaIII, 
as BfaI cuts the DNA less frequently than NlaIII.  
Figure 3.8: Example of DNA quality: 
Spleen tumour samples of undigested 
DNA show very high molecular weight 
(23130bp). Lamda-HindIII was used as a 
marker as well as 100bp ladder.  
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 To digest any untransposed T2Onc elements within the transgenic array and 
prevent these generating amplicons in subsequent PCRs, linkers were ligated and a 
second digestion was performed, using BamH1 and XhoI for Bfa1 and NlaIII digested 
samples respectively. These were then subject to primary PCR to specifically amplify 
from inside integrated T2/Onc elements out to the nearest Bfa1 or NlaIII site within 
surrounding genomic DNA (see Methods). Although undigested DNA acted as a control 
for XhoI and BamHI digestion efficiency, the ligation and first PCR were only checked 
if secondary PCR was unsuccessful (see Methods).  
Examples of secondary PCR products generated by the 2
nd
 nested PCR reaction, 
which eliminates non specific amplification products and incorporates the barcode and 
sequencing primer, are shown in Figure 3.10 and Figure 3.11 for BfaI and NlaIII 
respectively. BfaI secondary PCR generates a sample specific ladder of amplicons, 
consistent with the presence of a different spectrum of integration sites in each tumour. 
The majority of the amplicons range in size from 200-1000bp, an appropriate size for 
FLX amplification and sequencing. As the T2/Onc left hand priming site lies 
approximately 120bp from the terminus of the transposon, the minimum possible size of 
an intact amplicon is approximately 180bp (120bp + 60bp of primers). Amplicons 
smaller than 180bp are likely to be primer dimers, or ligation artefacts. It is also clear 
from Figure 3.10 that two ligations, MTS11-224ST and PTS11-93ST, failed to yield 
products. Subsequent checks on excision status in such cases (see methods) were used 
to establish whether this represented experimental failure, or no excision.  
Figure 3.9: A typical DNA digestion with Bfa1 and NlaIII: Results for 15 enlarged 
spleen are shown (A) Bfa1 (left side of T2/Onc) and (B) NlaIII (right side of T2/Onc) 
digestion. This pattern is typical of DNA after digestion. Marker is a 100bp ladder. 
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The results for secondary PCR of NlaIII digested DNA is shown in Figure 3.11. 
The results are essentially identical to the BfaI results, except that the average size of 
the PCR products is smaller, and appear to be more complex (smeared). This is 
consistent with results from other laboratories, and is due both to the right hand primer 
being closer to the terminus of the T2/Onc transposon (30bp), giving a minimum 
amplicon size of about 90bp, and the higher frequency of NlaIII restriction sites within 
mouse genomic DNA resulting in a larger number of inserts being recoverable by this 
method.  
Figure 3.10: Amplification of BfaI products. Mixed tumours samples BfaI 
digested and subjected to PCR. Amplicons range from 200 – >1000bp. Two 
samples failed to produce products (MTS11-224ST and PTS11-93ST). A 100bp 
Ladder is on the left end lane. H2O = no template. 
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3.2.5 Identification of T2Onc insertion sites by Pyrosequencing 
In total, 8 DNA sequencing runs were implemented; 3 FLX-GS20 runs were 
performed with a maximum of 48 samples per GS20 lane, and 5 FLX-Titanium runs 
with a maximum of 120 samples per lane. This produced a total of 265,793 raw 
sequencing reads from 359 tumour and control PCR reactions, with an average number 
of reads per sample of 1433 (left) and 778 (right). 
Generally, the reads lengths obtained from processed samples (tumours and 
controls) appeared to be distributed evenly.  An example of the output from a single 
FLX run is summarized in Figures 3.12 and 3.13. The distribution of read lengths 
obtained is shown in Figure 3.12, and it is clear that there is a wide range of read 
lengths from <100bp to over 400bp.  The prominent peaks between ~50–80bp are likely 
to be primer dimers and ligation artifacts. Additionally, the very prominent peak around 
~170bp is known to represent amplicons from the T2/Onc concatemer, suggesting that 
the second enzyme digestion was not complete. However, these observations are 
congruent with the gel pictures of secondary PCR of both BfaI and NlaIII (see Figure 
3.10 and 3.11, respectively).  
 
 
Figure 3.11: Amplification of NlaIII products. Mixed tumours samples NlaIII digested and 
subjected to PCR. Amplicon sizes range from ~90bp->1000bp. A 100bp Ladder is on the left end 
lane. H2O = no template.  is on the extreme right lane as a negative control. NlaIII digested 
T2Onc+/- DNA is shown as a negative control on the extreme right lane; the single band from 
the transgenic array is clearly visible.  
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To illustrate sample coverage in more detail, the number of reads for BfaI (left) 
side reactions of both tumour and control samples from this run are shown in Figure 
3.13. Most of the samples give read numbers between ~200 and 1000, significantly 
more than obtained using subcloning methods (Collier et al., 2005, Dupuy et al., 2005). 
However, two control samples (surrounded by the red rectangle) produced a very low 
number of reads (<~180bp), and several give read numbers of over 1000 (e.g. PTS11-
791). Samples with low read numbers were re-processed. As the number of individual 
amplicons in each sample was low relative to read number (e.g. see Figure 3.10) no 
normalization of read numbers between samples was performed prior to downstream 
processing.  
 
Figure 3.12: FLX pyrosequencing read length distribution. Read lengths from 1 
FLX run are shown. The prominent peak at ~170bp is known to be a product from the 
T2Onc concatemer. The peaks at ~50 – 80bp are primer dimers. 
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3.2.6 Manual assessment of sequence read consistency with SB system  
To confirm the quality of the sequence reads prior to analysis, and to establish if 
the insertion site distribution is consistent with what is known about SB mobilisation, 
the insertion sites of transposons identified from both BfaI and NlaIII products for 1 
spleen (leukaemic) tumour (PTS11-21 - run 3) was analysed in detail using BLAT. In 
this analysis, sequence reads were only called as inserts if the following criteria were 
met:  
 
1. The start of the identity to the mouse genome was approximately at position 
140bp for the left and 40bp for the right (+/-5bp): These positions are consistent 
with the known position of the amplification primers within T2Onc. 
 
2. The identity of the high scoring hit was between 96 and 100%.  
 
3. No higher scoring hit was obtained which mapped to different co-ordinates 
within the read (indicative of a PCR artefact). 
 
The insertion sites identified from this BLAT analysis are presented in Table 3.3 
and Table 3.4 for NlaIII and BfaI sites respectively. The initial observations obtained 
from the tables are as follows: First, 26 insertion sites have been identified. This is a 
Figure 3.13: Example of read numbers recovered from Bfa1 digestion. Number of 
reads obtained by FLX pyerosequencing for subsets of SB induced tumours and Controls 
from Bfa1 digestion are shown. The minimum target number of reads was  200 – 1000. 
Two controls samples (highlighted in red) produced a lower number of reads. 
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large number of inserts compared to the average obtained from standard subcloning and 
sequencing protocols (Collier et al., 2005; Dupuy et al., 2005) illustrating the power of 
FLX sequencing. In two cases, both the left and the right sides have been recovered; 
The A230020J21Rik gene has inserts scored on chromosome 1 at positions 192853626 
(left) and 192853627 (right) respectively. The Gm5069 gene, localized on the same 
chromosome, has an insert scored at positions 182259106 (left) and 182259109 (right), 
respectively. This confirms that the LM-PCR and sequencing from both Left and Right 
reactions has worked. Furthermore, approximately 54% of the insertions are located 
within genes, with 45% localised within intergenic DNA. This frequency of genic hits is 
consistent with previous analyses (Collier et al., 2005). Interestingly, the Prdm16 gene 
located on chromosome 4 has generated the most reads. The insertions into this gene 
accounts for ~11.6% of all reads identified from the NlaIII digest. This may be due to 
variation in digestion/amplification efficiency, or may reflect variation in insert sites 
between cells. However, it is interesting that this gene is already known to be involved 
in the promotion of haematological malignancies (Shing et al., 2007), suggesting that 
this insertion may be a key event in the development of this specific tumour. 
Approximately 39.2% of the transposition positions are within chromosome 1. 
This is much higher than the frequency expected by chance, and is due to the well 
known local hopping behaviour exhibited by the SB transposon. The T2/Onc transgenic 
array within line 76 is known to lie at position 166.788 Mb on mouse chromosome 1, as 
sequence flanking the array was recovered by LM-PCR (Collier et al., 2005). It is 
noteworthy that 12 out of the 19 insertions on chromosome 1 map to within 30Mb of 
this position.  
Overal, therefore, the insertion sites identified in this tumour indicate that the SB 
system is behaving as anticipated in terms of its transposition dynamics, and that the 
insertion site recovery is efficient. This suggested that the insertion site data generated 
was of sufficient quality to be subject to a full bioinformatic analysis to automatically 
assign insert position, and identify common insertion sequences (CISs) (Dupuy et al., 
2005). All samples were therefore taken through the CIS analysis pipeline (see 
Methods). 
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Table 3.3: Insertion sites identified within NlaIII restriction fragments. Both genic 
and intergenic insertions are presented. The inserts name and code, with the 
chromosomes (Chr) and gene orientation (Or) are shown together with the position of 
inserts mapped (Position start – end). Gene names and insert numbers are shown.  
Insert code Chr Or Position Start – End Genes No. of inserts 
GIUO1OD06G6TA7 1 - 192853553 – 192853627  A230020J21Rik 4 
GIUO1OD06HILZS 1 - 182259050 – 182259109  Gm5069 3 
GIUO1OD06HNVQO 1 - 128137770 – 128137856  Nckap5 4 
GIUO1OD06HJ4R3 1 - 107694701 – 107694832  Tnfrsf11a 1 
GIUO1OD06HI7UG 1 + 182604447 – 182604533  Lin9 1 
GIUO1OD06G9UOR 1 + 153867681 – 153867712  1700025G04Rik 1 
GIUO1OD06HA0WC 1 + 36210622 – 36210678  Ugcgl1 1 
GIUO1OD06HABGF 1 - 162517215 – 162517276  Rabgap1l 3 
GIUO1OD06HLBA3 1 + 110405740 – 110405800 intergenic 1 
GIUO1OD06HAJI1 1 + 192348485 – 192348523  intergenic 1 
GIUO1OD06HE9H5 1 - 163485580 – 163485654  intergenic 1 
GIUO1OD06HK4ZK 1 - 94066947 – 94067068  intergenic 1 
GIUO1OD06G7RE0 2 - 120253125 – 120253208  Ganc 1 
GIUO1OD06HPQ7I 4 - 153936641 – 153936686  Prdm16 13 
GIUO1OD06G5VZL 4 + 62734919 – 62734941  Zfp618 1 
GIUO1OD06G626K 4 + 32407598 – 32407625  intergenic c 6 
GIUO1OD06G5B02 6 - 31087927 – 31087962   5 
GIUO1OD06HMNX4 7 + 114459761 – 114459787  intergenic c 2 
GIUO1OD06G5RUT 8 - 91238964 – 91239019  Cy1d 1 
GIUO1OD06HOECH 10 - 20849509 – 20849662  Myb 3 
GIUO1OD06G3KTP 10 - 103129070 – 103129114  intergenic 1 
GIUO1OD06G4Q45 11 - 90134905 – 90134931  Mmd 4 
GIUO1OD06G3KTP 11 - 9222831 – 9222865  Abca13 1 
GIUO1OD06G3KTP 12 - 4626012 – 4626051  Itsn2 1 
GIUO1OD06HDJF8 12 + 119741135 – 119741259  intergenic 1 
GIUO1OD06HKHEL 14 - 61748860 – 61748887  intergenic 3 
GIUO1OD06HBPMD 15 - 42342061 – 42342216  Angpt1 1 
GIUO1OD06HNOXV 15 - 25487216 – 25487242  intergenic 1 
GIUO1OD06HOECH 17 + 55893137 – 55893156  Emr4 1 
GIUO1OD06G9QJW 17 + 3493680 – 3493708  Tiam2 1 
GIUO1OD06HLBA3 X - 157677067 – 157677086  Scm12 1 
GIUO1OD06HJO8O X_rand - 1508536 – 1508602  intergenic 1 
GIUO1OD06HF9K4 X - 18832143 – 18832166  intergenic 1 
GIUO1OD06G3KTP 
GIUO1OD06G3KTP 
GIUO1OD06G3KTP 
3 
16 
19 
- 
- 
+ 
137977321 – 137977364  
61030171 – 61030214  
19783450 – 19783493  
Unmappable 2 
GIUO1OD06G3KTP 
GIUO1OD06G3KTP 
GIUO1OD06G3KTP 
3 
4 
4 
- 
+ 
+ 
110954681 – 110954707  
96211275 – 96211301  
27073100 – 27073126  
Unmappable 1 
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Table 3.4: Insertion sites identified within Bfa1 restriction fragments. Both genic 
and intergenic insertions are presented. The inserts name and code, with the 
chromosomes (Chr) and gene orientation (Or) are shown together with the position of 
inserts mapped (Position start – end). Gene names and insert numbers are shown.  
Insert Code Chr Or Position Start - End Gene No. of inserts 
GIUO1OD06HB41H 1 + 192853626 – 192853811  A230020J21RiK 1 
GIUO1OD06G5LCV 1 + 182259106 – 182259128  Gm5069 1 
GIUO1OD06HN4RD 1 - 172298826 – 172298953  Nos1ap 1 
GIUO1OD06HG0J5 1 + 192853626 – 192853811  Intergenic 2 
GIUO1OD06HCYLB 1 + 192334903 – 192335003  Intergenic 2 
GIUO1OD06G8RTF 1 + 94068028 – 94068161  Intergenic 2 
GIUO1OD06HBA7N 1 + 166047280 – 166047301  Intergenic 1 
GIUO1OD06G4D04 1 - 415644 – 415756  Intergenic 3 
GIUO1OD06HAAA0 2 + 54158306 – 54158359  Intergenic 4 
GIUO1OD06HISWH 4 - 37938914 – 37938972  Intergenic 3 
GIUO1OD06HIRI3 6 + 31087959 – 31088181  Intergenic 1 
GIUO1OD06G9TMJ 9 + 44584022 – 44584092  Ift46 1 
GIUO1OD06HKVGV 9 - 69469549 – 69469829  Intergenic 1 
GIUO1OD06G5QPE 10 + 127902897 – 127902987  Smarcc2 1 
GIUO1OD06HK8D9 11 - 68244102 – 68244251  Intergenic 2 
GIUO1OD06HPLSF 17 + 80840228 – 80840298  Sos1 4 
GIUO1OD06HHVWI X + 108807692 – 108807829  Hdx 4 
GIUO1OD06G4D04 X + 99741305 – 99741325  Phka1 1 
GIUO1OD06HDIG9 
GIUO1OD06HDIG9 
GIUO1OD06HDIG9 
7 
18 
10 
- 
- 
- 
66411379 – 66411411  
39593716 – 39593748  
101757704 – 101757736  
Unmappable 2 
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3.2.7 Identification of insertion sites within MB tumours and controls 
The main aim of this project is to identify cancer genes and determine the 
initiation events in tumours generated within the Ptch1+/- mouse model, such as MB 
and rhabdomyosarcoma. To identify the insertion sites, 41 MBs, 28 rhabdomyosarcoma, 
123 haematological tumours and 27 adenomas from the experimental genotype, together 
with tissue specific control samples for MB and rhabdomyosarcoma from the 
transposition-only genotype, were analysed by linker-mediated PCR to amplify across 
insert/genomic DNA junction. The products were then bar-coded by nested PCR and 
sequenced using FLX pyrosequencing (Dupuy et al., 2009) aimed to a target depth of 
200-1000 reads/tumour. This gave a final total of 8,360 inserts with an average of ~204 
inserts/tumour in MB. These reads were mapped to the mouse genome (NCBI37/mm9). 
For more details about the inserts in the whole cohort of tumours, see Table 3.5. These 
inserts were further analysed with two statistical methods; Monte Carlo (MC) 
simulation and Gaussian Kernel Convolution (GKC) analysis by Dr David Adams and 
Alistair Rust (Welcome Trust Sanger Institute, UK) (Collier et al., 2005;de Ridder et 
al., 2006).  
 
Table 3.5: Tumours by type, with the number of reads. For details of stacking 
(inserts at the same dinucleotide) and firestorm (multiple inserts in one locus from the 
same sample) filtering, see following sections. 
 
 
 
 
	
Sample sets \ 
Counts 
Number of 
samples 
Insertions 
after 
filtering by 
samples 
Stacking 
insertions 
removed 
(one max per 
location) 
Firestorm 
insertions 
removed 
(max of 2 
per CIS) 
Final insertions 
count 
Adenomas 27 1220 14 0 1206 
Brain controls 31 4147 131 35 3981 
Haematological 123 14389 373 182 13834 
MB 41 8573 134 79 8360 
Muscle controls 40 2208 60 6 2142 
RMS 28 3308 20 14 3274 
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3.2.7.1 Monte Carlo (MC) and Gaussian Kernel Convolution (GKC) analysis 
In the MC method, the original data, consisting of insert positions within the 
genome, is used to generate pseudo-replicates (like bootstrap analysis) in which the 
insert positions are randomly distributed. Insert position in tumours is then analysed 
using different sized windows e.g. 10Kb, 30Kb, 60Kb, and 100Kb, and the original data 
is compared against the pseudo-replicates to localise sites within the genome where the 
number of inserts is greater than expected [termed common insertion sites (CISs)]. This 
method has the benefit of being relatively straightforward. However, it becomes less 
sensitive with larger window sizes, as it does not take into account genome structure 
(Copeland and Jenkins, 2010;Dupuy, 2010). 
The GKC method uses a kernel function, which is localised at every single insert 
within the genome; i.e. it estimates an insert probability function. This involves 
measuring the probability of an insert occurring within a particular region within a 
window of defined size. This analysis is performed several times using a variety of 
window sizes. The original data is analysed against a probability distribution curve to 
identify CISs. This allows for a higher number of CISs to be identified at a wider 
variety of scales, and to generate probabilities which are comparable across different 
Kernel widths (window sizes). This method is relatively fast and more sensitive than 
MC, but is mathematically more complex (Copeland and Jenkins, 2010;Dupuy, 2010). 
 
3.2.7.2. In Silico analysis to Identify MB CISs 
From a final cohort of 40 MB samples (1 of the 41 tumours failing to yield 
inserts), a set of 46 genic and 9 intergenic regions were defined as common insertion 
sites (CIS) using Monte Carlo simulation and Kernel Convolution methods. However, 
Some CISs were defined by inserts from different tumours at exactly the same 
dinucleotide position. Other CISs were defined by multiple inserts from the same 
tumours (e.g. Figure 3.14). The former could be due to PCR contamination or 
sequencing artifacts, while the latter could be due to secondary local hopping events. 
Both of these could confound the analysis (Starr et al., 2009) and could lead to false 
positives, as they violate the assumption of independence of insertions.  
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To take account of these possible confounding issues, the sequence data were 
reanalysed as follows: First, where multiple inserts were identified at the same position 
in more than one sample, the sample with the largest number of reads at that position 
was retained and others discarded. In the event of a tie, one sample was arbitrarily 
chosen. This conservative approach has been used before (Dupuy et al., 2009;Starr et 
al., 2009). To remove the “firestorm” CIS pattern, the GKC was re-run once with a 
kernel window of 15Kb and a maximum of 2 insertions from any single sample within a 
single CIS was retained. Additionally, in the case of tied numbers of mapped reads in a 
CIS, only the closest insertion to the kernel peak of the CIS was retained. Finally, any 
mapped reads with insertion sites shared with control samples were omitted from the 
analysis. The final reads number retained from all tumours types after this analysis are 
compiled within Table 3.5. 
 
3.2.7.3 CIS candidate genes in MB samples  
After reanalysis, 18 candidate genes and 3 intergenic regions were identified 
within 21 CISs recovered with median P-value = 0.008, and these are listed in Table 
3.5. Those genes were analysed bioinformatically to establish the number of inserts, 
insert orientation bias, inserts clusters with respect to gene structures, and gene 
transcriptional orientation, to infer the likely impact on the gene transcription (Starr et 
al., 2009). Several databases were investigated for previous identification for these CISs 
as tumourgenic genes. 
Figure 3.14: Example of CIS defined by inserts within one tumour. Image adapted 
from UCSC browser showing T2/Onc insert positions within a CIS from Cerebellum 
Controls. Thirteen out of fourteen inserts (red) are derived from a single tumour (SB116). 
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It is to be noted that 11 candidate genes (61.9%) were identified by both 
statistical methods. Interestingly, of the remaining 7 candidate genes, 6 were identified 
by GKC only, and 1 (Gli3) by MC only, suggesting that the combination of such 
statistical methods is highly recommended (Table 3.6). In the GKC analysis, there were 
two statistical cut-offs applied based on either genomic or chromosomal levels.  For 
each chromosome and GKC kernel size, potential CISs are assigned p-values.  For a 
CIS to be classified as significant, its p-value must be below 0.05 which is adjusted 
using a multiple test correction.  In the case of chromosomes this is 0.05 divided by the 
total number of CIS peaks on the current chromosome.  CIS selected in this way are 
thus significant for the specific chromosome they lie in. Then the multiple test corrected 
p-value for the CIS was implemented.  In this case it is the (raw p-value X the number 
of CIS peaks on its chromosome).  Values given must be less than 0.05 to satisfy the 
chromosome-by-chromosome cut-off.  
At the genomic level however, a CIS that is significant on a certain chromosome 
may not be significant on the genome-scale.  Therefore, a CIS to be called significant on 
the genome-scale, its p-value should be less than 0.05 but in this case will be corrected 
for the total number of CIS peaks over the whole genome.  Since this total number of 
peaks is greater than the individual numbers of peaks on chromosomes, the cut-off for a 
peak to be called significant becomes far more stringent (i.e. 0.05 divided by the total 
number of genome CIS peaks). This was carried out as the (raw p-value X the number 
of CIS on its chromosome X 19).  This is an approximate calculation adjusting by the 
"number of chromosomes".  It is only 19 as we don't look at chr1 and there are very few 
CIS peaks on chromosome Y. Accordingly, 6 genes (Nfia, Atxn2, Tead1, Tgif2, Crebbp, 
Dscr3) showed a significant p-value (p = <0.05) at the genomic level. While the rest are 
significant only at the chromosomal level (p = <0.05) (Table 3.6). However, the genome 
level cut off is considered to be very stringent, as it cannot account for chromosomal 
variation in size, gene number etc. As a result, the chromosome cut off is generally 
reported in exploratory datasets.  
 
3.2.7.4 Investigating the inferred Mode of Action of inserts upon candidate genes  
The orientation bias of the inserted transposon with genes, as well as the 
location of the inserts within the genes, can be used to infer of mode of action (MOA), 
and this information is specified in Table 3.6. Approximately 52.6% of the inserts were 
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in the positive orientation with respect to gene transcription, compared to about 47.5% 
that were orientated negatively, indicating no significant bias in orientation across the 
whole dataset. However, 6 CIS (Tgif2, Fgif13, Itgbl1, Gli3, Myt1l, and Adcy5) were 
determined to have statistically significant bias in insertion orientation, suggesting that 
the mode of action (MOA) could be clearly inferred. If the T2/Onc is in the same 
orientation as the gene transcript, the MSCV promoter may lead to overexpression of 
the gene. However, if the T2/Onc is in the opposite direction to the gene, this may lead 
to gene truncation and dysregulation due to splice acceptor signals (Dupuy, 2010). The 
insert orientation, the number of the inserts, and the location of the inserts that clustered 
within the 5' end of the genes suggested upregulation effects for 4 genes (Tgif2, Tead1, 
Adcy5, and Fgf13). In contrast, the rest of the genes have high numbers of inserts 
distributed on a wider scale, suggesting loss of function or more complex effects of 
insertion upon the affected genes. 
Two of the CISs, namely Pten and Crebbp, were identified as showing somatic 
mutation at low frequency within human MB during unsupervised sequencing assays; 
nonsense mutations within the human ortholog of Crebbp have been identified 
previously within WNT-subgroup tumours (Parsons et al., 2011;Robinson et al., 2012). 
Strikingly, 6 identified CISs (Nfia, Nfib, Tead1, Crebbp, Sfi1 and Pten) have been 
identified as MB CISs within an independent tissue-conditioned mutagenesis screen 
study of MB (Wu et al., 2012). Within the cerebellar controls, 3 out of the 5 CISs are 
genic, all with p-values between 0.01 and 0.05 (Table 3.6). This does suggest that a 
small number of the MB CISs with low p-values may be false positives. 
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Table 3.6: Identified Common insertion sites (CISs) in Medulloblastoma and normal Cerebellum controls. 
G
en
e
 
P
-v
a
lu
e 
G
en
e 
o
ri
en
ta
ti
o
n
 
N
 T
u
m
o
u
r
s 
N
 I
n
se
r
ti
o
n
 S
it
e
s 
In
se
r
t 
B
ia
s 
 
In
fe
rr
ed
 M
O
A
 
C
h
r 
–
 M
o
u
se
 
C
h
r-
 H
u
m
a
n
 
M
B
-M
u
t 
M
B
-C
IS
 
C
G
C
 
O
th
er
 g
en
es
 
MC+ GKC Genomic p<0.05  
                
Nfia <1E-14 + 20 27 .4/22 ORF Disruption 4 1p31.3-p31.2 
- 
Ptch 
- - 
Atxn2 <1E-14 + 6 6 .1/5 Unclear 5 12q24.1 - - - - 
Tead1 7.34E-13 + 6 7 .2/3 Gain 7 11p15.2 - Ptch - - 
Tgif2 0.0115 + 3 4 .4/0 Gain 2 20q11.2-q12 - - - - 
Crebbp 0.0170 - 5 5 .2/3 ORF Disruption 16 16p13.3 Y Ptch S - 
Dscr3 0.0178 - 5 6 .3/2 ORF Disruption 16 21q22.13 - - - - 
CIS13:72336914 0.0042   5 6     13       
MC+ GKC Chromosomal p<0.05                 
Pten 0.0046 + 4 5 .1/4 ORF disruption 19 10q23.3 Y Both S/G  
Itgbl1 0.0062 + 5 5 .5/0 Unclear 14 13q33 
- - - 
Fgf14 
Nfib 0.0072 - 7 9 .5/4 Gain 4 9p24.1 - Ptch S - 
Tmem45b 0.0195 - 4 5 .4/1 Unclear 9 11q24.3 - - - - 
Sfi1 0.0214 - 5 6 .3/3 ORF Disruption 11 22q12.2 - Both - - 
MC only                  
Gli3 n.a. + 3 4 .4/0 ORF Disruption 13 7p13 - - - - 
GKC-only Chromosomal p<0.05                  
Myt1l 0.0089 + 8 10 .7/3 ORF Disruption 12 2p25.3 - - - Pxdn,Tpo, Sntg2 
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Ankrd5 0.0092 - 8 15 .3/2 Unclear 2 20p12 - - - Plcb4,Pack7,Snap25 
Slit3 0.0122 + 8 12 .6/6 ORF Disruption 11 5q35 - - - - 
Fgf13 0.0254 - 3 4 .1/3 Gain X Xq26.3 - - - - 
CIS15:70979306 0.0279   4 4     15       
CIS3:147532546 0.0430   4 7     3       
L3mbtl4 0.0432   7 7 .2/5 ORF Disruption 17 Chr18p11.31 - - - Tmem200c 
Adcy5 0.0443 + 4 6 .4/2 ORF disruption 16 3q13.2-q21 - - - Ptblb 
Cerebellar Controls 
Faf1 0.01  4 4  Unclear 4      
I7Rn6 0.018  3 3  Unclear 7  
   
Ccdc81 
CIS36:31346217 0.045  6 8   6      
Ric3 0.035  4 4  Unclear 7  
   
Tub 
CIS9:68415409 0.016  9 11   9      
 
Genes identified the CISs. Chromosome in which the CISs mapped; P-value is from GKC analysis unless otherwise stated;Gene orientation and direction of gene 
transcription is according to UCSC - (+) positive , (-) negative orientation; (N tumour) is the number of tumours that defined the CIS; (N insertion site) is the number 
of T2/Onc insertions; (Insertion Bias) is the number of inserts in the same orientation right/ number of inserts opposite to gene orientation; (Inferred MOA) is the 
inferred mode of action based on the position and orientation of T2/Onc insertions - (open reading frame disruption, or upregulation); (Chr-Mouse) mouse chromosome 
in which the CISs mapped; (Chr-Human)  orthologous human chromosome; (MB-Mut) Somatic mutation previously identified (Parson et al., 2011; Jones et al., 2012; 
Pugh et al., 2012; Robinson et al., 2012), (Y) yes; (MB-CIS) gene previously identified as MB CISs (Wu et al., 2012) in (Ptch1) Ptch model or Ptch and p53 model 
(Both); (other gene) lists additional genes identified within the same GKC width. 
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3.2.8. Whole body SB mutagenesis identifies common Insertion sites in primary 
tumours other that MB 
Although the main focus of this study and thesis is CISs in MB and their impact 
upon MB development, there were a variety of other tumours generated within the 
model used in this experiment (Table 3.1). The vast majority were haematological 
tumours, and these are not dealt with here as they have been documented previously in 
this model (Collier et al., 2009). However, a number of rhabdomyosarcomas and liver 
adenomas were also identified, and the next sections will explore the CISs identified in 
these two tumours. 
 
3.2.8.1 CISs identified in Adenomas 
Transposon distribution was also analysed in liver adenomas as these have not 
previously been described in whole body SB mutagenesis. Because adenomas were 
often recovered in animals with haematological tumours and shown evidence of 
lymphocytic infiltration, CISs identified in this dataset which were identified at a higher 
p-value in the haematological tumours were excluded. Seven genic CISs were identified 
as being specific to adenomas (Table 3.7A) including 2 within genes recently shown to 
be subject to rare somatic mutation (TLK1) or focal amplification (ERBB2IP) in 
hepatocellular carcinoma (Guichard et al., 2012). However, the most significant CIS 
was centred on intron 24 of the Egfr gene (p<1E-14), the same location as the top 
scoring CIS in a conditional SB mutagenesis screen for genes associated with 
hepatocellular carcinoma (Keng et al., 2009), confirming both the specificity of the 
mutational event in this gene (truncation) and its importance in neoplasia of the liver. 
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Table 3.7: CISs identified within liver Adenomas by SB mutagenesis: 
Gene Chr CIS 
Width 
N I p-value Other 
Genes 
MOA CGC 
A. CISs in Adenomas 
Egfr 11 21.9 7 8 <0.0001   Orf 
Disruption 
S 
Ubr2 17 260 4 5 0.0049 Trerf1 Unclear NA 
Erbb2ip 13 780 6 6 0.0102   Orf 
Disruption 
S 
Rapgef6 11 8.8 3 3 0.0143   Unclear  NA 
Ovol2 2 27.7 3 3 0.0155 Csrp2bp Unclear NA 
Tlk1 2 134 3 4 0.0203   Orf 
Disruption 
S 
Rad23b 4 31.3 3 3 0.0264   Orf 
Disruption 
S 
B. CISs in Adenomas also identified as CISs in Haematological tumours 
Pten 19 36.1 5 6 <0.0001   Orf 
Disruption 
S 
Notch1 2 1.2 3 3 <0.0001   Gain G 
Ikzf1 11 62.7 5 7 0.0001   Orf 
Disruption 
G 
Mecom 3 24.6 3 4 0.0009   Unclear S 
Myb 10 3.4 3 3 0.0003   Gain G 
Foxp1 6 15.5 3 3 0.0089 Eif4e3 Orf 
Disruption 
S 
For details of columns see Legend to Table 3.6 
 
 
3.2.8.2 CISs identified in rhabdomyosarcoma 
The RMS and muscle control datasets were also analysed using both GKC and MC 
analyses. The only GKC CIS in the RMS data which was significant at the genome 
scale is the Chr7 insertion hotspot recovered in all CIS analyses, including controls. 
Two CISs were significant after correction at the chromosomal level (CIS2:99636326 
and Rin3), but two CISs were also recovered at this level of significance in the muscle 
control dataset (Table 3.8), suggesting that these CISs are likely to be false positives. 
The lack of a clear impact of transposition upon RMS incidence (Figure 3.7) and the 
small number of CISs recovered suggest that there is no interaction between the SB 
mutagenesis system used here and the Ptch induced predisposition to RMS. 
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Table 3.8: CISs identified within rhabdomyosarcoma by SB mutagenesis: 
Genes Chr N I P=value MOA 
A. CISs in RMS 
Ptgis 2 6 9 0.011 Orf Disruption 
CIS2:99636326 2 3 3 0.017 Orf Disruption 
Rin3 12 3 3 0.018 Gain 
Zfx X 3 3 0.022 Orf Disruption 
CIS13:48649631 13 3 3 0.024 Unclear 
Golim4 3 6 8 0.030 Orf Disruption 
Zmynd11 13 8 8 0.035 Orf Disruption 
Diap2 X 4 4 0.037 Unclear 
Ap3m1 14 8 12 0.040 Orf Disruption 
Foxp1 6 3 3 0.006 Unclear 
Erg 16 4 4 0.023 Orf Disruption 
Fgf14 14 3 4 0.037 Orf Disruption 
B. Muscle Controls 
 Iqcg 16 10 10 0.016 
 Ankrd52 10 4 4 0.020 
 Nfia 4 4 4 0.034 
 Mecom 3 3 4 0.004 
 Myb 10 3 3 0.028 
 Pten 19 3 3 0.032 
 Ikzf1 11 3 3 0.036 
 
 
For details of columns, see Legend to Table 3.6.  
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3.3 Discussion 
The Sleeping Beauty system has been successfully used to generate tumours in a 
variety of mouse cancer models and wild type mice. These tumours resemble human 
tumours, enabling novel genes that contribute to tumour formation to be identified and 
analysed. For instance, such identification has been carried out for sarcomas, T-cell 
lymphomas, hepatocellular carcinomas, and colorectal cancer (Collier et al., 2005; 
Dupuy et al., 2005; Collier et al., 2009, Keng, et al., 2009; Starr et al., 2009).  
In this screen, a cohort of Ptch1+/- mice and their wild type littermates were 
subjected to SB mutagenesis using the novel combination of the SB11 transposon and 
the T2/Onc mutagen. Several tumour types were generated, the main cancers being 
medulloblastomas, rhabdomyosarcomas, haematological malignancies (lymphoma and 
leukaemia) and liver adenomas. Critically, from the point of view of MB candidate gene 
identification, SB mutagenesis significantly increased the frequency of MB formation 
within Ptch1+/- animals relative to predisposition only controls, providing clear 
evidence that genes mutated by SB enhance the tumour predisposition, meaning that 
CISs identified within these tumours are likely to be involved in tumorigenesis. 
Although rhabdomyosarcomas were also generated by the model, there was no evidence 
of an impact of SB. Although the reason for this is unclear, it is possible that the MSCV 
enhancer does not function within the cell of origin of these tumours.  Despite this, 
tumours of all types, together with control samples, were taken through the insert 
identification process. 
In this project two different FLX next generation sequencing chemistries 
(GS20 and Titanium) were used in order to improve deep sequencing of inserts 
from tumours generated in the SB mutagenised mouse model.  run: Both refer to 
chips used by FLX next generation sequencing machine, but GS20 has  lower 
capacity in terms of read number and read length. Titanium-chemistry generates 
approximately 1.2 million reads with an average length of 350 – 450bp. In 
contrast, . GS20 chemistry can generate approximately 400,000 reads with an 
average read length of 350 – 450bp. Here, Titanum runs were used to analyse 
approximately 90 samples per run, while 40 -50 samples were loaded on GS20 
runs. In our study the length of the reads recovered was important as we have 
used a random cloning approach where the enzyme can cut within a position 
distributed within the genome. Titanum enables recovery of more TE inserts due 
to the longer reads been analysed (Bard-Chapeau et al., 2014). 
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 The preliminary analysis of 100 reads recovered by FLX sequencing within a 
single haematological tumour identified several genes, including the PR domain 
containing 16 (Prdm16) gene on chromosome 4. This gene has been shown to be over-
expressed in acute myeloid leukemia (AML), in both 5 human and 13 mice samples, 
suggesting that Prdm16 may contribute to AML formation (Shing et al., 2007). This 
result suggested that the Splinkerette PCR had worked effectively, and that insert 
identification would be successful. In addition, in this tumour the incidence of local 
hopping was about 39.2% on chromosome 1. This percentage is only an estimate as it 
was calculated from only 100 insertions. However, in previous analyses local hopping 
has been seen at frequencies ranging from 23% within 28 sarcomas (line 76, Collier et 
al., 2005), 6 – 11% from 16 haematological tumours (Dupuy et al., 2005;Collier et al., 
2009), and about 11.2% local hopping events within 25 Mb, 15.6% within 40 Mb and 
31.5% within the entire chromosome within 59 haematological malignancies (line 76, 
Collier et al., 2007). 
 Analysis of the MB insertion site data identified a total of 18 CIS genes using 
both GKC and MC methods. Until recently, only two of these (Pten and Crebbp) have 
been observed in previous analyses of other tumour types using the SB screening system 
(Collier et al., 2009;Berquam-Vrieze et al., 2011). These 18 CISs are likely to have a 
synergistic effect with the predisposition of Ptch during tumour development, as SB 
does not induce MBs alone. It is noteworthy that six CISs identified in this analysis 
have also recently been identified as MB CISs using a tissue-specific MB mutagenesis 
screen of the same model (Wu et al., 2012), The overlap between these two studies 
suggests that the genes identified are relevant to MB specifically, and are likely to be 
relevant to MB formation/development. 
Many of these CISs identified in the current study are known to play a role in 
neural development. This is consistent with the suggestion that a limited number of 
somatic mutations may be required to develop MB, compared to adult solid tumours, 
given the short time period of  cerebellar development (Parsons et al., 2011).   
Of those CISs which are neuronal development genes, Nfia is the most highly 
inserted CIS, and a paralog of this gene, Nfib, is also a CIS gene. Nfi genes act as 
transcriptional factors, and are involved in gliogenesis of the spinal cord and axonal 
outgrowth (Steele-Perkins et al., 2005;Deneen et al., 2006). In the cerebellum 
specifically, Nfia and Nfib were found to be highly expressed in the cell nuclei of 
immature GNPCs as they evolved to the postmitotic stage in the external germinal layer 
(Wang et al., 2007). And this expression was found to remain high until these cells 
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reach their final maturation in the internal granule cell layer of the cerebellum. 
Additionally, Nfia and Nfib have a significant role in axonal outgrowth, so when Nfi 
family expression was repressed by an Nfi dominant repressor, the outgrowth of axons 
was significantly affected. Moreover, Nfia knockout mice showed a dramatic defect in 
dendrite development, and large numbers of GNPCs were unable to migrate to the 
internal granule layer of the cerebellum, remaining in the molecular layer. Furthermore, 
Nfib knockout mice present with perinatal mortality and cerebellar foliation impairment 
was recorded (Wang et al., 2007). 
The identification of 3 CISs with low GKC p-values within the cerebellum 
control samples suggests that some of the CISs identified here may be false positives. 
Despite this, some of the CISs that have been identified by only a single statistical 
method are also plausible candidates.  For instance, Gli3, pulled out by the MC anaylsis, 
is a known downstream target of the SHH signalling pathway and it is also a known 
tumour suppressor gene (Erez et al., 2002). Recently, the role of Gli3 was identified in 
mouse brain development (Magnani et al., 2012). The Gli3 hypomorphic mouse mutant 
Polydactyly Nagoya (Pdn) shows features of agenesis of the corpus callosum (CC, a flat 
array of neural fibres that connect the two cerebral hemispheres) and misplaced glial 
and neuronal guidepost cells. Additionally, the expression levels of Nfi family members 
(Nfia, Nfib and Nfix) in the cortex (where they have to be at a higher expression level) 
and in the dorsal-most septum (where they have to be expressed at lower levels) were 
investigated. The results revealed the disappearance of all aforementioned gene 
expressions in the cortex, while the only Nfia expression was at higher levels in the 
septum. Finally, disruption of the FGF and WNT/β-catenin signalling pathways was 
also observed (Magnani et al., 2012). 
Of the genes only identified by GKC, Myt1L and Slit3 are of particular interest. 
Myt1L is a pan neural transcription factor which can help to convert fibroblasts to 
neurons (Vierbuchen et al., 2010), Slit3, with other Slit genes (Slit1 and Slit2) are 
known to play a role in stimulation of axonal branch formation and their expression is 
upregulated postnatally (Marillat et al., 2002). Furthermore, Slit3 controls axonal 
guidance and neuronal cell migration in the CNS midline (Yiin et al., 2009). 
Additionally, SLIT3 was found to be methylated in about 29% human glioma cell lines 
and in approximately 35% of human primary glioma tumours (Dickinson et al., 2004). 
In addition, in zebrafish neuronal development Slit3 has a role in directing glial cells 
localisation and position (Barresi et al., 2005). Slit3 is considered a tumour suppressor 
gene as its over-expression in the Sdf1/Cxcr4 mouse model of breast cancer reduced 
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tumour formation (Marlow et al., 2008). The inferred mode of action of the insertions 
within Slit3 is ORF disruption, consistent with this suggestion. The identification of 
these two genes by GKC alone is also to be expected, as both are very large genes 
(spanning ~385 and 590kb respectively. Both were only identified in the widest Kernel 
width analysis (120kb GKC scale), as the inserts were fairly evenly distributed within 
both genes (consistent with loss of function). This illustrates the effectiveness of 
combining the two statistical methods. 
Although, Liver adinomas generated in this study were small in number (19 
tumours) they are, to my knowledge, the only adenomas generated by whole-body SB 
mutagenesis. About 1206 transposon reads were recovered  from these and 7 CISs were 
identified. However, Keng et al., (2009) generated 68 nodules and recovered 8060 
insertions, and 19 CISs were identified by utilising conditioned mobilised SB 
transposase by Cre recombinase. Furthermore, as Egfr gene was identified by both 
study revels that this gene is specific and important for hepatocellular carcinoma 
generation. 
In conclusion, a whole-body SB mutagenesis system used with the Ptch1+/- 
murine model has increased the frequency of MB and decreased the latency. Efficient 
genotyping, high depth sequencing analysis for 40 MB samples and MC GKC statistical 
methods have identified 18 genic CISs, many of which are plausible candidates for 
involvement in MB. The validation of these gene CISs within experimental MB 
samples would be a high priority before downstream analyses, and this will be 
presented and discussed in the next chapter.  
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Chapter 4. (Results 2) 
 
Validation of CISs and their inferred mode of action 
 
 
4.1 Introduction 
Insertional mutagenesis is often used for somatic cell forward-genetic-screening 
in model organisms to identify tumour suppressor genes and oncogenes relevant to 
human cancer (Ivics et al., 1997) (Callahan and Smith, 2000;Uren et al., 2005;Collier 
and Largaespada, 2006). The mutagen has the ability to work as a molecular tag, 
allowing for the prompt identification of mutagenized genomic loci through the 
identification of common insertion sites [CISs (Starr et al., 2009)]. The Sleeping Beauty 
(SB) mutagenesis system is one of the current methods used for insertional mutagenesis 
screens (Collier et al., 2005;Kool and Berns, 2009;Starr et al., 2011) and has been 
coupled to next generation sequencing (NGS) technology to facilitate deep sampling 
and recovery of insertion sites. For instance, in a recent study conducted in colorectal 
cancer, where the SB system was used to identify candidate CISs, the insertion read 
recovery was about 347,993 sequence reads from 446 tumours (Starr et al., 2011).   
In Chapter 3 I presented the results of a whole body SB mutagenesis screen of 
the Ptch1+/- model of MB. Mutagenesis increased the frequency of MB in predisposed 
animals, but did not generate MBs in wild type littermates. It also generated additional 
tumour types including rhabdomyosarcomas and adenomas. However, as the primary 
aim of this screen was to identify genes involved in MB, the focus of my work was the 
CISs identified within the data from MB tumours. FLX sequencing recovered 
approximately 204 inserts per tumour, comparable to other analyses utilising this 
technique, and in total 18 CIS genes were identified using two different statistical 
methods, with 11 being identified using both methods (Table 3.6).   
Prioritisation of these candidate genes for downstream analysis could be done 
based solely on CIS p-value and known function. However, the SB mutagenesis system, 
and subsequent CIS identification steps, can yield false positives, and can confound 
such a direct approach. Tumour cells may comprise both clonal and subclonal insertions 
that enable the position of cancer-causing genes to be identified by mutagenesis. Most 
inserts in tumour cells consist of passenger mutations, which are also known as non-
lesion-causing insertions, and these could lead to false positives. Second, some tumours 
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may contain contaminating normal cells that will present with a variety of SB insertion 
patterns (Copeland and Jenkins, 2010;Brett et al., 2011). The SB system does also show 
some insertion site bias, which may also contribute to false positives. The use of 
statistical analyses and normal cerebellar samples act as controls for such false 
positives, and the recovery of a small number of CISs from the control samples suggests 
that some of the MB CISs with low p-values may indeed be false positives.  
In addition to the mutagenesis step, CIS identification uses both PCR and high 
throughput sequencing, both of which could be affected by experimental error such as 
PCR contamination, or errors in mapping due to low quality sequence reads. Removal 
of inserts in different tumours sharing the same insertion site is used here, and 
elsewhere, to control for the former. In addition, our HTG sequencing has identified a 
significant number of “firestorm” insertions, likely to be caused by secondary 
transposition events being picked up by the high depth of sequencing. Because of these 
different sources of potential false positives, it is also necessary to validate some of the 
mutation data experimentally.  
The insertion sites which define CISs need to be validated at the genomic level, 
to confirm the integrity of individual T2/Onc insertions. This validation process is 
presented here in this chapter, with the insertion’s location and impact being addressed 
at both the genomic and transcriptomic level for a subset of MB CIS genes, and for one 
CIS identified in liver adenomas; Egfr. Although adenomas were not the main focus of 
this thesis, Egfr inserts were chosen for analysis due to the large number and unusual 
distribution of the inserts within this gene, and because  the position of Egfr inserts has 
been analysed in a previous SB screening study (Keng et al., 2009) allowing the 
consistency of the mutagenesis to be assessed. 
Validation of inserts can also be performed at the transcriptional level, to 
confirm the impact of individual inserts on transcript structure and by extension, gene 
function. The SB transposon carries the murine stem cell virus’ (MSCV) long terminal 
repeat (LTR), and a splice donor (SD) from exon 1 of the murine FOXP2 gene.  These 
enable overexpression of oncogenes upon insertion upstream of, or within, a gene if 
insertion is in the same orientation as transcription. On the other hand, the transposon 
also carries a splice acceptor (SA) and polyadenylation signal (PA): Thus they have the 
ability to terminate transcription of a tumour suppressor gene upon insertion into the 
gene in either orientation (Figures 4.1 A and 4.1 B) (McIntyre et al., 2012). For 
example, Dupuy et al., 2005, established that about 60% of the T-cell leukaemias that 
were analysed in their first SB study contained insertions within intron 27 of Notch-1. 
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All the inserted transposons were located in the same transcriptional orientation as the 
gene, causing a 5’ truncated protein to be expressed due to the presence of the MSCV 
promoter. This allows the mode of action inferred from the position and orientation of 
inserts within genes to be verified (Collier and Largaespada, 2006). 
 
 
 
 
 
Before analysing specific genes, several MB screens have used both co-
occurence or mutual exclusion of CIS inserts within tumours, KEGG analyses, or 
Ontology analyses to infer functional redundancy (Wu et al., 2012). Due to the small 
number of inserts identified here, I analysed Ontology only. In addition, a number of 
gene expression analyses were analysed which have identified genes with expression 
differences in certain MB subgroups. Querying of this data may also provide insight 
into the candidature, or subgroup specificity, of the CIS identified. 
 
 
Figure 4.1. Sleeping Beauty system and the impact of insertions. (A) Sleeping Beauty 
mutagenesis system. The concatemerised copies of the transposon (T2/Onc) (highlighted) 
excise and mobilise (hop) from the donor chromosome/allele, with the aid of the transposase 
enzyme, and are pasted into a recipient gene (common insertion site: CIS). (B) Impact of the 
transposon on the affected gene. The transposon can trap the gene bi-directionally and, 
together with the promoter, it can terminate  transcription prematurely (SA and PA) or  
overexpress genes (via the MSCV and SD). IR/DR, indirect repeat/direct repeat; SA, splice 
acceptor, PA, polyadenylation signalling, SD, splice donor; MSCV 5’, murine stem cell virus 
promoter. (Figure adapted from Mclntyre et al., 2012). 
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4.1.1 Aims  
 The aims of the work presented here are therefore: 
 
1. To validate the SB insertion datasets at the genomic level, and assess the impact 
of insertion on gene expression in a small number of cases. To achieve this, I 
examined the inserted transposons within two genes, Tgif2 and Egfr, in detail. I 
also examined the impact of the insertions on the expression of several genes in 
terms of transcript structure and/or expression levels. 
 
2. To use Gene Ontology and analysis of gene expression in human tumour series 
to gain insight into the biology of the interacting mutations, and whether the 
genes identified are likely to be relevant to SHH subgroup MB, or the wider 
tumour type.  
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4.2 Results 
 
4.2.1 Validation of CIS Data within Tumour Samples 
 To validate the insertion site data, several genes were chosen to confirm the 
presence of specific insertion sites and to also confirm the impact of these insertions 
upon transcription. The following MB CIS genes were chosen based on GKC p-value, 
mode of action (both loss of function and upregulation), and ease of analysis in terms of 
clustering of insert location: Tgif2, NfiA, Tead1 and Myt1l. In addition, Egfr, the most 
significant CIS in the adenoma dataset (Table 3.7) was analysed, to allow direct 
comparison of insert distribution with a previous SB study of a hepatocellular 
carcinoma mouse model which identified Egfr as the top CIS hit (Keng et al., 2009).  
 
4.2.1.1 Validation of the genomic inserts 
First, to validate the FLX sequence data within a subset of CISs, genomic PCR 
assays were designed to confirm specific transposon insertional events, by amplifying 
the junction between the T2/Onc insertions and the flanking genomic DNA sequences. 
This assay consists of two genomic primers flanking the region where the inserts are 
present (as a positive control for wild-type DNA) and one transposon-specific primer 
that amplifies out from the IR/DR(R) region of the T2/Onc insert: when an insert is 
absent from the genome, an amplified control product of the expected size will be 
obtained using the genomic primers. In contrast, when the insert is present within the 
genome, the transposon-specific primer can give amplification with one of the gene-
specific primers (forward or reverse), depending on the insert orientation relative to the 
gene. 
For most CISs the inserts are spread throughout the targeted gene, making 
validation of multiple inserts labour intensive, e.g. Nfia. Two genes, Tgif2 and Egfr, 
were chosen for detailed analysis because their inserts were tightly clustered, allowing 
analysis of multiple independent insertions using a single gene-specific primer pair. In 
both cases, all the inserts were located within a single intron. In the case of Tgif2, all the 
inserts are located in the same orientation as the gene on the positive strand, implying 
upregulation. However, in the case of Egfr, the inserts are inserted in the negative 
orientation with respect to gene transcription, implying transcript truncation.  
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4.2.1.1.a Validation of Tgif2 inserts in MB samples 
Five MB samples were originally identified with inserts in Tgif2 using FLX 
sequencing and they were analysed by genomic PCR. However, two samples, 791 and 
793, had an insert within the same dinucleotide which suggests that one of them may be 
an artefact. All the inserts were located in the first intron and all were in the sense 
orientation (Figure 4.2 A). Therefore, the second (E2) exon-specific reverse primer and 
the transposon-specific IR/DR(R) primer were used to check for the presence of inserts. 
As shown in Figure 4.2, amplification products were generated from all of the samples 
with SB inserts except for sample 793, with amplicon size varying according to the 
distance of the transposon from E2. The expected sizes of the products were ~483 bp 
for sample 8, and ~1.3 kb for samples 580, 524, and 791, respectively. Additionally, 
four MB samples without inserts in this gene and three normal cerebellum samples were 
analysed, and no insertions were detected (Figure 4.2B). These results validate the FLX 
sequencing data. However, the failure to confirm the presence of an insert in sample 
793 highlights one potentially confounding factor when using LM-PCR and FLX 
sequencing for transposon insert detection, and confirms both that some inserts reported 
to be in the same dinucleotide are false-positives, and that these do need to be controlled 
for during the CIS analysis. These false positives could be due either to sample/PCR 
contamination or misreading of the sample specific barcode during FLX sequencing.  
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Figure 4.2. Validation of genomic inserts within Tgif2. (A) Location and orientation 
of T2/Onc within intron 1 of Tgif2. E - Represents the exon; half arrows represent the 
directions and positions of the inserts. Annotated tumours according to their distance 
are included. (B) Products amplified using primers from the right side of T2/Onc and 
Exon 2. Tumour id. and approximate product sizes are indicated. H2O = no template. 
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To confirm the integrity of the exonic primer, cDNA templates from all tumours 
were also analysed using the exon 2 primer in combination with a primer from exon 1 
(Figure 4.3). The expected amplicons were generated in all the samples. 
  
 
 
4.2.1.1.b Validation of the inserts within Nfia 
Nfia was the gene most frequently targeted by SB insertions in the MB dataset  
with 27 independent transposition events, and the majority of the inserts were in the 
antisense orientation (relative to Nfia transcription) (Figure 4.4 A). To confirm 
insertional events within this gene, genomic PCR was performed on one MB tumour 
(MB-P-540) and one wild-type cerebellar control, as shown in Figure 4.4 B; a product 
of the expected size was amplified from the primer pair flanking the junction between 
an intronic primer and the right IR/DR primer (3+1) in tumour with insert. Moreover, 
the expected ~200 bp amplicon was obtained from the wild-type allele using intronic 
primers (1+2). This finding provides additional evidence for to the insertional validation 
series within the MB samples. 
 
 
Figure 4.3. Expression of Tgif2 in MB. (A) Expression of Tgif2 
within MBs with inserts and with no inserts, assayed using primers 
from exons 1 and 2. Cerebellum control sample, and no template 
control (H2O) are also shown. The amplicon size of Tgif2 is ~117 
bp. (B) control Gapdh (~131 bp) amplification products. 
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4.2.1.1.c Validation of Egfr genomic inserts within liver adenomas 
As a further check of the insert site data, Egfr was also analysed within twelve 
liver adenomas by genomic PCR. All the inserts were located and distributed within 
intron 24 of Egfr and all were negatively (antisense) orientated with respect to the gene 
(Figure 4.5A). A specific endogenous forward and reverse primer pair, spanning all the 
inserted transposons within intron 24, was used to amplify the wild-type intronic region. 
The expected 713 bp amplicon was successfully amplified from 12 liver nodules with 
inserts, and from six liver nodules without inserts (Figure 4.5B). The endogenous 
Figure 4.4. Validation of genomic insert within Nfia. 
(A) Schematic diagram representing the location, size 
(2.2Kb)and orientation of T2/Onc within intron 2 of 
Nfia. The half arrows indicate the primer positions 
within the intron and T2/Onc. E2 and E3 represent the 
exons. (B) Amplification products obtained using the 
intronic primers.   Primers 1+2 generate a product from 
the wild type Nfia allele  (expected size ~200 bp). Use 
of intronic primer 1 with the primer from the right side 
(IR/DR) of T2/Onc generates a product when SB is 
inserted in the negative strand giving a  product which 
is larger than the normal allele (primers 3+1, expected 
size of ~260 bp). A water sample was used as a 
negative control (H2O) 
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forward primer and the transposon-specific IR/DR(R) primers were then used to 
amplify the transposon junctions. Amplicons of the expected sizes were amplified 
successfully from all the adenomas with inserts, with the expected sizes varying 
according to the position of the inserted T2/Onc element (ranging from ~195 - ~813bp) 
(Figure 4.5C). Furthermore, two samples, 277 and 751, generated two different product 
sizes corresponding to two different insertions at different positions within these 
adenomas. The other six liver nodules without insertions (630, 631, 262, 571, 312 and 
207) were included to confirm the integrity of the assay, and they showed no 
amplification. It is noteworthy that seven of the samples included insertions which were 
removed by the second statistical analysis as potential false positives as they were 
inserted into the same dinucleotide, leaving only a total of five totally independent 
insertion sites. These results establish that in this case the T2/Onc insertions in the same 
dinucleotide within different samples are genuine independent insertions at identical 
genomic locations and not artefacts. Moreover, the distribution of inserts within Egfr 
was focused within intron 24 in agreement with a previous SB screen analysis, and all 
were not in the same genic orientation (Keng et al., 2009), providing further evidence 
that Egfr is a key gene in hepatocellular carcinoma. 
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4.2.1.2 Validation of structural impact upon transcripts 
The genomic PCR above confirmed the integrity of the SB insertion site data 
generated by FLX sequencing. From the in silico analysis and the orientation bias of the 
inserts, it is clear that chimeric or truncated transcripts are expected to underpin the 
biological impact of the candidate CISs. To confirm the existence of chimeric 
transcripts in these genes, sets of primers were designed to amplify the exonic and 
Figure 4.5. Identification of transposons within the Egfr gene in liver 
adenomas. (A) Transposons number and orientation within intron 24 of Egfr. (B) 
Products amplified by the endogenous primers of intron 24 (713 bp) from both 
liver adenomas with inserts and liver adenomas without inserts. (C) Product 
amplification between the endogenous forward primer from Egfr intron 24 and the 
T2/Onc forward primer; the product sizes vary according to the position of 
T2/Onc within the gene. 
 101 
transposon junction at the transcriptomic level using RT-PCR. The results for Tgif2 and 
Egfr are shown in Section 4.3.1.2.a and Section 4.3.1.2.b below.  
 
4.2.1.2.a Identification of chimeric transcription from Tgif2 
  As shown in Figure 4.6 A and B, expression of the wild type Tgif2 allele was 
confirmed (320 bp) using E1 and E2 primers in both inserted and non-inserted tumours, 
as well as in control cerebellum samples (with very low expression). In contrast, 
amplification between an E1-specific forward primer and a T2/Onc Splice Acceptor 
reverse-specific primer was only observed in one of the samples, indicating low levels 
or no transcriptional integration between exon 1 and the downstream T2/Onc element in 
tumours with inserts (Figure 4.6C). However, amplification between the T2OncSD and 
Tgif2 E2 primers did occur (~230 bp) in the four tumours where genomic inserts were 
validated. This confirms that expression of the allele containing the inserts is being 
driven by the promoter within T2/Onc.  No amplification was observed in tumours 
without inserts, or in the control cerebellum samples using these primers (Figure 4.6D). 
It is noteworthy that tumours with no inserts also show Tgif2 expression, suggesting that 
this gene may be upregulated in these tumours via an SB-independent mechanism. 
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4.2.1.2.b Identification of chimeric transcripts from Egfr 
Analysis of Egfr, which was identified as a common insertion site within liver 
adenomas, is shown in Figure 4.7. The expression of the wild-type allele was confirmed 
(183 bp) using primers from the 24
th
 (E24) and 25
th
 (E25) exons of Egfr in both inserted 
and non-inserted adenomas (Figure 4.7 B). In tumours with inserts in intron 24, 
transcripts were captured between E24 and the polyadenylation (PA) signal of the 
transposon (393 bp, Figure 4.7 C), suggesting that a truncated protein is the outcome of 
insertion. Comparable results were also reported in a previous Sleeping Beauty study 
that sought to identify the cancer genes involved in hepatocellular carcinoma (Keng et 
al., 2009). 
 
 
Figure 4.6. Validation of chimeric transcriptional events for Tgif2 using reverse 
transcriptase PCR. (A) Primers between T2/Onc and Tgif2 exons, insert orientation, 
and the hypothetical transcriptional process of Tgif2. (B) Amplification of the exonic 
primers spanning exon 1 and exon 2 of Tgif2: the products sizes are 337 bp. (C) 
Amplification between SA of T2/Onc and exon 1 of Tgif2. (D) Amplification between 
SD of T2/Onc and exon 2 of Tgif2, confirming the integration of T2/Onc within the 
transcriptional process of Tgif2. The last panel shows Gapdh (131 bp) amplification for 
all the samples used. 
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 Overall, these results validate the genomic insertion sites, and confirm the 
existence of inferred transcriptional products which are consistent with a specific mode 
of action upon each gene (upregulation for Tgif2 and truncation for Egfr).  
 
4.2.2 Quantification of the Impact of Transposition on Gene Expression 
 The above analyses confirmed the presence of chimeric T2Onc/target gene 
transcripts: in several cases upregulation of the entire open reading frame is the inferred 
outcome of insertion when inserts are clustered upstream of the exon containing the 
translation start site, while downregulation of exons 3’ of T2Onc insertions is inferred 
for other genes. However, to fully validate the inferred mode of action it is necessary to 
quantify gene expression for specific genes.  Three MB CISs, namely Tgif2, Myt1l and 
Tead1, were chosen for analysis using TaqMan® qPCR. 
Figure 4.7. Validation of chimeric transcriptional events for Egfr 
using reverse transcriptase PCR. (A) Schematic showing the primers 
between T2/Onc and the Egfr exons 24, insert orientation, and the 
hypothetical transcriptional process of Egfr. (B) Amplification using 
the exonic primers spanning exon 24 and exon 25 of Egfr; the expected 
product size is 183 bp. (C) Amplification between PA of T2/Onc and 
exon 24 of Egfr. The expected product was amplified from tumours 
with inserts (~393 bp) confirming the integration of T2/Onc within the 
Egfr transcripts. The last panel shows Gapdh amplification. 
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4.2.2.1 Quantification of Tgif2 expression 
Initially, a real-time PCR assay was calibrated using tumour samples with Tgif2 
inserts to measure the efficiency of the assays and to select appropriate concentrations 
of sample, primers and probe (see Methods). For each sample, triplicate reactions were 
carried out to measure the average cycle threshold (Ct) value per sample. The average 
relative expression for Tgif2 was determined using the Ct method and normalised to 
a control gene (-Actin) and to the median Ct value obtained from six wild-type 
cerebella controls. As shown in Figure 4.8, Tgif2 expression in the tumours with inserts 
(pink) is appreciably higher than it is in the tumours without inserts. Moreover, the 
differential expression of Tgif2 between the inserted tumours and the tumours without 
inserts using qPCR was statistically significant (t-test p = 0.025). The differential 
expression was statistically highly significant between the tumours with inserts and the 
wild-type tumours (p = 0.00051).  The significantly higher expression of Tgif2 within 
the inserted tumours, as compared to the tumours without inserts, is consistent with the 
transposition having driven the expression upwards. Additionally, these results suggest 
that Tgif2 may exhibit oncogene-like behaviour and that it may play a role in MB 
formation. 
 
 
Figure 4.8. Expression of Tgif2 in MBs. Relative expression 
of Tgif2 analysed by qPCR in SB mutagenized MB mice. 
Relative expression was calculated according to the median 
expression of the six cerebellum controls. * (p=0.025), *** 
(p=0.00051). 
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4.2.2.2 Quantification of Myt1l expression 
 As Myt1l plays a major role in neuronal development (Kim et al., 1997), the 
impact of insertion upon expression levels may have an impact on tumour development. 
The inferred mode of action of Myt1l was downregulation, as most of the inserts were 
distributed evenly within the gene and in reverse orientations to the gene. Myt1l 
expression relative to wild-type cerebella controls was determined (Figure 4.9) using 
Ct methods, normalised to a reference gene (-Actin), but no statistically significant 
difference was observed  (p = 0.59).  However, as expected in all seven of the MB 
tumours, Myt1l was expressed at very a low level compared to the controls.  
 
 
 
 
 
Figure 4.9. Myt1l relative expression by qPCR. Differential 
expression of Myt1l within tumours with inserts (purple bars), 
and within tumours without inserts (blue bars). The expression 
was not significantly different (p = 0.59) between the tumours 
with inserts and the tumours without inserts. The reference 
control is set to 1 and indicated by a thick line. 
 106 
4.2.2.3 Quantification of Tead1 expression  
  The inferred mode of action for Tead1 expression was downregulation, based on 
the position and orientations of the inserts (see Table 3.6). Figure 4.10 presents the 
expression of the Tead1 gene relative to the reference cerebellar controls in MB 
tumours with inserts using the ∆∆Ct method, normalised to an endogenous gene (B-
Actin). The higher expression of Tead1 within both the five MB tumour samples with 
inserts (purple box) and the five MB tumour samples without inserts (blue bars) was 
statistically highly significant (p = 1.2E-05) compared to the expression in the 
cerebellum controls (indicated as the base line of 1). Furthermore, the expression of 
Tead1 in the tumours with inserts is 2.1X higher that the expression in the tumours 
without inserts, and this difference was also statistically significant (p = 0.04).  
 
 
 
  
Figure 4.10. Relative expression analysis of the Tead1 gene in the 
MB samples and cerebellum controls. The expression of the Tead1 
gene was significantly upregulated in MB tumours (inserted or without 
insertional mutation) compared to the cerebellum controls (p = 1.2E-05). 
Tead1 expression is also significant between tumours with inserts and tumours 
without, as shown in the figure (* p= 0.04). The average ΔCt of the 
cerebellum controls was set to 1 for presentation purposes. 
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The aforementioned results show that the use of qPCR assays to measure 
expression levels in tumours with inserts and tumours without inserts was highly 
informative in the case of the Tgif2 gene. The high expression in tumours with inserts is 
consistent with the inferred MOA and existence of chimeric transcripts. Moreover, 
consistency with the inferred MOA was also checked in two other CISs, namely Tead1 
and Myt1l. The former also showed evidence of upregulation, consistent with the 
inferred mode of action.  Although no evidence for downregulation was observed for 
Myt1l, the inferred mode of action is loss of function due to truncation. Overall, this 
study’s expression results are consistent with the identified CISs directly affecting 
transcription of the genes into which they insert, consistent with a role in tumour 
formation. 
 
4.2.3 CISs are neuronal developmental regulators 
After the inferred mode of action was confirmed for three genes using qPCR, the 
question remained as to whether or not these CISs have any biological function that is 
consistent with the development of cancer. To examine and potentially answer this 
question, Gene Ontology (GO) analysis was performed using the Generic Gene 
Ontology Term Finder (Boyle et al., 2004). This revealed that the identified MB CISs 
(Table 4.1) are enriched for genes involved in neuronal development (8/18 CIS genes; p 
= 0.0003), and transcriptional factors (7/18 CIS genes; p = 0.00002) or regulators of 
gene expression (9/18 CIS genes; p=0.00003). All 8 CIS genes implicated in neuronal 
development are transcriptional regulators (Atxn2, Tead1, Tgif2, Crebbp, Nfib, Pten, 
Slit3 and Gli3). It is noteworthy that several genes were identified as being implicated in 
cellular growth and/or fate determination (data not shown). This suggests that the CISs 
are involved in fundamental cellular developmental processes. As a result, it appears 
plausible that any imbalances in expression could lead to tumourgenesis. 
 
4.2.4 CISs are Differentially Expressed between MB subgroups.  
As the inferred mode of action was generally consistent with qPCR for the 
tested genes, and the results of the ontology analysis revealed important roles for CISs 
genes in neuronal development, I next examined the expression of CIS genes within 
human medullobastoma (MB) to establish whether MB CIS genes are differentially 
expressed in human clinicogenetic subgroups. To achieve this, I investigated the 
differential expression of human orthologs of CIS genes within the data generated by 
Kool et al., (2008) and subsequently re-grouped by Northcott et al., (2011). This data 
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consists of 63 human MB samples that exemplify the currently defined four different 
MB clinicogenetic subgroups—WNT, SHH, Group 3 and Group 4. Their expression 
patterns are presented in Table 4.1. Interestingly, 15 of the 19 CISs genes showed 
differential expression in one or more clinicogenetic subgroups, and strikingly, 4 genes 
show differential expression in the SHH subgroup only (ATXN2, CREBBP, TEAD1 and 
ITGBL1). However, some of the CISs show significant differential expression in non-
SHH subgroups, such as NFIA differentially expressed in Group 3, FGF13, SLIT3 and 
PTEN differentially expressed in group 4 only tumours, and NFIB which was 
differentially expressed in WNT subgroup tumours only. Finally, some CIS genes were 
expressed differentially in more than one subgroup beside SHH subgroup, such as 
(TGIF2, GLI3, MYT1L, ADCY5 and L3MBTL4). 
To view and compare the expression of CISs between the human MB 
clinicogenetic subgroups, a heatmap of differential expression of CISs using the method 
recommended by Kool et al., (2008) was generated (Figure 4.11). As expected, the 
majority of the CISs show clear differential expression between one or more of the 
human MB subgroups. Within the SHH subgroup tumours, it is striking to note that the 
genes show expression which is generally consistent with the inferred MOA. For 
instance, MYT1L is downregulated in the SHH subgroup, while TEAD1, TGIF2 and 
CD2AP, ANKRD5, ITGBL1 and NFIB are upregulated within the same tumours. As 
expected, the expression of GLI3, an effector of SHH signalling, was upregulated within 
the SHH subgroup as the SHH pathway was stimulated. 
Because several genes showed differential expression within the SHH human 
MB subgroup, this finding suggests that these CISs may interact with the PTCH gene, 
and, consequently, may contribute to MB formation within the current mouse model. 
However, the fact that some of the other genes were differentially expressed within 
other subgroups suggests that those genes may have a wider importance in MB 
development. 
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Nfia 
ORF 
disruption  
  C ↓ 
Dscr3 
ORF 
disruption    
 -    
Atxn2 Unclear 
  
SHH ↓ 
Tgif2 Up-R    SHH/D ↑/↓ 
Crebbp 
ORF 
disruption 
   SHH ↓ 
Tead1 Up-R    SHH ↑ 
Fgf13 Up-R 
   
D ↑ 
Nfib Up-R    Wnt ↓ 
Itgbl1 Unclear       SHH ↑ 
Pten 
ORF 
disruption 
    D ↑ 
Sfi1 
ORF 
disruption 
       -    
Slit3 
ORF 
disruption 
    D ↑ 
Gli3 
ORF 
disruption 
   SHH/D ↑/↓ 
Myt1l 
ORF 
disruption 
    
Wnt/SHH/
D 
↓/↓/↑ 
Tmem45b Unclear        -    
Adcy5 
ORF 
disruption 
      C/D  ↓/↑ 
L3mbtl4 
ORF 
disruption 
      SHH/D ↑/↓ 
Ankrd5 unclear       SHH/C ↑/↓ 
    42.90% 38.90% 47.60%   
    p=0.0003 p=0.00002 p=0.00003   
 
Table 4.1. CIS genes, enriched ontologies, and their differential expression 
within human MB subgroups. (ORF) open reading frame; (Up-R) upregulation; 
Arrows show the gene expression depending on the direction and relevance to the 
subgroup colour, () up-regulation, () down-regulation (expression data taken 
from Kool et al., 2008) . 
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Figure 4.11. Heatmap of CIS gene expression in human MB clinicogenetic 
subgroup tumours. The probe with the highest mean expression levels across all 
samples is presented. MOA represents the inferred mode of action with the SB 
insertion; the arrows represent the upregulation or downregulation pattern and dashes 
represent unclear interpretation. Two genes,Tmem45b and Sfi1, are not represented 
within the Affymetrix chip used. A colour bar representing specific expression levels 
is shown. Expression data taken from Kool et al., (2008). 
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4.3 Discussion  
In this chapter I confirmed the presence and impact of transposon insertions 
within a subset of CISs identified in the SB screen. This was achieved at both the levels 
of genomic sequence and chimeric transcripts. Q-PCR analysis was then employed to 
confirm the inferred mode of action of inserts upon Tgif2, Tead1 and Myt1l. Ontology 
analysis was also performed, and this identified a significant enrichment of neuronal 
and transcription factor CISs.   
To validate the bioinformatic identification of CISs, genomic PCR was first 
applied to three genes from different tumour types, Tgif2 and Nfia from the MB dataset 
and Egfr which was identified as the top CIS in liver adenomas. Despite the depth of 
next generation sequencing, CIS identification is error-prone, and this was exemplified 
by the Tgif2 analysis where an insertion in one of the MB samples proved to be a false 
positive. Additionally, chimeric transcripts were successfully identified for Tgif2 and 
Egfr using reverse transcriptase PCR, confirming the presence of T2/Onc fusion 
transcripts from both genes. These results support the inference that the effect of 
insertion on gene function was upregulation in the case of Tgif2 and truncation of the 
Egfr gene product. 
 A previous study proved qPCR’s superior sensitivity in comparison to that of 
the Illumina microarray (Guo et al., 2010). To confirm the impact of SB insertion upon 
gene expression, the Tgif2, Tead1 and Myt1L genes were all analysed by qPCR. Tgif2 
expression was found to by significantly higher within the tumours with inserts as 
compared to the tumours without inserts (2.1X), consistent with Tgif2 exhibiting 
oncogene-like behaviour. This is the first time this gene has been implicated in MB. 
Tgif2 is a member of TG-interacting factor gene family (TGIFs), which belongs to the 
TALE superfamily of homeodomain proteins (Imoto et al., 2000). Tgif2 has the ability 
to repress Smad-mediated transcription through interaction with TGF-β-activated Smad 
proteins (Melhuish et al., 2001). Tgif2 expression has been detected in the developing 
brain tissues of mouse embryos, specifically within the proliferating cerebellar 
neuroepithelium (Bertolino et al., 1996). In a recent study conducted by Taniguchi et al. 
(2012), both Tgif1 and Tgif2 have been reported to be involved in Holoprosencephaly 
(HPE) in mouse. This occurs when mutations of Tgif1 and 2 inhibit Shh signalling and 
cause malformation of the forebrain of mouse models. The authors concluded that the 
mutation of Tgif family members in mouse is involved in HPE, and suggested that this 
occurs due to Shh signalling pathway interruption. 
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I also showed that the Tead1 gene was significantly upregulated within the MB 
samples, as compared to the controls, with a significantly higher expression within 
tumours with inserts compared to tumours without inserts. This finding is also 
consistent with the MOA inferred from the CISs in silico,  as all inserts are clustered at 
the 5’ end of the gene consistent with upregulation. Tead1 is a family member of the 
TEAD (TEA domain) group of transcription factors that possess a DNA-binding domain 
(Anbanandam et al., 2006). The activity of this gene depends on a transcriptional 
coactivator called YAP (Cao et al., 2008;Sawada et al., 2008). YAP is known to be the 
downstream effector of the Hippo pathway, and recent studies have demonstrated its 
role in controlling cellular proliferation in Drosophila (Fernandez et al., 2009). Cao et 
al., 2008, demonstrated that upregulated YAP and TEAD1 promote the growth of 
neuronal progenitor cells via the activation of the cell cycle through the induction of 
cyclin D1. Moreover, they provided evidence that both these genes have the ability to 
disrupt progenitor cell differentiation via the suppression of NeuroM. Importantly, a 
recent study investigated the role of YAP1 and TEAD1 in MB subgroups. Fernandez et 
al. noted that the overexpression of both YAP1 and TEAD1 was associated with the 
SHH MB subgroup. This is congruent with our identification of Tead1 as a candidate 
cancer gene in MB. 
Myt1l, myelin transcription 1-like, is a zinc finger gene (MYT1 or NZF3) and 
belongs to the Myt1l family. In rodents, it has been shown to be predominantly 
expressed in the developing brain. The highest expression of this gene was recorded in 
the brain and spinal cord in adult rodents, whereas no expression was observed in the 
glial cells, suggesting that Myt1l is strictly expressed in neurons (Kim et al., 1997). 
Despite the significant difference in Tgif2 and Tead1 expression between tumours with 
inserts and tumours without inserts, no difference could be found for Myt1l. However, 
Myt1l expression was significantly lower in all tumours compared to the controls and 
this finding is consistent with the inferred MOA. The most plausible explanations for 
this finding are either that the expression of the disrupted gene is irrelevant, and that 
knock out of one allele through truncation of the protein is the MOA in this case 
(perhaps interfering with function of the wild type protein), or that reduction in Myt1l 
expression has been achieved by an SB-independent mechanism in tumours with no 
inserts in this gene. It is also possible that the expression of Myt1l within the MB 
precursor cell, rather than the mature tumour, is critical. Although these are all plausible 
explanations, distinguishing between them would be technically challenging and time 
consuming, as MB insertions within the gene would have to be engineered (or be 
 113 
germline) to allow straightforward analysis. As the Myt1l CIS is highly significant, and 
Myt1l is a known pan neural differentiation gene, it remains a strong candidate gene 
despite the lack of a clear impact of insertion upon expression in mature tumours.  
Primers were also generated for Nfia and Tead1, and these genes were also 
analysed at the transcriptional level (data not shown). These genes have an insertion 
bias opposite to their orientation, as the genes are positively orientated and the T2/Onc 
inserts are negatively orientated. No evidence of gene transcripts could be found linking 
the nearest exons and transposon from either site (data not shown). This might be due to 
the fact that the inserted transposons have an effect on the gene function without 
contributing to the transcriptional process. Alternatively, the impact on the transcripts 
might have occurred in the developing tumours prior to sampling. 
It is important to note that nine of the 19 CISs identified in this current study 
(Atxn2, Tgif2, Crebbp, Tead1, Itgbl1, Gli3, Myt1l, L3mbtl4 and Ankrd5), were reported 
to have differential expression within the human SHH MB subgroup in at least one of 
two recent tumour series analysed (Kool et al., 2008;Northcott et al., 2011). This 
provides further evidence that these genes could have a significant impact on the 
generation of medulloblastoma.  
 In conclusion, the insertional events, and the significant impact they have had on 
the expression of genes currently identified, suggest that many of the genes identified 
are plausible candidates for involvement in MB. Additionally, Gene Ontology 
investigation revealed that CISs are enriched for transcription factor genes which 
contribute to neuronal development and control cellular outgrowth. Moreover, It is clear 
from the discussion of individual CIS gene functions that several are very suitable 
candidate genes for MB development. However the ontology analysis has established 
that many genes have similar or overlapping functions in developmental processes 
within the neuronal system. This raises the possibility that the individual genes mutated 
affect the same or convergent developmental pathways which are key to SHH subgroup 
MB development. If so, identification and understanding of these pathways may shed 
light on tumour development and allow rational targets for therapeutic intervention to 
be identified.  A more detailed investigation of these genes within MB tumours, and the 
possibility that they work in co-ordinated developmental pathways, is presented in the 
next chapter. 
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Chapter 5. (Results 3) 
 
MB CISs define a network involved in neuronal development and 
human disease 
 
 
5.1 Introduction 
Brain and Central nervous system tumours comprises the second most prevalent 
cancer in childhood after leukaemias (Cancer Research UK, 2013b), and MB accounts 
for about 20-30% of the CNS in children (Li et al., 2013). Cancer genome sequencing 
and microarray expression analyses have identified a minimum of four molecular 
clinicogenetic subgroups of human MB; known as SHH, WNT (where SHH and WNT 
signalling pathways respectively have been critically disrupted), Groups 3 and Group 4 
(Tylor et al., 2012; Robinson et al., 2012).  
Studies conducted on mice revealed that the SHH MB subtype arises from 
granule neuron precursor cells (GNPCs) of Ptch1
+/-
 mice, that Wnt subtype tumours can 
originate from lower rhombic lip progenitors (LRLP) cells of Blbp-
Cre;Ctnnb1
+/lox(Ex3)
;Tp53
flx/flx
 mice,  and that Group 3 MB tumours are likely to arise 
from as yet undefined cerebellar progenitor cells. A Group 4 tumour cell of origin has 
yet to be identified (Schuller et al., 2008;Gibson et al., 2010;Kawauchi et al., 2012). 
These data are consistent with the widely held view that Medulloblastomas, like many 
paediatric cancers, arise due to the breakdown of normal developmental processes 
(Ellison, 2010).  
 In the previous chapters I presented the results from a whole body SB 
mutagenesis screen of the Ptch1+/- murine model of MB which identified candidate 
genes for involvement in disease (Table 3.6), and showed that the majority of these are 
differentially expressed in one or more MB subgroup. I also established that the 
candidate genes are significantly enriched for transcription factors and genes involved 
in neuronal development. This observation is consistent with the hypothesis that the 
neuronal transcription factor CISs affect key signalling pathways within the developing 
cerebellum, and that their disruption by SB enhances MB formation. As transcription 
factors act within carefully regulated cascades often with complex feedback 
mechanisms and interactions (Vaquerizas et al., 2009),it is possible that the 
transcription factors within the CIS list are influencing one, or a small number of 
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interacting, developmental pathways in the Ptch1+/- model.  Before analysing any 
candidates experimentally, it was decided to investigate this possibility by analysing 
microarray gene expression data generated from primary human MBs.  
 A dataset generated from 72 paediatric MB analysed by comparative genomic 
hybridization (CGH) and gene expression assay (Fattet et al., 2009) is publically 
available. The main focus of this study was the investigation of the role of WNT/β-
catenin pathway in MB and to identify a general and effective biomarker for this lesion. 
β-catenin protein was expressed in more than 50% of the investigated cases. However, 
mutated CTNNB1 was extensively expressed in the nucleus of all β-catenin positive 
samples. Furthermore, this study analysed the clinical features of the MB patients, and 
longer survival rates were recorded in patients with CTNNB1 positive tumours 
compared to the negative tumours (mean 5-year of overall survivals of 53.7%). The data 
from this study was combined with those generated by Kool et al., (2008) by Dr Dan 
Williamson (Newcastle University) and used in the analyses presented in this chapter. 
A variety of techniques have been developed to identify putative gene 
interactions within complex expression datasets (Elkon et al., 2003)(Elkon et al., 2003). 
One of the most widely used is ARACNe (algorithm for the reconstruction of accurate 
cellular networks), which was specifically developed to identify direct gene-gene or 
gene-protein interactions of the type expected to exist between transcription factors and 
their targets. This method can create gene interaction networks by analysing expression 
data from large datasets (Carro et al., 2010), and is characterised by its ability to 
overcome the limitations of some other algorithmic methods such as correlation 
methods. For instance, it possesses a low computational complexity, uses the full range 
of expression data, and exhibits a very low false positive rate (Margolin et al., 2006). 
ARACNe has been successfully used to identify two transcription factors (C/EBPβ and 
STAT3) acting as synergic initiators and the main regulators of mesenchymal 
transformation in human malignant glioma (Carro et al., 2010). 
For these reasons, ARACNe was chosen for the analysis of MB CISs in human 
expression data.  The availability of clinical data from one of the human datasets (Fattet 
et al., 2009) also meant that the relationship between individual genes or CIS networks 
and survival/clinical features could be investigated.  
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5.1.1 Aims 
 
5.1.1.1 To generate a human MB gene expression network using publically available 
microarray gene expression data from primary tumours. 
 
5.1.1.2 To investigate the relationship between CIS genes in human data sets through 
the analysis of the network and presentation of heat maps. 
 
5.1.1.3 To use bioinformatic analysis to establish the relationship between CIS gene 
expression and survival in human datasets.  
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5.2 Results 
 
5.2.1 MB CISs define a neuronal transcription factor gene network 
 To investigate the possibility that the CISs presented in chapter 3 are 
functionally linked within MBs, an ARACNe analysis was performed by Dr D 
Williamson (NICR) using the merged data of Kool et al., (2008) and Fattet et al., 
(2009) which consisted of data from 119 MB human tumours generated using the 
Affymetrix HGU133 Plus 2.0 genechip. Briefly, the method involves the assembly of a 
genome-wide collection of gene expression relationships, and systematic removal of 
indirect relationships by the algorithm, to reverse engineer a single network of putative 
TF-Target relationships.   Affymetrix probes were filtered down from the original 
~500,000 by inspecting for probes that were expressed in at least 10% of the samples 
with a range greater than 500 and an overall fold change of 3. Then, only probes with a 
significant mutual information (MI) association with at least one other node,  connected 
to each other with a bootstrapped P-value of <10E-8, were retained. This left 8,749 
probes in the network. To eliminate possible bias introduced by merging data from two 
different CIS calling algorithms, only the 17 MB CISs identified using the Genome 
Kernel Convolution method were analysed. The Cytoscape representation of the full 
Affymetrix network generated by ARACNe analysis is shown in Figure 5.1. 
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When the position of the CIS genes within this network was examined, seven 
genes, including four of those with the highest GKC P-values (Table 3.6), were found to 
be connected to each other via nearest neighbours (Figure 5.2). This clustering of 7 CIS 
genes was found to be statistically significant (p<0.006). This significance was tested by 
examining the topological rearrangement of the 7 genes defining the network, and 
performing simulations tests by calculating the mean of the shortest path distance to the 
nearest joining CISs genes and then permuting this 10000 times with randomly 
identified genes in order to generate a null distribution. The distance observed was 
found to be shorter for the 7 CISs than in 99.7% of simulations.  
Strikingly, the CISs genes linked within the network were all defined by gene 
ontology analysis as transcriptional factors, neuronal development genes or both; 
CREBBP, NFIA, NFIB, TGIF2, TEAD1 and MYT1L are neuronal transcription factors 
Figure 5.1: Affymetrix ARACNe network of human MB with identified CIS. The 
complete Affymetrix gene network generated using expression from 119 Human MB 
samples. It consists of ~8749 Affymetrix probes. Nodes represent probes, and edges 
connect nodes which show a significant mutual information association. The MB CISs 
within the network are shown as yellow nodes. 
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or co-factors, while FGF13 is a neuronal growth factor known to be required for 
Xenopus central nervous system development (Nishimoto and Nishida, 2007). 
Furthermore, the application of gene ontology analysis to the networked genes which 
are linked to the CISs identified significant enrichment for genes involved in neuronal 
architecture and functions (p=0.019–0.0042 Table 5.1, and highlighted in green in 
Figure 5.2). This suggests that the network as a whole consists of neuronal transcription 
factors mutated by Sleeping Beauty, and their targets, and that collectively these genes 
influence neuronal differentiation programmes. 
  
 
 
 120 
Table 5.1: Ontology Analysis of genes linked within CIS network. Cellular Component and 
Molecular Function Ontologies over-represented in the Network are shown. P-value correction 
was achieved using a Benjamini and Hochberg False Discovery rate of 0.05. Gene frequencies 
in the network list and genome are shown. Ontologies marked with an asterisk are not 
significantly enriched when CIS genes are excluded. The neuronal and TF gene lists are 
highlighted. 
 
Cellular Component 
GO-ID p-value corr p-value Network Freq Total Freq Ontology Description 
43226 3.82E-05 3.29E-03 65 /83 9336 /16374 organelle 
45202 9.87E-05 4.24E-03 9 /83 367 /16374 synapse 
5622 1.51E-04 5.20E-03 72 /83 11306 /16374 intracellular 
44456 4.47E-04 1.28E-02 7 /83 271 /16374 synapse part 
43228 7.43E-04 1.60E-02 24 /83 2432 /16374 
non-membrane-bounded 
organelle 
43232 7.43E-04 1.60E-02 24 /83 2432 /16374 
intracellular non-
membrane-bounded 
organelle 
45211 9.87E-04 1.89E-02 5 /83 150 /16374 postsynaptic membrane 
5634 1.19E-03 2.05E-02 40 /83 5183 /16374 nucleus 
5856 1.62E-03 2.29E-02 16 /83 1402 /16374 cytoskeleton 
43231 1.69E-03 2.29E-02 56 /83 8347 /16374 
intracellular membrane-
bounded organelle 
43005 2.83E-03 3.48E-02 7 /83 373 /16374 neuron projection 
43198 3.68E-03 4.23E-02 2 /83 18 /16374 dendritic shaft 
Molecular Function 
GO-ID p-value corr p-value Network Freq Total Freq Ontology Description 
3700* 1.71E-05 2.62E-03 16 /78 949 /15440 
transcription factor 
activity* 
32452 1.99E-05 2.62E-03 3 /78 11 /15440 
histone demethylase 
activity 
30528* 4.18E-05 3.50E-03 20 /78 1506 /15440 
transcription 
regulator activity* 
8134* 5.94E-05 3.50E-03 11 /78 522 /15440 
transcription factor 
binding* 
32451 6.62E-05 3.50E-03 3 /78 16 /15440 demethylase activity 
5515 1.65E-04 7.28E-03 57 /78 8119 /15440 protein binding 
16563* 3.03E-04 1.14E-02 9 /78 429 /15440 
transcription activator 
activity* 
5522 3.73E-04 1.23E-02 2 /78 6 /15440 profilin binding 
16706 6.07E-04 1.40E-02 3 /78 33 /15440 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 
reduction of molecular 
oxygen 
51213 6.17E-04 1.40E-02 4 /78 77 /15440 dioxygenase activity 
43425* 6.92E-04 1.40E-02 2 /78 8 /15440 
bHLH transcription 
factor binding* 
5488 7.85E-04 1.48E-02 73 /78 12364 /15440 binding 
3677* 8.64E-04 1.52E-02 23 /78 2327 /15440 DNA binding* 
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Figure 5.2: ARACNe expression subnetwork defined by MB CIS genes. Only MB 
CISs genes linked via nearest neighbours are shown. MB CISs are shown enlarged; genes 
also identified as biallelically mutated MB CISs by Wu et al., (2012) are shown as 
diamonds. Genes with transcription factor activity are shown in yellow; Genes with 
enriched ontologies associated with differentiated neurons are shown in green. Genes with 
a known role in neuronal development are shown with a green border 
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5.2.2 Analysis of CIS gene expression with respect to patient survival 
Only 17 CIS genes were identified using the GKC analysis (Table 3.6) out of a 
total of ~20,000 murine genes. This represents approximately 0.1% of all genes. To 
investigate whether the expression of any of these genes associate with patient survival, 
log rank (Mantel-Cox) tests were performed and Kaplan-Meier (KM) plots were created 
for all 17 CISs.  Overall patient survival was analysed by Daniel Williamson (NICR) 
using median split data taken from (Cho et al., 2011). Strikingly, the expression of two 
CISs genes, namely PTEN (a defined suppressor gene previously involved in MB 
development, (Hartmann et al., 2006) and MYT1L (a pan neural transcription factor, 
(Vierbuchen et al., 2010;Pang et al., 2011) were significantly associated with poorer 
overall survival ((p=0.019 and p=0.016 by log rank test respectively, Figure 5.3A and 
B). Consistent with the poorer outcome of patients with low gene expression, the 
inferred mode of action (MOA) of SB insertions targeting these genes was down-
regulation (Table 3.5). This is also consistent with the inference from the highly 
networked position of Myt1l that it is a key gene. 
 
 
  
 
Figure 5.3: Expression correlation of MYT1L and PTEN with patients survival: 
Kaplan Meier curves presenting the correlation between the expression of MYT1L (a) and 
PTEN (b) (defined CISs) at both high and low levels, and patient’s survival data (Cho, 
Tsherniak et al. 2011) split by median with regardless  MB subtypes (follow up in months). 
Sample numbers and Log-ratio test p values are shown. 
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5.2.3 MB CISs and the network they define are differentially expressed within 
human MB clinicogenetic subgroups: 
 To investigate the relative activities of genes within the network, an expression 
heatmap of all probes (259) exemplifying the genes was generated using publicly 
available gene expression data (Kool et al., 2008). To view only the most informative 
probe for each gene, the average expression across all samples for all available probes 
from all genes was calculated, and the most highly expressed probe for each gene was 
chosen for display. This gave a final number of 81 high quality probes, exemplifying 81 
genes and gives an overview of how the network genes are behaving within human 
MBs (Figure 5.4). 
It is clear that there are distinctions between the different MB subgroups. 
Interestingly, the majority of the genes in the network show a low level of expression 
within the WNT and SHH subgroups and higher expression in the other two subgroups. 
These patterns of expression may be due, at least in part, to the inferred mode of action 
(MOA) of the insertions as most of them were loss of function. In contrast, a small 
subset of genes show high expression within WNT and SHH tumours, while they 
showed low expression within the other sub groups, namely PLXNC1, CALU, 
LOC100127983, NECAB1, TEAD1, TCF3, DC2, TRAM1, P4HA1, CREB3L2, CKLF, 
RPLP0, SPC18, MPST, TFDP2, TEAD2, TGIF2 and TDLG1. Two of these, TGIF2 and 
TEAD1, are MB CISs identified here, and have been shown by q-PCR analysis to be up-
regulated by SB insertions (Figure 4.8 and 4.10 respectively). It is noteworthy that in 
the original subgroup specific analysis of this expression data (Kool et al., 2008), four 
of these genes were shown to be significantly up-regulated in the WNT subgroup 
(TCF3, TRAM1, P4HA1 and CKLF), and others were identified as being expressed at a 
significantly higher level within the SHH tumour subgroup (DC2, CREB3L2, RPLPO 
and MPST). Only TFDP2 was identified within Group 3 and at a significantly lower 
expression, with PLXNCI and CALU being found to be expressed at a low level within 
Group 4 (Kool, et al., 2008). This diversity of expression of network genes within 
human MB subgroups suggests that some of these genes may contribute to the 
development of more than one MB subgroup of tumour.  
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5.2.4 Network genes investigated separately according to GO analysis 
Although the expression heatmap shows clear differences between subgroups, it 
does not allow any insight into the function of the genes due to the large number in the 
network. To specifically investigate the activity of the different enriched ontological 
genesets within the network, the genes were separated for the purpose of presentation 
into CIS genes, transcription factors other than CISs within the network, and neuronal 
development genes. Expression heatmaps were established separately for each of these. 
Figure 5.4: Differential expression of all CISs networked genes. An expression 
heatmap of 81 genes representing the CISs network within human MB subgroups. 
The probe with the highest mean expression level across all sample is shown for each 
gene. The majority of genes are expressed at relatively low levels within both WNT 
and SHH sugroubs, compared to a small subset being expressed at low levels within 
Group 3 and Group 4. The colour bar shows relative expression levels. 
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Fig 5.5A shows the heatmap of the seven CISs which define the network. MYT1L and 
FGF13 are highly expressed in Group 3 and Group 4, whereas in the WNT and SHH 
subgroups, TGIF2 was highly expressed. In contrast, NFIB shows very low expression 
in the WNT subgroup, whereas TEAD1 and NFIA show variable expression among all 
subgroups. 
The expression heatmap of other transcription-factors within the network is 
depicted in Figure 5.5B. These genes show two basic patterns of expression within 
human MB subgroups. TEAD2, TCF3, CKLF, CREB3L2 and TFDP2 show high 
expression behaviour in the WNT/SHH subgroups, while EBF1, CDK5R1, NEUROD2 
and ZBTB38 show high expression in Group 4. 
Fig 5.5C presents the expression heatmap of neuronal genes in the network. The 
majority of these genes are expressed at low levels within WNT/SHH subgroups, 
including SEPT3, CDK5R1, EB-1, GPHN, NSF, GPR51, MYCBP2, PCLO, ERBB4 and 
MAP2. Only DLG1 is expressed at a high level (this gene is known to have an important 
role in cell proliferation and synaptogenesis), suggesting that the CIS network has a 
significant impact on the neuronal differentiation process. It is clear that most of the 
neuronal genes, together with most of the other genes in the network, show consistently 
lower expression within human SHH and WNT MB subgroups tumours, and this is 
consistent with the MOA of the insertion affecting the CISs (that defined the network) 
being loss of function. It is also consistent with previous observations that Group 4 
tumours show high levels of neuronal gene expression (Kool et al., 2008). Also, from 
the function of the genes it could be inferred that mutation of the network TF CISs work 
synergistically with the disrupted SHH signalling pathway in the mouse model to 
maintain undifferentiated, highly proliferative cells, one of the known hallmarks of 
tumourgenesis. 
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Figure 5.5: Network activity correlates with human MB clinicogenetic subgroups: 
gene expression heatmaps of the network genes based on enriched GO specifications 
in all MB subgroups are shown. Where more than one probe per gene was present, the 
probe with the highest mean expression level across all samples is shown. A. 
Expression of CIS genes, which define the network. B. Expression of other 10 
transcription factors in the network. C. Expression of 13 neuronal genes in the 
network. The colour bar indicates relative expression.  
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5.2.5 Metagene activity in humans correlates with advanced disease in SHH 
subgroup tumours  
The expression heat maps of individual genes in the network, above, showed 
significant differential expression between tumour subgroups, and consistently high 
expression of neuronal genes in group 4 tumours. This raises the possibility that 
network activity as a whole could both discriminate between subgroups, and be of 
biological/clinical relevance. To investigate the possibility, the overall activity of 
network genes was assessed within human datasets by deriving a single network 
“metagene” score. To do this, the expression of each individual gene was first marked, 
(signed) depending on the direction of correlation with other CISs. The direction of this 
sign was arbitrarily chosen, and here low expression of genes with an inferred mode of 
action (MOA) of loss of function (e.g. MYT1L) correlates with a low metagene score, 
while low expression of CISs with an inferred MOA of upregulation (e.g. TGIF2) 
correlates with a high metagene score. A single metagene metric for the network was 
established, and the clinical features of all patients within the Kool et al., (2008) and 
Fattet et al., (2009) studies were analysed.  
The results of this analysis, which was performed by Dr. D. Williamson (NICR), 
are presented in Figure 5.6. As expected from the heat maps previously shown in 
Figures 5.3 and 5.4, the activity of the metagene is significantly different between MB 
subgroups (F=26.8; p < 0.0001, as shown in Figure 5.6A). The highest network activity 
was recorded within Group 4 tumours. This activity is presented at moderately higher 
levels within subgroup SHH and Group 3. However, the metagene activity is shown to 
be expressed at the lowest levels within the WNT subgroup. 
Moreover, in the same dataset, the metagene was observed to be differentially 
active in tumours with metastasis compared to those without (t = 2.107, p<0.038) 
(Figure 5.6B). This is consistent with the human MB Group 3 and Group 4 being 
associated with a high frequency of metastatic disease. Interestingly, the investigation of 
publicly available survival data for human MB patients (Cho et al., 2011) revealed a 
significant correlation between network activity and survival outcome, but only within 
the SHH subgroup tumours (Log-rank 8.03, p<0.005, as shown in Figure 5.6C). 
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Figure 5.6: Network activity: relationship with Metastasis and survival. A. 
Box and whisker plot showing log of metagene expression in MB clinicogenetic 
subgroups. ANOVA p-value is shown.  Boxes represent the 25
th
 to 75
th
 
percentile, with median values shown as solid lines. Whiskers represent 95
th
 
percentile, and outliers are shown individually.  B. Log of metagene expression 
in tumours with metastases and those without. T-test p-value is shown. C. 
Kaplan Meier curve of SHH subgroup tumours relative to Metagene score. Data 
generated by D. Williamson (NICR). 
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5.2.6 SB mutagenised murine model is representative of human MB SHH tumours  
The results above support the hypothesis that the neuronal transcription factor 
network identified within human MB expression data using genes mutated in the 
Ptch1+/- murine model is central to the development of MB in both species. To 
corroborate the human data, and to attempt to identify specific outputs of the network, I 
generated expression data from SB mutagenised MBs using the Illumina bead array 
platform. This technology was selected based on several advantages: increasing 
popularity, low cost, and the highly replicated probe features that increase the accuracy 
of beads type measurements. This technology is principally based on extremely small 
sized Bead-Arrays, with a 3-micron silica bead size, with the beads being covered with 
a high copy number of oligonucleotides (Cordero et al., 2007).  
I isolated total RNA from thirty tumours from the SB mutagenized experimental 
group (24 tumours with network mutations), together with six tumours from the 
Ptch1+/- predisposition control group, and six cerebella from 6-8 week old wild type 
mice. The quality of all RNA samples used in the microarray analysis was then checked 
using an Agilent Bioanalyser. All the samples had an RNA integrity number (RIN) 8.0 
or above, with the exception of two samples, MB524 (7.7) and MB244 (6.7) (Table 
5.2). An example of the quality of two SB induced murine MB (experimental group) 
samples are shown in Figure 5.7A. The investigated RNA shows two distinct peaks 
corresponding to the 18S and 28S ribosomal RNAs. About 200ng of each sample of 
high quality RNA was then taken through to amplification and cRNA was generated. 
Each cRNA size distribution was tested using an Agilent Bioanalyser and an example of 
two SB induced murine MB samples of cRNA are shown in Figure 5.7B. These cRNAs 
were labelled and used to probe the Illumina Mouse 8 Reference Array (see Methods).  
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Figure 5.7: RNA and labelled cRNA quality and distribution. A. Agilent Bioanalyser 
electropherogram results show the high quality and size distribution of 2 experimental 
group samples (SB induced murine MB) used for Illumina bead microarray. Gel 
electrophoresis distributed bands representing  rRNA isoforms are included. Detailed 
samples information about RNA concentration, ratio and RIN number are shown. B. 
Agilent Bioanalyser electropherogram results show cRNA size distribution of 2 
experimental group samples used in Illumina bead microarray are shown. the X axis 
shows the time in seconds (S) and the Y axis shows florescence (FU). 
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Table 5.2: SB induced murine samples, Ptch1+/- control tumours and normal cerebella 
used in Illumina beads microarray analysis. RIN - RNA integrity number. 
Sample ID RIN 
MB/SB11   
MB-P-008-T-Brain_PTS11-008 9.3 
MB-P-048-T-Brain_PTS11-048 9.8 
MB-P-068-T-Brain_PTS11-068 8.8 
MB-P-116-T-Brain_PTS11-116 8.9 
MB-P-146-T-Brain_PTS11-146 9.8 
MB-P-224-T-Brain_PTS11-224 6.7 
MB-P-260-T-Brain_PTS11-260 9.8 
MB-P-280-T-Brain_PTS11-280 10 
MB-P-286-T-Brain_PTS11-286 10 
MB-P-349-T-Brain_PTS11-349 8.3 
MB-P-366-T-Brain_PTS11-366 9.6 
MB-P-386-T-Brain_PTS11-386 8.7 
MB-P-421-T-Brain_PTS11-421 9.7 
MB-P-457-T-Brain_PTS11-457 8.1 
MB-P-524-T-Brain_PTS11-524 7.7 
MB-P-540-T-Brain_PTS11-540 8.2 
MB-P-565-T-Brain_PTS11-565 9.8 
MB-P-580-T-Brain_PTS11-580 8.7 
MB-P-619-T-Brain_PTS11-619 10 
MB-P-730-T-Brain_PTS11-730 10 
MB-P-751-T-Brain_PTS11-751 9.2 
MB-P-754-T-Brain_PTS11-754 9.2 
MB-P-756-T-Brain_PTS11-756 9.5 
MB-P-786-T-Brain_PTS11-786 9.4 
MB-P-791-T-Brain_PTS11-791 8.6 
MB-P-793-T-Brain_PTS11-793 9.4 
MB-P-833-T-Brain_PTS11-833 8 
MB-P-835-T-Brain_PTS11-835 10 
MB-P-849-T-Brain_PTS11-849 10 
MB-P-731-T-Brain_PTS11-731 10 
MB/PTCH   
MB-P-19-T-Brain_Ptch-19 9.5 
MB-P-104-T-Brain_Ptch-104 8.9 
MB-P-105-T-Brain_Ptch-105 9.3 
MB-P-105-T-Brain_Ptch-159 9.3 
MB-P-300-T-Brain_Ptch-300 9.1 
MB-P-483-T-Brain_Ptch-483 8.5 
Control /cerebellum   
PTS11-Cerebellum-908 9.3 
PTS11-Cerebellum-910 9.5 
PTS11-Cerebellum-1014 8.9 
PTS11-Cerebellum-1018 9.4 
PTS11-Cerebellum-1020 9.1 
PTS11-Cerebellum-1012 8.8 
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After hybridisation and data generation, the gene expression data from the 
mutagenized mouse model tumours was first analysed by D. Williamson (NICR, 
Newcastle University) to assess if it was consistent with human MB expression. Briefly, 
Non-Negative Matrix Factorisation (NMF) (Tamayo et al., 2007) was employed to 
define metagenes from all four clinicogenetic subgroups using the human expression 
data (Kool et al., 2008; Fattet et al., 2009). Then, these metagenes were projected across 
the mouse tumour expression data using all available orthologous probes. Both the 
predisposed only Ptch1+/- control tumours and the mutagenized experimental murine 
model tumours are seen to cluster with human SHH subgroup tumours (Figure 5.8A). 
 To establish more precise categorisation of the mutagenized mouse model 
expression data, the murine tumour subgroup identities were tested via a Support Vector 
Machine (SVM). This was performed using human data metagene scores as a guidance 
(training) set and then using the murine tumour data as the test set. All human tumours 
were trained correctly with zero errors, and ~96% (29/30) of the transgenic murine 
tumours were significantly categorised to be SHH subgroup tumours, together with 6/6 
(100%) of the predisposed to Ptch+/- control murine tumours. This indicates that the 
gene expression within SB mutagenized murine tumours is similar to human SHH 
subgroup tumour expression (Figure 5.8B), confirming the appropriateness of the 
Ptch1+/- SB model. 
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5.2.7 Microarray expression analysis of mutagenized tumours identifies Igf2 as a 
key network-associated gene 
Having established that the tumours generated by SB mutagenesis of Ptch1+/- 
mice are representative of the human MB SHH subgroup tumours, the next question 
was what impact disruption of the expression network by SB insertion in one or more 
network CIS gene had upon gene expression. Hence, the mouse expression data were 
split into network-hit and non-network-hit samples. Very few significantly differentially 
expressed genes were defined by this approach, with the top genes shown in Table 5.3. 
Igf2 was the highest differentially expressed gene with a mean fold change of 3.58 
(p=0.002). This suggests that the network activity may have an effect on some aspects 
of the insulin-signalling pathway.  
To validate the relationship between the activity of the CISs within the network 
and Igf2 expression, a quantitative RNA expression analysis using TaqMan real-time 
Figure 5.8: SB induced murine and Ptch
+/-
 MBs are SHH subgroup tumours. Projection 
of four sub-group specific metagenes derived from 108 human primary MB expression 
profiles (Training Set) onto MB mouse model expression profiles (Test Set) using Non-
negative Matrix Factorisation (NMF). A. Heatmaps depicting expression of metagenes 
within human cancers (training; left panel) and expression of metagenes throughout murine 
tumours (test; right panel). B. Pseudo-plot of NMF projections coloured according to 
confident MB sub-group classifications by Support Vector Machine trained on human 
primary medulloblastoma using metagene expression values. This unsupervised analysis 
shows that the majority of Ptch mouse model samples recapitulate the expression profiles of 
primary SHH MB. Figures generated by D. Williamson (NICR). 
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PCR was carried out to confirm and quantify the expression of Igf2 in all available MB 
mouse tumours used for the insertion site analysis, compared with the normal 
cerebellum.  
 
 
Illumina 
Probe_ID 
Gene Name 
Mean Fold Change in 
Expression: Network vs. 
non-Network 
P-value 
LMN_2597769 Igf2 3.58 0.002 
ILMN_1255871 Loxl1 1.64 0.029 
ILMN_2757232 Aqp4 1.64 0.037 
ILMN_1242456 Kank1 0.66 0.002 
ILMN_2642012 LOC100046457 0.65 0.007 
ILMN_2731265 Hsd11b2 0.65 0.026 
ILMN_1252076 Lyz2 0.64 0.040 
ILMN_1230157 Rnd3 0.61 0.038 
 
 
The expression of Igf2 was analysed in tumours with hits in the network and 
those without. Confirming the Illumina bead array result, a significantly higher 
expression of Igf2 was detected in tumours with inserts in the network than in tumours 
without a network hit (p=5.2 E-06, Figure 5.9A). Moreover, Igf2 expression was 
significantly higher in tumours with hits in Nfia, the most frequently inserted CIS gene, 
than tumours with no inserts in the Nfia gene (p=0.018, Figure 5.9B). It is also 
noteworthy that Igf2 was expressed at a very high level within some network tumours, 
when compared to expression in the normal cerebella, with expression in some non-
network tumours being very low (Figure 5.9C).  
 
 
 
Table 5.3: Gene expression difference between tumours with and without 
network hits. 
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Figure 5.9: Relative Igf2 expression in network and Nfia inserted tumours. A. 
Box and whisker plots showing Igf2 expression in tumours with inserts in 1 or more 
network CIS versus tumours with no inserts. B. Igf2 expression in tumours with 1 or 
more insertions in Nfia, versus tumours with no Nfia insert but with inserts in at least 1 
other network CIS gene. Boxes represent the 25
th
 to 75
th
 percentile, with median 
values shown as solid lines. Whiskers represent 95
th
 percentile, and outliers are shown 
individually. C. Relative Igf2 expression in murine tumours and cerebellum. 
Relative gene expression is shown, calculated using the 2
-ΔΔCt
 method, using the 
highest cerebellar RNA expression value as reference (C4). 
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5.3 Discussion 
 
 Gene expression data sets obtained both from publicly available sources, 
and generated de novo from murine tumours generated during the SB screen, have been 
used here to investigate the possibility of interactions between CIS genes, and to check 
the appropriateness of the Ptch1+/- model for comparative studies. Reassuringly, the 
results confirm that the tumours induced by whole-body SB mutagenesis most closely 
resemble human SHH subgroup tumours in terms of gene expression patterns. This is 
clearly seen through the NMF and SVM results (Figure 5.8 A and B). All SB induced 
murine tumours and Ptch1+/- tumours clustered with human SHH subgroup tumours. 
The network and gene ontology analysis used here provides a more in-depth 
look at how the CISs identified in the SB screen may interact with each other, and 
implies a role for the network in both neuronal development and cancer formation. The 
ARACNe analysis suggests that at least 7 CIS genes identified in this study are linked 
to each other within a single transcription factor network which does not map directly to 
a known signalling pathway. Interestingly, four out of the seven MB CIS genes that 
defined the network, namely CREBBP, NF1A, NFIB and TEAD1, as well as three other 
genes within the network (ERBB4, DIP2C and EDIL3), have been identified as MB 
CISs in a recent tissue specific SB mutagenesis screen of primary tumours within the 
Ptch1 model (Wu et al., 2012) shown as diamonds in Figure 5.2). It is also noteworthy 
that MYT1L is the most highly-networked gene among the CISs, indicative of an 
important role as a key co-ordinator. Furthermore, expression of MYT1L impacts upon 
survival. 
The gene ontology results  suggest  that the normal biological impact of these 
CISs in the cerebellum is integrated toward a single output, neuronal 
differentiation/development, and that perturbation of this network (through SB mutation 
in mouse or expression changes in human) enhances tumour formation. 
The significant enrichment for genes critical for neuronal architecture within the 
network is of particular interest, and many individual genes have important known 
neuronal functions. For example, one of these genes, Pclo (Presynaptic cytomatrix 
protein), is involved in synaptic formation where it can negatively regulate synaptic 
vesicle (SV) exocytosis (Leal-Ortiz et al., 2008), and the network analysis suggest that 
this gene may be a target gene for Tgif2. PPM1A is known to be essential for neuroblast 
migration to the olfactory bulb (Khodosevich et al., 2009). This gene is a member of the 
PP2C family, which is involved in negative regulation of the cell stress response 
pathway (Wu et al., 2007). Additionally, this gene was shown to drive different types of 
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cells, such as neuronal cells, toward apoptosis (Klumpp et al., 2006) suggesting its role 
in cancer formation needs to be assessed further. From the network analysis, this gene 
may be a target of Tgif2 and Myt1l. Dendrite microtubule-associated protein MAP2 is a 
large neuronal protein expressed predominantly within dendrites of mammalian brain 
tissues. It is considered a neuronal marker as it is involved in the microtubule-associated 
complex that is necessary for neurogenesis (Johnson and Jope, 1992;Sanchez et al., 
2000;Suzuki et al., 2011). Another important networked gene involved in regulating 
neuronal activities is Gamma-aminobutyric acid B receptor (GABBR2). This gene is 
highly expressed in the dendrites of Purkinje cells (Chung et al., 2008a). It has an 
inhibitive neurotransmitter effect in the central nervous system. It is believed that the 
dysfunction of this gene governs a variety of nervous system disorders. For example, 
hypoactivity of this gene is associated with schizophrenia and bipolar disorder, based on 
analysis of post-mortem samples (Fatemi et al., 2011). Furthermore, GPHN is a 
cornerstone of the inhibitory process of neurotransmitter receptors to the microtubule 
matrix of the postsynaptic cytoskeleton. This process is performed via highly active 
binding to a tubulin dimer and inhibitory glycine receptor (Gly R) domain. Missense 
and deletion mutations of this gene may cause hyperekplexia and MoCo deficiency-like 
symptoms, respectively (Reiss et al., 2001;Rees et al., 2003). Both disorders display 
severe and fatal neurological damage.  
All of these genes are involved in processes, or structures, associated with 
differenting/differentiated neurons, and are expressed at a lower level in SHH subgroup 
tumours than group 3 and 4 tumours. This is consistent with a block/downregulation of 
expression by the SB mutations within the linked CIS genes, leading to maintenance of 
an immature cellular phenotype, diverting the normal direction of neuronal cells from 
the differentiation process toward proliferation. Also, from the function of the genes it 
could be inferred that the mutation of the network TF CISs work synergistically with 
the disrupted SHH signalling pathway in the mouse model to maintain undifferentiated, 
highly proliferative cells, one of the known hallmarks of tumourgenesis. 
One of the key observations from this analysis is that the mutated CISs 
identified here appear to synergise to increase the expression of Igf2 – a key gene 
already known to be critical for medulloblastoma development in the Ptch1+/- mouse 
model. The higher expression of Igf2 within SB induced tumours with insertion in the 
network reported here provides further evidence for the importance of Igf2 in terms of 
MB generation, and potentially identifies key genes involved in regulating the 
expression of this gene in developing cerebellar GNPCs.  
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The first clear indication for Igf2 involvement in MB was a study conducted by 
Hahn et al., 2000, which aimed to assess the impact of Igf2 upon MB and 
rhabdomyosarcoma (RMS) tumourgenesis. The Igf2 gene is imprinted with only the 
paternal allele being expressed and they found that Igf2 was upregulated in Ptch1
+/- 
RMSs due to high expression of the imprinted allele driven by one alternative promoter 
(P3). To assess the impact of Igf2 upon MB and RMS formation, the murine Ptch1
+/-
 
allele used here was transferred into an Igf2 null background. This resulted in the 
frequency of tumour formation dropping to almost zero, indicating that Igf2 expression 
is essential for tumour formation. Furthermore, loss of the Ptch1 wild type allele from 
embryonic tissue was accompanied by increased Igf2 expression, suggesting that the 
gene may also be a target of the Shh signalling pathway. 
Subsequently, Rao et al., 2004, used cell-type specific postnatal gene transfer to 
express Igf2 and Shh alone and in combination in cerebellar granule neuron precursor 
cells (GNPCs), to investigate the roles of Igf2 and Shh in MB formation. Transfection of 
Igf2 alone resulted in no tumour generation. However, co-transfection of Igf2 with Shh 
increased the frequency of tumours relative to Shh alone from 15% to 39%. 
Immunohistochemical analysis of Igf2/Shh tumours established that they were classical 
MBs expressing neural progenitor/early differentiation markers (β-III Tubulin and Neu 
N), but not markers of terminal differentiation such as glial fibrillar acidic protein 
(GFAP) and neurofilament protein.  Immunoperoxide staining using antibodies against 
components of the Igf2 signalling pathway (Igf1R, IRS-1, AKt) establishing that Igf2 
signalling was activated in MBs generated by both Shh only and through the 
combination of Igf2 and Shh. 
Recently, Igf signalling pathways were assessed in terms of their synergistic 
action with Shh induced proliferative cells. Immunocytochemistry was used to establish 
the precise location of Igf signalling elements in the developing mouse cerebellum 
(Fernandez et al., 2010). Igfr1 (the main Igf receptor) was observed to be expressed 
ubiquitously at all stages and very strongly in the external granule layer (EGL). Igf1 was 
expressed in Purkinje neurons from E17.5, but not uniformly, and peaked at postnatal 
day 5 (P5). In contrast, the expression of Igf2 was specific to the meninges overlaying 
the EGL and choroid plexus. Igf binding proteins 1-6 (Igfbps 1-6) showed varied 
expression patterns, some mimicking Igf2, with Igfbp5 being strongly expressed in both 
the EGL and GNPCs. The potency and synergy of Shh and Igf mitogens upon GNPCs 
proliferation was then analysed using cerebellar explants, purified GNPCs culture 
aggregates, and isolated GNPCs cultures, assessing proliferation using BrdU 
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incorporation. As expected, all showed mitogenic effects, with SHH being most strong. 
Synergy was clear as Shh plus either Igf increased BrdU incorporation ~3X relative to 
Shh only, and ~7X relative to either Igf.  Inhibition of smoothened (SMO) using 
cyclopamine drastically reduced the impact of Shh, but had no effect upon Igf induced 
proliferation. Antagonism of Igfr1 with a blocking antibody effectively blocked the 
response in Igf treated cells, while Shh induced proliferation was inhibited by >50% by 
blocking Igfr1 as well.  Furthermore, while Igfbp2, 3 and 5 were all able to inhibit the 
impact of Igf upon proliferation, Igfbp5 was also able to inhibit the impact of Shh. 
Collectively, these findings illustrate the significant synergistic impact of Igfs upon Shh 
induced proliferation, and also indicate that Igfbps can modulate both signalling 
networks in a complex manner (Fernandez et al., 2010). 
It is also noteworthy that several of the CIS genes identified by the SB screen 
have already been implicated in Igf2 regulation. For instance, in prostate cancer Igf2 
expression is elevated due to the EGR1 gene, a gene that is co-activated by CREBBP, 
one of our network CIS genes (Svaren et al., 2000;Yu et al., 2004;Lai and Wade, 2011). 
Furthermore, the expression of IGF2 is downregulated by the increased expression of 
PTEN in hepatoma tumours (Kang-Park et al., 2003): We would therefore predict Igf2 
expression to be induced by PTEN loss of function, the inferred impact of SB insertion 
observed here. Collectively, the high Igf2 expression in murine tumours with network 
hits, the evidence that specific network CIS play an role in Igf2 expression, and the 
proven synergy between Shh and Igf2 in tumour development, provide strong evidence 
that the network identified here underpins Igf2 upregulation, critical for MB 
progression. 
 An obvious question which remains unanswered by this analysis is why, if the 
Ptch1+/- model accurately mimics gene expression in human SHH subgroup tumours, 
has Igf2 not been identified as a key SHH upregulated gene in any human microarray 
study to date.  The Affymetrix probes for Igf2 on human microarray chips are known to 
have low specificity due, at least in part, to the existence of readthrough transcripts from 
an upstream gene (INS). For example probesets 202409_at, 202410_x_at and 210881_s, 
which are on the U133 Plus 2 chip, hybridise to a minimum of 2 genes, raising the 
possibility that Igf2 expression is not accurately assayed. This is supported by recent 
analyses by collaborators in Newcastle using RNAseq which have established that 
increased Igf2 expression is one of the strongest SHH specific expression signals (S. 
Clifford and D. Williamson, personal communication). More importantly, this accounts 
for an apparent anomaly between the human and mouse datasets analysed here, and 
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further supports the conclusion that the transcription factor network defined here 
undperpins Igf2 upregulation and MB progression in both mouse and human. This 
suggests that further analysis of the genes identified, and the processes they affect, may 
identify valid targets for novel therapeutic strategies. It is the prioritisation of these 
genes for further study, and their preliminary analysis, which is the subject of the final 
results chapter. 
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Chapter 6 (Result 4) 
Identification and preliminary functional analysis of key candidate 
genes 
 
6.1. Introduction 
In the previous chapter, I presented evidence that a subset of TF CISs identified 
in the current study, namely Nfia, Nfib, Tgif2, Tgf13, Myt1l, Tead1, and Crebbp, are 
linked within a transcription network that is enriched for both TFs and genes involved 
in neuronal development. NMF analyses using metagene scores from all human MB 
subgroups, and expression data from Ptch1+/- only control and SB mutagenised murine 
tumours, revealed that genes in murine SHH tumours were expressed in a similar 
pattern to genes in human SHH subgroup tumours. Moreover, Support Vector Machine 
(SVM) analysis accurately grouped both SB murine tumours and Ptch1+/- control 
murine tumours with human SHH subgroup tumours, providing strong evidence that SB 
mutagenised murine tumours faithfully model human SHH subgroup tumours. Detailed 
analysis of gene and metagene expression further suggested an impact of the expression 
of network genes upon survival within SHH subgroup human tumours, and identified 
Igf2 as a key output of network activity.  
All of these results are consistent with the CIS genes identified here being 
involved in MB development. A logical and essential extension of this work is the 
functional analysis of specific candidate CISs thought to have an impact on MB 
generation. For simplicity, initial experiments would ideally be performed in human or 
mouse SHH subgroup MB cell lines, and would use transient transfection of siRNAs to 
modulate gene expression of specific genes. However, no MB cell line exists which has 
been shown to model SHH subgroup tumours, making the use of cell lines (or the 
interpretation of the results that would be obtained) problematic. GNPCs are the cell of 
choice because of the  difficulty of establishing and maintaining Shh cell lines. To 
date, no confirmed SHH subgroup MB cell line has been established, as during 
culture Shh signalling is switched off for reasons that remain unclear, unlike cells 
isolated from WNT MB subgroup which conserve WNT signalling activity (Sasai et 
al., 2006). GNPCs are believed to be the cell type in which SHH subgroup MBs 
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originate, and primary GNPC cell culture is widely used to investigate Shh signalling 
during post natal murine development (Rao et al., 2004). I therefore decided to use 
primary GNPC culture for downstream analyses of individual genes. As the efficiency 
of transient transfection is low in many primary cultures, lentiviral vectors were chosen 
to facilitate high efficiency stable transduction of constructs and/or shRNAs for 
functional analyses. 
The CIS and network genes identified here include a large number with 
functions of potential relevance to MB, or linked to SHH signalling, making it unclear 
which CIS genes should be singled out for analysis: For instance, Pten and Crebbp are 
already candidates for involvement in disease as human orthologs are somatically 
mutated at low frequency in human MBs (Parsons et al., 2011;Robinson et al., 2012). 
TEAD1 has been shown to be up-regulated and to co-activate YAP1 in human SHH 
subgroup tumours (Fernandez et al., 2009), and the Nfi family that includes Nfia and 
Nfib are believed to have a major role in axonal extension during cerebellar 
development (Wang et al., 2004;Wang et al., 2007). In addition, Myt1l is a neuronal 
gene which has been utilized in combination with other transcription factors to 
reprogramme mouse fibroblasts to a mixed neuronal lineage (glutamatergic and 
GABAergic neurons, (Vierbuchen et al., 2010). Tgif2 functions are also related to 
central nervous system development, and mutations in Tgif genes can cause 
holoprosencephaly (HPE), a developmental disorder affecting craniofacial development 
which can also be caused by mutations in SHH (Taniguchi et al., 2012).  
In addition to known functions, the consistency of expression patterns in both 
human MBs and the SB murine tumours can also be used to help prioritise these 
candidate genes for downstream functional analysis. Because GNPCs are extensively 
used to analyse SHH signalling, two microarray based expression datasets are publicly 
available and can be used to further prioritise candidate genes prior to function analysis. 
The first (Subkhankulova et al., 2010) analysed the gene Bmi1 to investigate its role in 
cerebellar GNPC development, with expression data being generated from normal 
Bmi1+/+ GNPCs samples, Bmi1+/+ GNPCs treated with Shh, Bmi1-/- GNPCs, and 
Bmi1-/- GNPCs treated with Shh. The second was a study conducted by Gibson et al., 
(2010) in which the cellular origins of WNT and SHH MB subtypes were investigated; 
expression data were generated from embryonic day 16.5 dorsal brainstem (E16.5 
DBS), Ctnnb1
+/lox(ex3)
;Tp53
flx/flx
 MB GNPCs, normal P7 GNPCs and Ptch1
+/-
;Tp53
-/-
 
MB GNPCs. Analysis of the expression of network genes in these datasets was 
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therefore also undertaken to identify those genes whose direction of expression change 
is consistent with CIS mode of action and/or expression in MBs, to provide further 
criteria to prioritise candidate genes, prior to  functional analysis in GNPCs.  
 
 
6.1.1. Aims: 
The aims of the work presented in this chapter are, therefore: 
 
6.1.1.1. To analyse network gene expression in both Ptch1+/- tumours / wt GNPCs, and 
SHH treated / untreated GNPCs using the data of Subkhankulova et al., (2010) and 
Gibson et al., (2010) to further prioritise candidate genes. 
 
6.1.1.2. To use shRNA and/or overexpression of prioritised candidate genes to modulate 
gene expression in GNPCs, and assess the impact of this modulation upon the 
expression of genes involved in GNPC development and SHH signalling. 
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6.2. Results 
 
6.2.1. Network gene expression in Ptch1+/- MB mimics expression in human MB 
 
To provide further evidence for the importance of network genes in SHH MB, and 
to define the most promising genes for downstream functional analysis, the expression 
of the network genes was first analysed in the dataset of Gibson et at., (2010). Their 
data from 3 wild type GNPC samples isolated from P7 days cerebella was compared to 
the data from 6 Ptch1+/- MB samples from the same developmental stage. The raw 
data, generated using the Affymetrix mouse 430_2 GeneChip, was first imported into 
GeneSpring, and subjected to standard normalisation (see Methods). A total of 81 
human network genes have orthologous Affymetrix probes, and the expression of these 
orthologs in the cerebellar and Ptch1+/- MB samples was compared using T-tests.  A 
total of 51 of these genes (single probe per gene) showed a statistically significant 
expression difference between wild type GNPCs and Ptch1+/- tumours, providing 
further confirmation that the network genes identified within the human expression 
dataset are relevant to SHH signalling.  The expression of all 51 significant probes (with 
p-values ranging from 0.0114 - 9E-04) is shown visually in the heatmap in Figure 6.1.  
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 To present the expression of specific candidate genes more clearly, the 
expression of network CIS genes, networked transcription factors, and network genes 
with neuronal ontologies (which are enriched within the network) are shown separately 
in Figure 6.2. Amongst the 7 MB CIS genes in the network (Figure 6.2A), 3 genes 
(Nfib, Tgif2 and Tead1) show a significant elevation of their expression within Ptch1+/- 
tumours compared to wild type GNPCs, consistent with their inferred mode of action 
from CIS data (see Table 3.6). In contrast, Myt1l shows downregulation within Ptch1+/- 
MB compared to wild type cells. This is also wholly consistent with the same 
Figure 6.1: Expression of 51 networked genes showing significant differential 
expression. Expression heatmap of 51 genes within the CIS network which are 
differentially expressed between GNPCs from wild type mice and Ptch+/- MBs. One 
probe per gene is shown. The colour bar shows relative expression levels. 
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expression behaviour of these genes in human MB and the hypothesised mode of action 
within the transgenic model. Strikingly however, the expression of two  genes (Nfia and 
Fgf13)  is inconsistent with the MOA. Nfia is hypothesised to be down-regulated in the 
transgenic mice model on the basis of CIS data, but shows significant up-regulation in 
Ptch1+/- tumours, while Fgf13 shows the opposite pattern. This inconsistency makes 
them less attractive for downstream analysis. 
Regarding transcription factors other than CISs, the expression heatmap (Figure 
6.2B) shows a significant over expression of three genes, namely Cklf, Tcf3, and Tead2 
within the Ptch1+/- MBs. This is also consistent with the expression of these genes 
within the SHH subgroup of human MB (see Figure 5.5).  
Finally, the expression heatmap of neuronal genes in the network is presented in 
Figure 6.2C. These genes are expressed in general at low levels in Ptch1+/- MB 
compared to normal GNPCs. Specifically, Pclo, Nsf, Neurod2 and Nbea show 
discernible lower expression within Ptch1+/- MB compared to wild type GNPCs. This 
behaviour of expression is very similar to expression in human MB. Some neuronal 
genes (Gphn, Gria2, Mycbp2, and Cdk5r1) do show lower expression within Ptch1+/- 
tumours compared to wild type, however, and one neuronal gene (Ppm1a) was 
expressed equally within both groups. 
This general concordance of gene expression patterns within murine Ptch1+/- 
MB with the pattern of network activation seen in human MBs, provides further 
supporting evidence for the importance of these genes in MB development. In addition, 
the consistent behaviour of Myt1L, and Tgif2, together with the high p-values (Tgif2- 
p=6.83E-5 and Myt1l- p=0.00327), and their known functions, highlights these genes as 
prime candidates for downstream functional analysis.   
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Figure 6.2: Expression heatmaps of selected network genes based on gene 
ontology (GO): Gene expression heatmaps of the network genes based on 
enriched GO specifications between normal GNPCs (3 riplicates) and Ptch+/-MB 
(6 riplicates) are shown. Probes with statistical significant values are shown. A. 
Expression of CIS genes which define the network. B. Expression of other 10 
transcription factors in the network. C. Expression of 13 neuronal genes in the 
network.  
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6.2.2. Network genes exhibit differential expression in SHH treated GNPCs 
compared to normal GNPCs 
 To assess if the expression of the network genes is altered by Shh 
overexpression alone, as opposed to within tumours where multiple secondary 
alterations may have occurred, the data of Subkhankulova et al., (2010) was also 
analysed.  Specifically, gene expression within postnatal day P5-7 murine GNPCs with 
and without Shh treatment was compared. In this study the Affymetrix 430 murine 
GeneChip was used to analyse gene expression. A total of 81 human network genes 
have orthologous Affymetrix probes on this chip, and the expression of these was again 
compared between the two groups using T-tests. A total of 56 of these genes (single 
probe per gene) showed statistically significant expression differences between wild 
type GNPCs and Shh treated GNPCs (p-values ranging from 0.00214 to 2.26E-05, data 
not shown), confirming that the network genes identified within the human expression 
dataset are relevant to SHH signalling. The expression of network CIS genes, and 
network genes with transcription factor or neuronal ontologies (which are enriched 
within the network) are shown in Figure 6.3.  
As expected, several CISs that define the neuronal network in human tumours 
show higher expression in Shh-treated GNPCs (Tgif2, Tead1 Figure 6.3A), which is 
consistent with the inferred mode of action and qPCR (see Figure 4.11, 4.8 and 4.10 
respectively). Myt1l expression is also consistent with the inferred mode of action from 
SB mutagenesis and qPCR (Figure 4.11 and 4.9), as it is lower in Shh treated GNPCs 
than untreated. Moreover, the expression of these genes is also consistent with human 
tumour data. Fgf13, Nfia and Nfib recorded a higher expression within Shh-GNPCs, 
also consistent with the inferred mode of action for these genes, with the exception of 
Nfia.  
 Transcription factors within the neuronal network show an obvious differential 
expression between the shh-GNPCs and the wild-type (Figure 6.3B). For instance, 
Tead2 was expressed at a higher level within Shh-GNPCs, as it was in the Ptch1+/- 
MBs.  
 The expression of Neuronal genes in the network is presented in Figure 6.3C. As 
shown there are several genes have shown higher expression within Shh-GNPCs, such 
as Cdk5r1, Nsf, Dlg1, Dcx and Gphn. However, many neuronal genes shows 
downregulated expression within Shh-GNPCs, e.g. Neurod2, Ppm1a, Mycbp2 and Pclo. 
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These results mimic those obtained from the network genes expression in human 
medulloblastoma data presented in Chapter 5. Moreover, many of these genes have 
shown a similar expression change in the mouse study where Ptch1+/- tumours were 
analysed (Gibson et al., 2010, Figure 6.2C). 
  The above results indicate that the CISs identified from the SB whole body 
mutagenized mice, and the network genes they have defined, show broadly consistent 
differential expression between Ptch1+/- MBs and GNPCs, and between Shh-treated 
GNPCs and untreated GNPCs isolated from independent studies (Gibson et al., 
2010;Subkhankulova et al., 2010). This suggests that not only are the network genes 
involved in MB development, their expression is also influenced by Shh signalling, 
providing further evidence for the importance of these genes specifically in SHH 
subgroup tumours. 
Importantly, the results also help to define the most appropriate candidates for 
downstream analysis. While the expression of most CIS genes analysed are consistent 
with the inferred CIS mode of action, the data for Nfia and Fgf13 are not consistent.  
This could complicate downstream analysis of this gene, and effectively eliminate it as 
a straightforward candidate for analysis. Of the remaining CISs, two stand out as 
showing consistent expression, relevant function, but having not previously been 
implicated in MB development. Tgif2 (up-regulated) and Myt1l (down-regulated) 
exhibit consistent expression in all investigated datasets. Their expression is also 
consistent with the inferred mode of action caused by transposons insertions, with 
qPCR results from SB whole body mutagenised medulloblastoma samples, and with 
microarray expression data extracted from human MBs. Given the known function of 
these genes, both being involved in neuronal development, they are strong candidate 
MB genes. They were therefore chosen for downstream analysis within GNPCs through 
overexpression using ORF-cDNA (Tgif2), and knockout using shRNA (Myt1l).  
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Figure 6.3: expression of CISs TF and Neuronal network genes in 
GNPCs. network genes expression according to GO analysis in Normal 
GNPCs (3 replicates samples) and shh treated GNPC (shh-GNPC) (2 
replicates samples). P=values ranged from 0.011 – 3E-04 for TF genes 
and 0.013 – 4E-04 for Neuronal genes. 
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6.2.3. Isolation and preliminary analysis of GNPCs: 
GNPCs were isolated from CBA wild type postnatal (P) day 4-7 mice, and 
cultured according to established protocols (see Methods). To confirm their ability to 
respond to Shh induction, cell counts were applied to GNPCs isolated from normal 
littermates at postnatal (P) day 4-7 in the presence or absence of Shh (3μg/ml) after 
72hrs. This time point was chosen as it is appropriate to assess induction of proliferation 
upon Shh stimulation of these cultures (Wechsler-Rreya and Scott, 1999). 
Differentiation was also assessed visually. To account for biological sample variability, 
all experiments were conducted in triplicate on independently derived cultures of two 
groups –cerebellar GNPCs treated with Shh (Shh+/+) and cerebellar GNPCs without 
(Shh-/-). The results are shown in Figure 6.4.   
Initially, the cells were seeded at a density of 3.65X10
5
 cell/cm
2
/24 well plate. 
Shh was supplied at 3μg/ml at the seeding time where applicable. After 72hrs the cells 
were harvested and quantified automatically. As shown in Figure 6.4, the number of 
Shh+/+ GNPCs was significantly higher than the number of control Shh-/- GNPCs 
(1.39X10
6
 and 0.65X10
6
, respectively p = 0.0007) after 72 hours. This suggested that 
with the addition of recombinant Shh protein , GNPC proliferation was induced 
significantly. 
 
 
 
Figure 6.4: Assessment of Shh signaling pathway induction in GNPCs. 
Normal cerebellar GNPCs were cultured in presence of Shh (Shh+/+) or 
absence of Shh (Shh-/-) for 3 days. 0 day = normal GNPCs numbers at 
seeding time.  (***p=0.00074). 
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6.2.4. Investigation of candidate gene expression in GNPCs  
 The expression of the two candidate CIS genes (Myt1l and Tgif2) was then 
investigated in cerebellar GNPCs treated with Shh or without, to establish the impact of 
the addition of Shhrecombinant Shh protein . In each case, expression was assessed in 
normal cerebellar GNPCs treated with Shh (Shh+/+ GNPCs), control normal cerebellar 
GNPCs treated with no Shh (Shh-/- GNPCs), and normal cerebellar GNPCs (0 day) that 
had been isolated and RNA extracted without culturing. The cells were cultured for 3 
days and supplied with 3g/ml Shh protein where applicable. For each sample, triplicate 
reactions were carried out to measure the average cycle threshold (Ct) value per sample. 
The average relative expression for each gene, relative to the 0-day control sample, was 
determined using the Ct method and expression was normalised to the reference gene 
-Actin.  
As shown in Figure 6.5, the expression levels of Tgif2 was significantly elevated 
in Shh+/+ GNPCs (p= 0.037) compared to both Shh-/- GNPCs and 0-day GNPCs. This 
result is in agreement with the expression levels that had been recorded in both murine 
and human tumours (and the Shh treated murine GNPCs, Figure 6.3A), and suggests 
that activation of the Shh signalling pathway has the ability to upregulate Tgif2 
expression.  
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The expression of Myt1l, the other candidate CIS gene analysed here, is shown 
in Figure 6.6. Expression is slightly lower in Shh+/+ GNPCs compared to 0-day GNPCs 
but the difference is not statistically significant (p=0.45). The expression of Myt1l was, 
however, significantly higher in the Shh-/-GNPCs (p= 0.007). As Shh will be active in 
0-day cells, this suggests that the effective withdrawal of Shh results in the upregulation 
of the pro-neural Myt1l gene. This is also in agreement with the Myt1l expression in 
murine and human medulloblastoma, and the murine GNPCs (Figure 6.3A). Moreover, 
these results reveal the impact of the Shh signalling pathway upon Myt1l and may 
reflect the maintenance of an undifferentiated phenotype, as Myt1l is known to function 
by driving neuronal cells toward differentiation.  
 
 
Figure 6.5: Expression of Tgif2 in different cerebellar GNPC samples. 
qPCR results showing relative expression of Tgif2 in isolated but not 
cultured GNPCs (0-day GNPCs), GNPCs cultured for 3 days without Shh 
recombinant (Shh-/-GNPCs), and GNPCs cultured for 3 days with the 
addition of 3μg/ml Shh recombinant are shown. The expression levels of 
Tgif2 was significantly elevated in Shh+/+ GNPCs (p= 0.037) compared to 
both Shh-/- GNPCs and 0-day GNPCs The ΔΔCt method was applied to 
calculate the expression relative to 0-day cultures. 
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In summary, the expression of both Tgif2 and Myt1l in the Shh-treated GNPCs 
here is consistant with the expression data from Gibson et al., (2010), and indicates that 
the expression of both Myt1L and Tgif2 are influenced by Shh signalling. This is 
consistent with mutagenesis of these genes by SB enhancing or altering the timing of 
existing Shh transcription circuitry to affect tumour penetrance.  
 
6.2.5 Expression of Gli1 and Math1 in Shh-treated CGPCs. 
To prove that the Shh signalling pathway is stimulated byrecombinant Shh 
protein , expression of the transcription factor Gli1 (a major effector of the Shh 
pathway – Wechsler-Reya and Scott, 1999) was also analysed in cerebellar Shh+/+ 
GNPCs, Shh-/- GNPCs and 0-day GNPCs (Figure 6.7).  Consistent with Shh pathway 
activation, the expression of Gli1 was significantly elevated in Shh+/+GNPCs relative 
to both controls Shh-/-GNPCs and 0-day GNPCs. Furthermore, the expression of Gli1 
was completely absent in Shh-/- GNPCs, consistent with downregulation of the Shh 
pathway relative to 0-day cells. These results confirm that the Shh pathway is efficiently 
stimulated in this GNPC culture model upon addition of recombinant Shh protein.  
 
 
Figure 6.6: Expression of Myt1l in different cerebellar GNPCs groups. qPCR 
results showing ΔCt expression of Myt1l in isolated but not cultured GNPCs (0-
day GNPCs), GNPCs cultured for 3 days without Shh recombinant (Shh-/- 
GNPCs) and GNPCs cultured for 3 days with the addition of 3μg/ml Shh 
recombinant (Shh+/+ GNPCs). The expression of Myt1l was, however, 
significantly higher in the Shh-/-GNPCs (p= 0.007). 
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Finally, as a marker of proliferation and an undifferentiated phenotype in 
cerebellar GNPCs, expression of the early neuronal marker Math1 was also analysed 
(Wechsler-Reya and Scott, 1999). Math1, as a neural specific TF, is expressed 
predominantly in the external germinal layer of the developing cerebellum (Alder et al., 
1996). Helms and Johnson, (1998) provided evidence that Math1 was expressed 
exclusively in proliferating and undifferentiated GNPCs. Thus, Math1 expression 
should be high in undifferentiated neuronal cells. As shown in Figure 6.8, the 
expression of Math1 was significantly upregulated in Shh+/+ GNPCs relative to both 
controls Shh-/- GNPCs and 0-day GNPCs. Furthermore, Math1 expression was 
observed to be absent in Shh-/- GNPCs. These results confirm that after 72 hours of 
culture in the presence of Shh, the GNPCs are still expressing this marker of 
undifferentiated neuronal cells, consistent with the expected impact of Shh signalling 
upon cerebellar GNPCs. It also confirms that withdrawal of Shh leads to loss of Math1 
expression.  
 
 
Figure 6.7: Expression of Gli1 in different cerebellar GNPCs groups. qPCR 
results of relative expression of Gli1 in isolated but not cultured GNPCs (0day-
GNPCs), GNPCs cultured for 3 days without Shh recombinant (Shh-/-GNPCs) and 
GNPCs cultured for 3 days with the addition of 3μg/ml Shh recombinant. The ΔΔCt 
method was applied to calculate the relative expression. 
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All of the results obtained with the GNPC cultures, both in terms of 
proliferation, expression of candidate genes, and expression of Gli1 and Math1, are 
consistent with these primary cells being an appropriate model in which to examine the 
role of Tgif2 and Myt1l in both GNPC development and Shh signalling using lentiviral 
transduction techniques. Appropriate lentiviral clones, utilising a Puromycin selection 
system, were therefore obtained from Gencopia (http://www.genecopoeia.com) and 
used for all subsequent experiments. 
 
6. 2.6. Puromycin kill curve to optimise transduction selection conditions. 
 Having confirmed that the cultured GNPCs were reacting to Shh as anticipated, I 
then performed a kill curve to identify the optimal puromycin concentration for use 
during transduction experiments. This step is required because cell lines/types can vary 
extensively in their sensitivity to puromycin.  
 The cerebellar GNPCs were seeded in a 24 well plate at 2.3X10
5
 cell/well, and 
supplied with 3g/ml of recombinant Shh protein as the puromycin works most 
Figure 6.8: Expression of Math1 in different GNPCs groups. qPCR results of 
relative expression of Math1 in isolated but not cultured GNPCs (0 day-GNPCs), 
GNPCs cultured for 3 days without Shh recombinant (Shh-/-GNPCs) and GNPCs 
cultured for 3 days with the addition of 3μg/ml Shh recombinant. The ΔΔCt 
method was applied to calculate the relative expression. 
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efficiently when the cells are highly proliferative. The concentrations of puromycin 
used were 0g/ml, 0.5g/ml, 1g/ml, 2g/ml, 4g/ml and 8g/ml. The cells were 
harvested and quantified at day 2, 4 and 6 after the seeding time. As shown in Figure 
6.9, GNPS are very sensitive to puromycin, as concentrations of puromycin as low as 
0.5g/ml are sufficient to kill cerebellar GNPCs after 4 days. As expected, control 
GNPCs with no puromycin showed significant growth and proliferation over the same 
period. 
 
 
 
 
6.2.7. Over-expression of Tgif2 in GNPCs 
 To artificially upregulate Tgif2 in CGNPs, an expression clone containing a 
CMV promotor and puromycin cassette was obtained from Genecopia 
(http://www.genecopoeia.com).  This ORF clone was constructed to include an N-
terminal FLAG-epitope tag in order to facilitate the detection of the protein produced by 
western blot (WB) and immunocytochemistry (IM) techniques. As a preliminary 
analysis to establish titre and transduction conditions, the ORF-Tgif2 clone, and a 
negative control empty vector, were separately transduced into 3T3 cells (see Methods).  
 
 
Figure 6.9: Puromycin kill curve for GNPCs. Wild type cerebellar GNPCs were 
isolated and cultured for 6 days. All groups were supplied with 3μg/ml Shh 
recombinant. Puromycin concentration is colour coded (see key). 
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6.2.7.1. Preliminary analysis of ORF-Tgif2 transduced cells 
 The preliminary experiment was performed in 3T3 cells to check the quality and 
integrity of the system and to reduce both cost and time required. 3T3 cells were seeded 
and transduced with ORF-Tgif2 lentiviral stocks at a range of Multiplicity of infection 
(MOI) as follows: 1 MOI, 5 MOI and 10 MOI, in order to check system efficiency. As a 
negative control wt-3T3 cells were cultured at the same seeding density until the end of 
the experiment. Then the transduced cells were selected using puromycin at a 
concentration of 2μg/ml, administered 24 hour after transduction. One 3T3 cell line 
culture was used to check the puromycin kill efficiency. After three days post 
transduction, cells were harvested and mRNA was isolated.  
To establish if the FLAG-epitope-tag was expressed along with ORF-Tgif2, a 
standard PCR assay was conducted to analyse mRNA in all experimental transduced 
3T3 cell lines and the wt-3T3 cell line. Vector isolated from transformed bacteria was 
also analysed. This was performed using primers spanning the FLAG-tag and ORF-
Tgif2. As expected, amplified products were obtained from all experimental transduced 
3T3 cell line with ORF-Tgif2 and the plasmid (Figure 6.10). The expected amplicon 
size is ~199bp. There was no product from the wt-3T3 cell line negative control. -
Actin gene expression was used as an endogenous control, and all samples gave the 
anticipated amplification products of ~133bp, except for the Tgif2 plasmid which gave a 
product size of ~228bp derived from the bacterial genomic DNA. The explanation for 
this is the primers were designed to span an exon-exon boundary. Therefore, the product 
is larger from plasmid DNA isolated from the bacteria, as the intronic sequence is still 
between the two exons. However, in the mouse cDNA the intronic sequence is absent. 
Collectively, these results indicate that the ORF-Tgif2 is being transcribed within the 
cell line system. 
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To quantify expression of the ORF-Tgif2 at different MOIs, Real Time PCR 
expression analysis of all transduced 3T3 cell cultures and the negative control were 
also performed, and the results of these are shown in Figure 6.11. As anticipated, the 
Tgif2 transcript was expressed in transduced cells at a level dependent upon MOI , with 
the fold changes relative to the negative control being 91.9X, 198.1X and 572.8X for 1 
MOI, 5 MOI and 10 MOI respectively. This indicates that the vector expressing the 
cDNA for Tgif2 is working appropriately at the transcription level for tranduction into 
GNPCs. 
  
  
 
Figure 6.10: Expression analysis of ORF-Tgif2 and FLAG-epitope tag in the 
transduced 3T3 cell line. Standard PCR results using cDNA templates 
generated from RNA isolated from 3T3 cell line transduced with different MOI 
as follows: 1, 5 and 10 MOI. (A) Panel are primers used span part of ORF-Tgif2 
and the FLAG-epitope tag to give an amplicon size of ~199bp. Untransduced 
3T3 cells cDNA was used as a negative control, lentiviral ORF-Tgif2-FLAG-
epitop tag as a positive control. (B) β-Actin (133bp/228bp) was included as an 
endogenous control. 
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6.2.7.2 investigation of Tgif2 protein expression in transduced 3T3 cells 
 Next, Western blotting was performed in order to establish if the Tgif2 transcript 
was being translated, and to establish the level of Tgif2 protein in the 3T3 transduced 
cell line. Whole cell protein lysates were isolated from all transduced cell groups and 
the wt-3T3 control cell line. An independent FLAG-tag protein was utilised as a 
positive control. Different quantities of the protein, depending on availability, were 
utilised. The primary antibody (Ab) was applied at a concentration of 1:500. As 
depicted in Figure 6.12, no Tgif2 protein could be detected in any of the transduced 3T3 
cell lines, regardless of the MOI; the expected protein size is 28Kd. Moreover, there 
was no expression detection from wt-3T3, with the only expression observed from the 
independent positive control. β–Actin expression was, however, detected as an 
endogenous control. Importantly, these results revealed that the primary Ab was 
working efficiently, and that the protein lysates were of sufficient quality for Western 
analysis. 
 
Figure 6.11:  Relative expression of Tgif2 in transduced 3T3 cells. The 
cells were harvested 3 days after transduction with Lentivirus expressing the 
cDNA for Tgif2. Samples are shown according to different viral MOI (1 MOI, 
5 MOI and 10 MOI). qPCR expression was calculated using β-Acin as a 
reference gene and is shown relative to control samples with no viral 
transduction. The expression axis is shown in a log scale, with the normalized 
untransduced control sample set to 1. 
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These results established that the ORF-Tgif2 construct was efficiently 
transduced into 3T3 cells, was expressed at a high level at the transcriptional level, but 
that no FLAG tag could be detected. This indicated that further analysis of the system, 
both in terms of further blotting experiments and sequence analysis of the vector, would 
be required to establish the reason for the negative result with the anti-FLAG antibody. 
However, due to time limitations the analysis of Tgif2 was suspended at this stage to 
concentrate on the analysis of the other prime candidate, Myt1l. 
 
6.2.8. Myt1l knockdown in GNPCs 
 To investigate the functional impact of Myt1l upon medulloblastoma generation, 
lentiviral short hairpin RNA (shRNA) gene silencing technology was used. GNPCs 
were transduced with lentiviral vector expressing short hairpin RNAs for Myt1l 
(shRNA-Myt1l). Two shRNA-Myt1ls were utilised for transduction, namely shRNA-
Figure 6.12: Western blot analysis of Tgif2 in transduced 3T3 cells. Whole 
protein lysate isolated from transduced 3T3 cells were used (1 MOI; 50μg, 5 MOI; 
25μg and 10 MOI; 25μg), wild type 3T3 cell were used as a negative control (25μg 
and 50μg) and ~15μg of a lysate from a cell line expressing an  independent FLAG-
epitope tag protein was used as a positive control. β-Actin was used as an 
endogenous control. 
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Myt1l-8 and shRNA-Myt1l-9. Moreover, a mock knockdown lentiviral empty vector 
(shRNA-Mock) was utilised as a knockdown control. GNPCs were isolated from P6 
mice, and seeded at a density of 5X10
5
cells/cm
2
 in 96-well plates.  The experimental 
groups were as follows; shRNA-Myt1l-8, shRNA-Myt1l-9, shRNA-Mock and 
Shh+/+GNPCs with no transduction. The viral stocks were applied 24 hours post 
seeding time at a MOI of 3 where applicable. Shh+/+GNPCs were also cultured to 
assess puromycin selection efficiency.  All groups were supplied with Shh 
recombinant Shh protein at 3μg/ml upon seeding. mRNA was isolated from the 
transduced puromycin resistant GNPCs 3 days post transduction.  
The relative expression of Shh+/+GNPCs, shRNA-Mock, shRNA-Myt1l-8 and 
shRNA-Myt1l-9 was quantified using the ΔΔCt methods, and the results are shown in 
Figure 6.13.  Myt1l mRNA expression in shRNA-Myt1l-9 GNPCs was decreased by 
about 66% compared to Shh+/+GNPCs. A modest and non significant ~6% 
downregulation was also observed with shRNA-Myt1l-8.  However, the shRNA-Mock 
samples showed significantly higher expression of Myt1l compared to Shh+/+GNPCs. 
This contrasts with the earlier analysis of GNPCs which indicated no significant impact 
on Myt1l expression after 3 days of Shh culture, and suggests that transduction per se 
may impact upon Myt1l gene expression.  Irrespective of the underlying cause of the 
increase observed with the empty vector, these results indicate that efficient knockdown 
is obtained with shRNA-Myt1l-9. 
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6.2.8.1 Impact of Myt1l knock down on Gli1 and Math1 expression 
To begin to investigate the impact of Myt1l knock down on Shh signalling and 
neuronal differentiation, the mRNA expression levels of Gli1 and Math1 were analysed 
in all GNPCs groups. As shown in figure 6.14, the expression of Gli1 was significantly 
(P=0.00018) higher (~2.4X) in shRNA-Myt1l-9 GNPCs relative to Shh+/+GNPCs. This 
result suggests that Myt1l knock down may further stimulate the Shh signalling 
pathway. Furthermore, the level of Gli1 was reduced in the mock transduction where 
Myt1l expression was increased relative to 0-day cells (Figure 6.14), further suggesting 
that Myt1l expression affects the expression of Shh pathway genes.  
 
 
 
 
 
Figure 6.13: Expression of Myt1l in different transduced GNPCs groups. 
qPCR results showing relative expression of Myt1l in mRNA isolated from 0-day 
Shh+/+GNPCs, transduced GNPCs with virus expressing the empty vector 
(shRNA-Mock), and transduced GNPCs with lentivirus expressing shRNA-Myt1l-
8 (ShRNA-Myt1l-8) or shRNA-Myt1l-9 (shRNA-Myt1l-9). All transduced 
samples were cultured in the presence of 3μg/ml Shh recombinant. The cells were 
harvested after 3 days of transduction based on 1μg/ml of puromycin selection. 
Expression was calculated using the ΔΔCt method relative to 0-day Shh+/+ 
GNPcs. β-Actin was used as an endogenous reference gene. 
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The expression of Math1 (a marker for undifferentiated neuronal cells) was also 
found to be significantly different between the transduced groups, as shown in figure 
6.15. The expression of Math1 was significantly (P= 3.39752E-05) higher in shRNA-
Myt1l-9 (~2.5X) relative to 0-day Shh+/+GNPCs, while the expression of Math1 was 
modestly increased in shRNA-Myt1l-8 (~1.5X). This result is consistent with an inverse 
relationship between the expression of the 2 genes; the expression of Math1 is increased 
as Myt1l expression is decreased. However, there was no significant difference between 
Math1 expression in the shRNA-Mock compared to Shh+/+GNPCs.  
 
 
Figure 6.14: Expression of Gli1 in different transduced GNPCs groups. qPCR 
results showing expression of Gli1 in mRNA isolated from tranduced GNPCs with 
viral expressing empty vector (shRNA-Mock), and transduced GNPCs with 
lentiviral expressing shRNA-Myt1l-8 (ShRNA-Myt1l-8) or shRNA-Myt1l-9 
(shRNA-Myt1l-9). Expression is shown relative to 0-day Shh+/+GNPCs. The 
expression of Gli1 was significant (P=0.00018) in shRNA-Myt1l-9 GNPCs relative to 
Shh+/+GNPCs.  All samples were cultured in the presence of 3μg/ml Shh 
recombinant protein. The transduced cells were harvested after 3 days based on 
1μg/ml of puromycin selection. Relative expression was calculated using the ΔΔCt 
method. β-Actin was used as an endogenous reference gene. 
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6.2.8.2 Investigation of Myt1l expression in Brain and GNPCs protein by WB 
To confirm that Myt1l silencing was successful at the protein level, investigation 
of Myt1l protein is required in both mouse brain and cerebellar GNPCs. Initially, the 
primary Ab was optimised in P4-6 mouse brain and cerebellar GNPCs. Firstly, whole 
tissue protein lysate was isolated using urea buffer (see Methods). Isolated protein 
concentration was established via a BCA protein assay (Thermo Scientific).  
Aproximately 50μg of whole protein lysate was examined with different primary Ab 
concentrations (1:200, 1:500, 1:1000 and 1:2000) (Figure 6.16). Whole protein lysate 
isolated from 3T3 cell line (30μg) was used as a negative control, as Myt1l is not 
expressed in this cell line. As shown in Figure 6.16, Myt1l protein was detected in 
Figure 6.15: Expression of Math1 in different transduced GNPCs groups. QPCR 
results of relative expression of Math1 gene in mRNA isolated from Shh+/+GNPCs, 
tranduced GNPCs with viral expressing empty vector (shRNA-Mock), transduced 
GNPCs with lentiviral expressing shRNA-Myt1l-8 (ShRNA-Myt1l-8) or shRNA-Myt1l-
9 (shRNA-Myt1l-9). The expression of Math1 was significant (P= 3.39752E-05) in shRNA-
Myt1l-9  relative to 0-day Shh+/+GNPCs. All samples exemplify cultured cells in the 
presence of 3μg/ml Shh recombinant. The cells were harvested after 3 days of 
transduction based on 1μg/ml of puromycin selection. Relative expression calculated 
based on ΔΔCt method. β-Actin was used as a an endogenous reference gene. 
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whole brain tissue at all the primary Ab concentrations used. In addition, there was no 
expression observed in the 3T3 cell line. 
 
 
 
 
 
Since the primary Ab successfully detected the expression of Myt1l in mouse 
brain, an investigation of Myt1l protein expression in GNPCs was undertaken. Whole 
cell protein lysate was isolated from 0-day GNPCs, Shh+/+ GNPCs and Shh-/- GNPCs, 
using urea buffer. Moreover, protein from P4-6 day mouse brain tissue was used as a 
positive control, and the 3T3 cell line was used as a negative control. Western blot 
results are shown in Figure 6.17. No expression of Myt1l was detected in 0-day GNPCs, 
Shh-/- GNPCs or Shh+/+ GNPCs, although expression was clearly observed in brain 
tissue.  
 
 
 
Figure 6.16: Preliminary investigation of Myt1l protein expression in whole 
mouse brain tissue. Whole mouse brain tissue was investigated to detect Myt1l 
protein expression using different anti-Myt1l antibody (1:200, 1:500, 1:1000 and 
1:2000) with 50μg of brain tissue. -Actin was used as endogenous control. Myt1l 
protein was also investigated in 3T3 cells as a negative control. 
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These results suggest either that Myt1l is expressed at a very low level in 
GNPCs relative to brain, that the protein is not accessible to the antibody in a whole cell 
lysate of these cells, or that GNPCs express an isoform which does not react with the 
specific antibody used. Despite the inability to detect Myt1l protein in GNPCs here, the 
significant changes in expression of both Gli1 and Math1 observed upon Myt1l shRNA 
knockdown strongly suggest that the knockdown is effective at the protein level. 
Confirmation of this will, however, require further work. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.17: Western blot analysis of Myt1l 
gene in mouse brain and GNPCs. Whole protein 
lysates isolated from P6 mouse brain, 0 Day-
GNPCs, Shh-/-GNPCs, Shh+/+GNPCs and the 
3T3 cell line were examined for Myt1l expression 
by WB. 1:1000 dilution of Myt1l Ab was applied. 
The product size is ~170KD. β-Actin was 
examined as an endogenous control. 
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6.3. Discussion 
 
In this chapter, I have outlined preliminary analysis of two candidate genes 
within murine GNPCs. As an initial step, the expression of neuronal network genes 
identified in the current study was analysed within two publicly available and 
independent datasets; one generated from wild type GNPCs and MBs from Ptch1
+/-
 
mice (Gibson et al., 2010), the other generated from wild type GNPCs cultured with 
and without shh (Subkhankulova et al., 2010). This step was performed to further 
prioritise the most promising candidate genes for functional analysis in terms of 
consistency of expression behaviour, in addition to novelty and known functional 
considerations.   
The majority of the network genes showed significant differential expression in 
these datasets, providing further evidence for the connectivity of the network. 
Interestingly, the CISs which define the network, and the neuronal genes within it, 
showed consistent expression changes within the two datasets; genes expressed more 
highly in Ptch1+/- tumours relative to GNPCs were also more highly expressed in shh 
treated GNPCs than untreated. Furthermore, the expression of most CIS genes was 
consistent with the inferred mode of action (MOA) from insertion site data. This 
provides further evidence that the network genes are relevant to both MB development, 
and more specifically to SHH signalling. A noteworthy exception to this is Nfia, the 
gene most frequently targeted by SB inserts identified here. The inferred mode of action 
is loss of function, due to the mixed orientation of insertions and their wide distribution 
within the gene. However, in both murine datasets analysed here Nfia was more highly 
expressed when shh signalling was active (Ptch1+/- tumours or shh treated GNPCs). 
Nfia, although potentially an important gene in SHH subgroup MB, was not chosen for 
downstream analysis because of this inconsistency which could complicate the 
interpretation of any results obtained. However, based on consistency of expression 
patterns in human and mouse, clarity of mode of action, novelty, and known function, 
two genes were chosen for downstream analysis; Tgif2 and Myt1l.  
Tgif2 is a member of Tgif family, known to repress neuronal genes and play an 
important role in neuronal development. Mutation of TGIF1, a paralog of TGIF2 have 
been shown to cause some forms of holoprosencephaly (HPE) (Gripp et al., 2000), a 
serious genetic disease affecting human craniofacial development which can also be 
caused by mutations in SHH. Recently, Taniguchi et al., (2012) showed that mice 
lacking both Tgif1 and Tgif2 showed HPE-like phenotypes which mimic those seen in 
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Shh-/- mice embryos. The authors showed that growth factor β/Nodal signalling was 
disrupted in the TGIF double mutant. Tgif2 overexpression has also been found to 
repress a subset of neuronal genes such as Cath1, Msx2, Pax6, and Wnt1 (Knepper et 
al., 2006).  
In the analyses presented here, Tgif2 was expressed persistently at high levels in 
all tumour or SHH treated datasets, suggesting that this gene may have a role in MB 
generation. Consistent with this, SB insertions in Tgif2 resulted in upregulation of the 
gene, expression being driven by the SB enhancer (see Figure 4.8), and its expression 
was significantly higher in the murine samples where shh is active when analysed in 
this chapter (see Figure 6.4 and 6.2).  
Collectively, these results raise the possibility that Tgif2 is a direct or indirect 
target of Shh, and that genes downstream of Tgif2 promote tumorigenesis by repressing 
neuronal specific genes and maintaining an undifferentiated state. SB mutagenesis of 
Tgif2 may therefore overexpress a gene normally upregulated during Shh signalling 
pathway. Finally, to my knowledge there has been no study that has investigated the 
role of Tgif2 in MB generation, making it a prime candidate for downstream analysis. 
 The second gene I analysed, Myt1l, was already a good candidate gene prior to 
the analyses of murine data for several reasons; because of its position as the most 
highly networked gene (Figure 5.2), because it showed consistently lower expression 
within tumour generated by whole-body SB mutagenised mice and human MB data 
(Figures 4.9 and 5.5, respectively), because low expression was associated with poorer 
patients survival (Figure 5.3), and because of its known function as a pan neural 
differentiation gene (Pang et al., 2011). Its candidature was further supported by the 
analysis of both murine datasets, as its expression was lower within Ptch1+/- tumours 
and Shh treated GNPCs compared to normal cerebellar GNPCs (Gibson et al., 2010; 
Subkhankulova et al., 2010). 
Myt1l, myelin transcription 1-like, is a zinc finger gene (also called Myt1 and 
NZF3) and belongs to the Myt1 family. It is widely expressed in the murine developing 
brain. In one study, the highest expression of this gene was obseved in the adult murine 
brain and spinal cord, whereas no expression was observed in glial cells, suggesting that 
Myt1l is strictly expressed in neurons (Kim et al., 1997). In terms of the role Myt1l 
plays in neuronal development, Vierbuchen et al., (2010) found that Myt1l in 
combination with 2 other transcriptional factors, Ascl1 and Brn2, can accelerate the 
transformation of mouse embryonic fibroblasts into functional neurons in vitro. 
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Additionally, Myt1l has the ability to enhance the conversion of human pluripotent stem 
cells into functional neurons in the presence of POU3F2 and Ascl1 (Pang et al., 2011). 
Prior to lentiviral transduction experiments, I first assessed the suitability of 
GNPC cultures for analysis of these genes by checking their response to shh signalling. 
This was achieved by culturing them with and without 3μg/ml of recombinant Shh 
protein for 3 days and assessing proliferation and expression of key reporter genes. 
This steps was essential to assess the ability of these cells to be maintained in vitro. I 
measured the expression of both candidate CISs (Tgif2 and Myt1l), an effector of the 
Shh signalling pathway (Gli1) and a marker for neuron progenitor cells (Math1). This 
analysis revealed that GNPCs proliferation was significantly higher within cells treated 
with Shh compared to wild type GNPCs, congruent with the known proliferative impact 
of Shh upon cultured GNPCs (Dahmane and Altaba, 1999). Additionally, initial qPCR 
expression analysis of Tgif2 and Myt1l was consistent with the mode of action of SB 
insertion, with these genes showing up-regulation and down regulation respectively in 
Shh treated GNPCs compared to wild type (see Figure 4.7 and 4.8). Moreover, both 
Gli1 and Math1 showed higher expression in Shh treated GNPCs compared to wild 
types, and this was expected as both are markers for Shh induction in GNPCs 
(Wechsler-Reya and Scott, 1999).   
Having established the suitability of the primary cell culture model, I went 
forward to lentiviral based analysis of both Tgif2 and Myt1l. I confirmed the elevated 
expression of Tgif2 in Shh+/+GNPCs, and successfully transduced the lentiviral ORF-
Tgif2 clone into 3T3 cells, confirming gene expression at the mRNA level in a MOI 
dependent fashion. However I could not confirm expression at the protein level. This 
could be due to the translation period of the protein not being sufficient to be detected 
by WB. Moreover, I did not have time to check the viability of the FLAG-tag 
expression, or check the reading frame of the vector (although it was purchased as a 
validated intact ORF). It is also possible that the FLAG tag is not accessible to the 
antibody, due to specificities of the protein conformation. Owing to time constraints, 
troubleshooting of this issue had to be postponed for future work. Despite this, the 
results presented here suggest that Tgif2 is a valid target for further analysis in SHH 
subgroup tumours. 
My analysis of Myt1l, however, was more informative, as I successfully 
knocked down expression and showed that this increased Gli1 and Math1 expression, 
providing confirmatory evidence that Myt1l expression does affect both SHH signalling 
and neuronal differentiation. This suggests that GNPCs where Myt1l is knocked down 
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are highly proliferative and maintained in an undifferentiated state. It is also of interest 
that Myt1l expression and Math1 expression are reduced as a result of Shh signalling, 
while both Shh signalling (as assayed by Gli1 expression) and Math1 expression are 
induced or enhanced as a result of Myt1l knock down. These results are consistent with 
these genes being functionally linked, and further validate the relevance of the gene 
expression network identified here to Shh signalling and MB development.  
Additional work remains to be done in the analysis of Myt11, however, as I was 
unable to demonstrate knockdown at the protein level. The failure to detect protein 
expression by WB could be due to several reasons. First, Myt1l protein is localised in 
the nucleus, and the current analysis was performed upon whole cell protein lysates, in 
which dilution of Myt1l may take place. Furthermore, the time of the protein isolation 
may not have given enough time for high protein expression, as it was 3 days after 
transduction. In addition, the Ab used in these analyses was monoclonal, therefore the 
application of a polyclonal Ab would be worth trying as Myt1l has several protein 
isoforms.   
Further experiments involving Myt1l silencing are desirable as  the impact upon 
phenotype/proliferation remains to be assessed. Despite the need for further analyses, 
the results presented here provide initial validation of Myt1l as a key gene involved in 
the regulation of SHH signalling and GNPC development, and suggest that further 
analysis of this gene may identify targets for therapeutic assessment within SHH 
subgroup MB. 
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Chapter 7 
 
General Discussion 
 
In the work presented here I have demonstrated that MB development was 
enhanced significantly by the application of whole-body SB mutagenesis of the Ptch
+/-
 
murine model, and this was achieved without affecting tumour latency. Furthermore, 
this system has no tumour induction within wild type mice. However, for the RMSs that 
developed within this model there was no significant impact on mortality relative to 
predisposition control animals. This suggests that the mutagenesis had no direct impact 
upon MRSs development. The whole-body SB mutagenesis system utilised in the 
current study also produced a high frequency of haematological tumours, consistent 
with one other screen using this combination of transposase and mutagen (Collier et al., 
2009;Bender et al., 2010), in addition to several solid malignancies at lower frequency. 
The generation of 19 liver adenomas in this screen was unexpected, as this tumour type 
has only been observed previously in a tissue specific screen using conditioned 
mobilisation of SB within the liver by using Cre under the control of an albumin 
enhancer (Keng et al., 2009). The data here indicated that this tumour type can be 
induced by SB mutagenesis alone. The most significant CIS within the adenomas was in 
the 24
th
 intron of Egfr, with inserts showing a virtually identical pattern to that observed 
by Keng et al., (2009) where Egfr was also the top CIS. This demonstrates the 
specificity and power of SB mutagenesis, and the importance of this gene in terms of 
hepatocellular carcinoma.  
The CISs identified within SB induced MB primary tumours, 11 of which had 
not been implicated in MB before, were found to be enriched for transcription factors 
and to have functions involved in neuronal development, differentiation and/or 
migration and cell death. The majority of the candidate genes also showed significant 
expression differences between the human MB subgroups. Low expression levels of one 
gene – Myt1l – were significantly associated with poor outcome within human MBs. 
Collectively, these data indicated that the MB CISs identified here are promising 
candidates for involvement in the disease process, and can be considered for further 
investigation to identify new therapeutic targets or MB markers that may be of use in 
the treatment or management of this disease. 
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 Because of the significant excess of transcription factors in the MB CIS list, 
ARACNe expression network analysis was applied to human MB expression data to 
identify networks of transcription factors and their targets of relevance to MB. This is 
the first time, to my knowledge, that ARACNe expression network analysis has been 
applied to the results of a mutagenesis screen to gain insight into a disease process. 
Interestingly, 7 CISs were tightly linked within a single network. This network consists 
mainly of transcription factors and their target genes critical for neuronal differentiation 
and proliferation. 
Further investigation of the network components via human heatmaps of gene 
expression revealed that network genes are differentially expressed in human MB 
subgroups and that expression of two of the CIS genes, TGIF2 and MYT1L, showed 
strong correlation with network activity. These two CIS genes were of particular interest 
because of their impact upon the SHH signalling pathway and neuronal differentiation 
respectively. Both the inferred MOA of transposon inserts and qPCR validations 
revealed that Tgif2 was showing oncogene-like behaviour. This is supported by a recent 
study where the double knock out of Tgif1 and Tgif2 showed the inhibitory effect upon 
Shh expression in the developing brain (Taniguchi et al., 2012). In contrast, the inferred 
MOA and qPCR data suggested that Myt1l is likely to act as a tumour suppressor. 
Consistent with this, low expression of MYT1L was associated with poor survival rates 
within MB patients. Furthermore, this gene has been shown recently to be involved in 
the reprogramming of mouse and human fibroblasts into neuron-like cells (Ambasudhan 
et al., 2011;Pang et al., 2011), suggesting that reduced expression may help to maintain 
the undifferentiated cellular phenotype of MBs. To my knowledge neither of the above 
genes has been implicated in MB before, and both are valid targets for further functional 
analysis. 
Importantly, analysis of network activity as a whole, both within human and 
mouse expression data, suggests that one of the major outputs of network perturbation 
during tumourigenesis is upregulation of the Igf2 gene. Investigation of the genes 
differentially expressed between tumours with transposons hits in the CISs and those 
without hits in the CISs within the putative neuronal network, identified the most 
differentially expressed gene as Ifg2. My quantitative analysis of Igf2 expression also 
revealed that Igf2 expression was significantly higher within tumours with insertions 
within network CIS genes than those without. A previous study has concluded that Igf2 
expression is an absolute requirement for MB generation, as Igf2
-/-
; Ptch1
+/-
 mice do not 
develop tumours (Rao et al., 2004). Foci of proliferating GNPCs are, however, still 
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observed on the surface of the cerebellum in juveniles mice of this genotype, suggesting 
that Igf2 expression is required for transformation of pre-cancerous lesions. The 
identification of a neuronal gene network underpinning the expression of Igf2 in GNPCs 
therefore elaborates upon the existing model of tumour formation within Ptch1+/- mice.  
The summary above indicates that the integration of expression networks and 
mutagenesis data has been very informative here.  It may, therefore, also be a useful 
tool in other mutagenesis studies, particularly in screens where modest numbers of CISs 
are identified. In large screens, it has been possible to infer gene networks directly from 
co-occurrence of CISs within tumours, For instance, a recent SB mutagenesis forward 
screen study to identify candidate genes involved in intestinal polyposis. March et al., 
(2011) identified co-occurring networks, but this involved pairwise comparisons of 
>900 CISs.  
 Because of the strong candidature of both Tgif2 and Myt1L I also initiated 
functional analysis and downstream investigation of these two CISs to provide further 
information concerning their role in MB formation. I over-expressed Tgif2 within 3T3 
cells by transducing retroviral costructs carrying ORF-Tgif2. The overexpression of 
Tgif2 was quantified by qPCR, but expression at the protein level could not be 
confirmed. Myt1l was, however, successfully knocked down in GNPCs treated with 
recombinant Shh protein in culture. Two neuronal progenitor cell markers, Gli1 and 
Math1 were shown by qPCR to be upregulated in these cells. This is consistent with 
reduced expression of this gene maintaining the GNPCs progenitor characteristics and 
reducing neuronal differentiation. As far as I am aware this is the first demonstration of 
a link between Myt1l and the Shh signalling pahway. Unfortunately, Myt1l protein 
expression could not be detected within GNPCs. 
 It is also worth noting that the bioinformatic analysis of subgroup specific 
metagenes within human and mouse MB data, and especially the NMF projection, has 
provided the first comprehensive evidence that the Ptch1+/- mouse is an appropriate 
model of SHH subgroup MB at the level of gene expression. Although the tumours 
generated by this model resemble human SHH MBs in terms of pathology (Goodrich et 
al., 1997), confirmation that gene expression is comparable indicate that this model can 
be usefully examined and manipulated to search for both tumour biomarkers and 
therapeutic targets for human MB. 
 Recently, an independent SB mutagenesis screen of the Ptch1+/- model has been 
conducted using a tissue specific SB mutagenesis screen system (Wu et al., 2012). This 
was performed by expressing SB11 under the control of the Math1 promoter in the 
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GNPCs of transgenic Ptch1
+/-
 mice. This was a highly penetrant screen, with 
mutagenesis enhancing MB penetrance from ~39% (54/139) in no predisposition 
controls up to ~97% (271/279) in experimental (Ptch1
+/-
;Math1;SB11;T2/Onc) mice. 
This contrasts with the screen reported here where the frequency of MB was only 6% in 
controls and ~23% in the experimental group. However, because of the high penetrance, 
139 primary mice tumours were available for analysis resulting in the identification of 
350 CISs, compared to 18 CISs from 41 primary MB generated here.  
In addition to affecting penetrance, the tissue specific screen had a significant 
impact upon latency, reducing it from 8 to 2.5 months. This suggests that some of the 
mutations affected the aggressiveness/development of disease, as opposed to being 
transformative. Consistent with this interpretation, the Math1 conditional SB screen 
study generated metastatic disease via the cerebrospinal fluid pathways in 
approximately 80% of cases (Wu et al., 2012), whereas there was no macroscopic 
evidence of metastatic disease within the tumours analysed here. This is important 
because metastases are uncommon both within the Ptch1+/- model (Goodrich et al., 
1997) and within human SHH tumours (Kool et al., 2008). 
The large number of CISs identified, and the large number of metastases, 
enabled (Wu et al., 2012) to establish that the spectra of alterations in primary and 
metastatic tumours are distinct, highlighting the difference of the metastatic niche and 
the potential problems for therapeutic intervention based on analysis of primary tumours 
alone. Although the two screens are not comparable, Wu et al., 2012, identified a subset 
of 17 CISs with mutations in both alleles, suggesting that they were key genes in 
tumour development. Interestingly, 4 of the network CIS genes here were identified by 
Wu et al. (Crebbp, Nfia, Nfib and Tead1) and a further 3 are within the network (Dip2c, 
Edil3 and Erbb4): All but one of these genes (Tead1) are biallelically mutated in the 
(Wu et al., 2012) data, consistent with the network being critical for tumour formation 
rather than progression. It is also noteworthy that Igfr1 and Ifg2 were both identified as 
CIS genes within the SB conditioned mutagenesis screen of (Wu et al., 2012), Igfr1 
being the main receptor that transfers Ifg2 gene signals within GNPCs (Corcoran et al., 
2008). Thus, while the penetrance of the model and aggressiveness of the mutagen were 
much higher in the (Wu et al., 2012) study, the footprint of the network identified here 
is present within their data. 
The idea that GNPCs are the only known source of neuron granule cells and the 
cells of origin of MB has dominated thinking for nearly a decade, and has only recently 
been revised as other, distinct, cells of origin have been identified. Li et al. (2013) 
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identified a rare population of neuronal progenitor cells that, surprisingly, also generate 
granule cells and MB in mouse cerebellum. Although Nestin expression has been 
identified in the cerebellum [neural stem cells (NSCs) and radial glia specifically], its 
expression in GNPCs has remained debatable (Sotele  et al., 1994; Lee et al., 2005). 
Some reports have suggested that Nestin is downregulated in these cells prior to 
commitment to the granule lineage (Alder et al., 1996), although some studies have 
reported that GNPCs can be Nestin positive (Tanori at al., 2010). This is complicated 
by the fact that it is difficult to identify Nestin-positive cells from Nestin-positive fibers. 
Several studies have targeted GNPCs through engineered animals that expressed Cre 
recombinase under the control of the Nestin promoter (Milles et al., 2006; Frappart et 
al., 2007).  
The study by Li et al., (2013) aimed to identify the cells of origin of Nestin 
expression and its developmental role within the murine cerebellum.  The authors, 
primarily, determined that Nestin protein (a marker of multipotent stem cells that have 
committed to the granule neuron lineage) is expressed in the cerebellum of mice at 
postnatal day 4 (P) in Nestin-CFP transgenic mice. The reason behind the usage of cyan 
fluorescent protein (CFP) was to allow this reporter to fuse to nuclear localized Nestin 
Protein to discriminate the Nestin positive cell bodies from glial fibres which also 
express Nestin (Shi et al., 2008; Vukojevic et al., 2010).  Surprisingly, these CFP 
positive cells (Nestin-expressing progenitors, NEPs) did not express Math1, a well-
recognised marker for GNPCs (Ben-Arie et al., 1997).   
For further purification and cell quantification in the cerebellar EGL, Nestin-
CFP mice were crossed with Math1-GFP mice in order to create Nestin-CFP-Math1-
GFP animals.  This allowed NEPs to be distinguished from GNPCs within the 
cerebellum of single animals so that GFP could be used to exclusively label GNPCs for 
fate mapping. Use of this approach to analyse microdissected cerebellar EGL from P4 
Math1-GFP-Nestin-CFP mice established that approximately 3-5% of the labelled cells 
expressed Nestin-CFP. Furthermore, no cells expressed both GFP and CFP, as recorded 
by flow cytometric analysis, suggesting that these cells are distinct populations. 
Contrary to the prevailing assumption, that GNPCs give arise to granule neurons 
exclusively, Li et al. (2013) demonstrated that NEPs also have the ability to generate 
granule neurons during cerebellar development.  
In this study, the lineage relationship between NEPs and GNPCs was then 
analysed by crossing Math1-CreR26R-GFP mice with Nestin-CFP mice to generate a 
Math1-CreR26R-GFP-Nestin-CFP model. The flow cytometry results indicated that 
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about 58% of cells in the EGL were GFP positive, while only ~4% were CFP positive, 
and none of the cells expressed both at the same time. On the other hand, to establish if 
GNPCs may develop from NEPs, Nestin-Cre
T2
-R26R-GFP mice were developed and 
then treated with tamoxifen. The immunostaining of cerebella from P8 mice indicated 
that Math1
+
GNPCs were preferentially stationed in the outer tissue of cerebellar EGL.  
This confirmed that none of GNPCs or NEP give rise to, or were derived from, each 
other. Furthermore, NEP cells showed a capacity to respond to recombinant Shh 
protein , as both GNPC and NEP cell populations were significantly increased in the 
presence of Shh protein (P=0.00077 for NEP), while they became quiescent in the 
absence of Shh in vitro.  
More evidence for the distinctive behaviour of NEPs from either GNPCs or 
neuronal stem cells (NSCs) came from microarray analyses of RNAs from each cell 
population purified from the cerebellum of P4 Nestin-CFP-Math1-GFP mice. The two 
populations differed in gene expression patterns, as established by principal component 
analysis. Approximately, 10.87% genes (4902 out of 45,101 probes) were significantly 
differentially expressed (increased or decreased by ≥2-fold, false discovery rate <0.01 
by paired t test). Interestingly, 179 genes involved in DNA damage and repair, 62 
(34.64%) were differentially expressed between NEPs and GNPCs (P<0.001). These 62 
genes were downregulated in NEPs compared to GNPCs. Among these, Chek1, Lig3 
and Parp1 expression was validated utilising qPCR. 
These two cell population were also found to differ in terms of genomic 
instability, in particular chromosomal breaks, and centromere separation.  Ptch1 was 
deleted in the experimental mice to continuously stimulate the Shh pathway, by 
crossing Nestin-CFP-Math1-GFP and Ptch1
C/C
  to generate Nestin-CFP-Math1-GFP-
Ptch1
C/C
 mice. Upon purification of NEPs and GNPCs from P4 Nestin-CFP-Math1-
GFP-Ptch1
C/C
 cerebellar mice, metaphase spread chromosome analysis using Giemsa-
banding established that NEPs have significantly higher levels of  genomic instability 
than GNPCs, ~62% of cells compared to ~20.0%. This led the authors to postulate that 
NEPs might drive tumourigenicity more aggressively that GNPCs, based on genomic 
instability due to Ptch1 deletion. Based on this, Ptch1 was deleted from NEPs and 
GNPCs, derived from Nestin-CreER
T2
-Ptch1
C/C
 and Math1-CreER
T2
-Ptch1
C/C
 mice 
respectively. Animals of both genotypes developed tumours resembling those generated 
in human medulloblastoma based on histopathological appearance.  In regards to 
molecular comparisons, cells (NEPs or GNPCs) isolated from tumours within these 
experimental animals showed very similar gene expression patterns compared to human 
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MB tumours, as assessed by principal component analysis. The tumour penetrance 
recorded approached 100% in both models.  
Interestingly, as few as, 5000 transplanted NEPs produced medulloblastoma in 
50% of Nude mice recipients compared to 0% within the same number of GNPCs 
recipients. However, 20000 cells of each NEPs and GNPCs gave rise to 
medulloblastoma in 100% and 60% of transplanted recipients, respectively. With the 
number of transplanted NEPs and GNPCs increased to ~50000, medulloblastoma 
generation was 100% within recipient’s animals. This suggests that NEPs have 
enhanced tumourigenic potential compared to GNPCs. This study raises the possibility 
that Shh subgroup tumours could arise in Nestin expressing cells and could be distinct 
in terms of disease course.  It is interesting in this regard that analysis of Nestin 
expression within the murine Illumina beads microarray data generated here established 
that Nestin is only expressed in tumours generated within the experimental SB model 
and the Ptch1 predisposition model, and not within P53
+/-
 and wild type cerebella 
controls (data not shown).  Further analysis of Nestin expression within Shh subgroup 
tumours may therefore be of interest. The use of SB to target Nestin expressing cells via 
the generation of Ptch1
+/-
/Nestin-SB/T2Onc murine models could also identify 
candidate CISs involved in Nestin derived MB. 
 
Future Work 
 The results presented here define a novel neuronal transcription factor network 
involved in MB development, and highlight genes of particular interest. My preliminary 
experiments where Tgif2 was overexpressed through retroviral transduction require 
further work to establish why no protein could be detected despite successful expression 
at the RNA level. Although the ORF clone was purchased as “sequence verified” it will 
be necessary to first confirm the existence of an intact open reading frame. It is also 
possible that the FLAG tag may not be accessible in the protein produced, so an N 
terminal flag may need to be tried. Alternatively, currently available antibodies raised 
against human Igf2 should cross react with the mouse protein, so it may be possible to 
avoid the use of tagged ORFs should it be necessary.  
The Myt1l work is very encouraging as the preliminary data suggests that 
knockdown is having the predicted effect in terms of the expression of the neuronal 
marker Math1, and that this gene affects SHH signalling as assessed by the expression 
of the effector Gli1. However, the negative result obtained with the Western indicated 
that the protein detection of this gene also requires more troubleshooting. Expression in 
 179 
GNPCs is low, and sensitivity may be an issue. In addition, the antibody utilised here is 
a monoclonal version. There are 3 different isoforms of the Myt1l protein, and this 
antibody will not cross react with all of the isoforms. A polyclonal antibody may prove 
more robust. 
Once these issues with protein detection are resolved, the transduced cGNPCs 
can be analysed to further analyse these genes in particular, and the network in general. 
First, microarray expression analyses or RNAseq could be used to confirm the activity 
of the network, and the role of these genes within it. In addition, RNAseq data is 
currently being generated from several hundred primary tumours in Newcastle, and re-
generation of the network in this data will be useful as the accuracy of ARACNe 
network is affected by sample size and dynamic range of expression.  Finally, the 
impact of gene knockdown/overexpression on cellular phenotype in terms of 
proliferation, differentiation and invasiveness etc. can all be analysed, and it is also 
possible to assess the cancer forming potential of transduced cGNPCs in nude mice. 
The link between insulin signalling and MB has been highlighted both by the 
Igf2 data presented here, but also by ontology analyses in the (Wu et al., 2012) secreen.  
Synergy between the Shh pathway and Igf2 upon MB development has been shown as 
the co-supplementation of Shh protein and Ifg family genes significantly induced BrDu 
uptake by GNPCs more than separate application of these substances. Furthermore, 
blocking the activity of Igfr1 (the Igf2 receptor) drastically reduced the proliferation of 
GNPCs, even in the presence of Shh alone (Fernandez et al., 2010). The analysis 
applied here suggests that the mutations disrupting the network should inhibit neuronal 
differentiation and lead to proliferation induction through Igf2 stimulation. Consistent 
with this, several CISs defining the neuronal network established here have been shown 
to affect Ifg2 expression such as TEAD1, the co-activator of YAP (Fernandez et al., 
2012). The same thing is possible for NFI family elements (NFIA, NFIB) as these have 
been shown to modulate the expression of IGFBR5 in a human osteoblastoma cell line 
(Perez-Casellas et al., 2009). There is also evidence that Crebbp mutation may activate 
Ifg2 via induction of EGR1 (Svaren et al., 2000). 
 The identification of these genes which may modulate Igf2 gene expression is of 
particular interest. Inhibitors of SHH signalling are being used therapeutically to treat 
SHH subgroup MB, but acquired resistance has been documented (Yauch et al., 2009), 
making the identification of further agents to treat SHH subgroup tumours desireable. 
Targetting of Igf2, perhaps in conjunction with SHH inhibitors, is therefore a plausible 
avenue for further therapeutic development.  
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Finally, two studies have recently successfully generated highly aggressive MB 
models using MYC overexpression. Human Group 3 MBs frequently overexpress 
MYC, tend to present a very poor prognosis, and are aggressive and invasive tumours 
with very large cell and anaplastic histological features (Cho et al., 2011;Northcott et 
al., 2011). MYC is usually not expressed in GNPCs (Zindy et al., 2006), suggesting that 
this is unlikely to be the cell of origin.  MYC is overexpressed in human MB subgroups 
3 and 4, with the highest levels of MYC expression detected within Group 3 (Swartling 
et al., 2010;Northcott et al., 2011). To model these MYC-amplified tumours t Myc was -
overexpressed in Cdkn2c
-/-
; Trp53
-/-
 or Trp53-/- mutant mice (Kawauchi et al., 2012;Pei 
et al., 2012). In one study cerebellar stem cells (CD133+) with a stabilised form of Myc 
(Myc
T5BA
) and a highly proliferative activity in culture were transplanted into 
immunedeficient mice, and small foci of these cells was detected within 2 weeks. 
However, when these Myc expressing cells were infected with a dominant-negative p53 
(DNp53) vector and transplanted into the cerebellum of mice, highly aggressive tumour 
accumulations were seen within 6-12 weeks compared to Myc only mice. The 
immunohistochemical assay revealed a larger tumour cells and more necrotic features 
within Myc tumours compared to those raised from Ptch1
+/-
 mice.  The availability of 
new models for highly aggressive forms of the disease open up new avenues for 
research, The results here suggest that utilising SB mutagenesis with these MB models 
could identify new biomarkers and therapeutic targets in this aggressive disease subset. 
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